SET DOCUMENT Name        = "Tau Modifications"
SET DOCUMENT Version     = "1.9.5"
SET DOCUMENT Description = "Tau Modifications Sections of TauBase"
SET DOCUMENT Copyright   = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved"
SET DOCUMENT Authors     = "Kristian Kolpeja, Esther Wollert, Sandra Spalek"
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
# DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"


# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
DEFINE NAMESPACE CL             AS PATTERN "^\d{7}$"


###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
##############
# Statements #
##############

# Locally defined annotations
# ---------------------------
DEFINE ANNOTATION Tau_Structure AS LIST {"microtubule-binding region", "projection domain"}
DEFINE ANNOTATION Tau_Domain AS LIST {"proline-rich domain"}
DEFINE ANNOTATION Tau_Motif AS LIST {"PHF6", "KXGS"}
DEFINE ANNOTATION Tau_State AS LIST {"Paired Helical Filament"}
DEFINE ANNOTATION Tau_Antibody AS LIST {"Tau-5", "Tau-12", "Tau-13","9G3", "pY18","TN1","TOC1","Anti-pS422","TauC3"}
DEFINE ANNOTATION Method AS LIST {"Fluorescence Resonance Energy Transfer", "Dephosphorylation Assay, Colorimetric", "Pull-down Assay, GFP", "Microtubule Co-Sedimentation Assay", "Chromatography, Ni-NTA-Sepharose", "Tandem Affinity Purification, TAP", "Chromatography", "In-vivo two photon calcium imaging", "Confocal Microscopy, Laser Scanning", "Chromatography, Gel filtration", "Scanning electron microscopy (SEM)", "Deglycosylation Assay", "Enhanced Chemioluminescence visualization (ECL)", "Immunofluorescence Imaging", "Transmission electron microscopy (TEM)", "Microarray", "Surface Plasmon Resonance", "Ubiquitination Assay", "Chymotrypsin Assay", "RNA Interference, shRNA", "Yeast Two-Hybrid Assay", "F-actin depolymerization assay", "Microtubule Sedimentation Assay", "Laser Capture Microdissection", "Microtubule polymerization Assay", "Degradation Assay, 20S Proteasomal", "Protease-coupled Assay", "Comet Assay", "Non-denaturing Fast Halo Assay", "Chromatography, FPLC", "Phosphorylation Assay", "Dephosphorylation Assay", "In vitro actin-bundling assay", "Pull-down Assay", "Pull-down Assay, GST", "Chromatin Immunoprecipitation", "LDH Assay", "Electron Microscopy, Immunological", "Chromatography, Affinity", "Co-Immunoprecipitation", "RP HPLC", "Pull-down assay, His-tagged", "Pull-down assay, GST", "Immunoaffinity Chromatography", "Immunocytochemistry", "Microtubule-binding Assay", "Terminal Continuation RNA Amplification" , "NMR Spectroscopy", "Transglutaminase Assay", "Immunoaffinity purification", "Fluorescence Microscopy", "Thioflavin T Assay", "Turbidometric Analysis","Immunoblotting", "Bradford Assay","SDS-PAGE","Immunofluorescence", "Electron Microscopy, Transmission", "Confocal Microscopy", "Electron Microscopy", "RNA Interference, siRNA","Electrophoretic Mobility Shift Assay", "RT-PCR","Atomic Force Microscopy", "Flow Cytometry", "NBT colorimetric fructosamine assay", "Fluorescence Spectrophotometry", "Western Blot","Immunoprecipitation","Liquid Chromatography","Mass Spectrometry","Immunohistochemistry","Immunofluorescence","ELISA","Tubulin polymerization assay, light scattering method", "Tau aggregation assay", "CD Spectroscopy", "Chromatography, Immunoaffinity", "Fluorescence Microscopy, Confocal", "Cell Viability Assay, MTT", "Confocal Laser Microscopy","Thioflavin T Fluorescence Assay","Dot Blot"}
DEFINE ANNOTATION ExpMethod AS LIST {"in vitro", "in vivo"}
DEFINE ANNOTATION Braak_Stage AS LIST {"Stage I", "Stage II", "Stage III", "Stage IV", "Stage V", "Stage VI"}
DEFINE ANNOTATION Enzyme_Acitvity AS LIST {"1 U/ml"}
DEFINE ANNOTATION Vmax AS LIST {"2400 nM/min/mg", "80 nM/min/mg", "59 μM", "106 nM/min/mg", "140 nM/min/mg", "650 nM/min/mg", "656 nM/min/mg", "0.8-4 μM/min/mg"}
DEFINE ANNOTATION Km AS LIST {"2.7 µM", "200 μM", "59 μM", "114 μM", "5 μM", "16 μM", "8-15 μM"}
DEFINE ANNOTATION Km_ATP AS LIST {"2 μM", "10 μM"}
DEFINE ANNOTATION IC50 AS LIST {"65 nM", "50 mM", "0.2 mM", "0.6 mM", "2 mM", "0.4 mg/ml", "160 mM", "35 mM", "0.4 mM", "4.5 mM", "5-50 nM", "54 nM", "450 nM", "78 nM", "30 nM", "45 nM", "62 nM", "19 nM", "90 nM", "38 nM"}
DEFINE ANNOTATION Study_Group AS LIST {"Korean population", "Spanish cohort", "Han chinese", "Tet-mev-1 mice"}
DEFINE ANNOTATION Research_Model AS LIST {"streptozotocin (STZ)-induced DB murine model", "HD murine model", "APPswe x P301L transgenic mice", "APP/PS1 x rTg4510 mice", "PS19 mice", "P301S mice", "APPPS1 mice","K3 model with hyperphoshorylated tau resembling FTD", "Ts65Dn mice", "rTg4510 mice", "SAMP8 mice", "5xFAD mice", "hTau E391 transgenic mice", "LRRK2 transgenic mice", "p25 transgenic mice", "TPR50 mice", "pR5 mice", "E4FAD mice", "APPPS1 mice"}
DEFINE ANNOTATION Ki AS LIST {"5 nM", "210 nM", "40 nM", "4-80 nM", "39 nM", "38 μM", "8 μM", "110 nM"}
DEFINE ANNOTATION Substrate_Concentration AS LIST {"0.5 M"}
DEFINE ANNOTATION Duration AS LIST {"2 hours"}
DEFINE ANNOTATION Cell_Line AS LIST {"HEK293", "BV2","N2a", "SH-SY5Y", "neural stem cell", "PC12", "SK-N-SH", "HEK293T","HNPC", "NT2","HeLa", "Chicken embryo fibroblasts", "Human fibroblasts", "CHO", "NIH/3T3", "COS7", "HCN2A", "CG-4"}
DEFINE ANNOTATION HBP_Disease AS LIST {"Corticobasal Degeneration", "Autism Spectrum Disorder (ASD)", "Lewy Body Disease, Diffuse", "Frontotemporal Lobar Degeneration"}
DEFINE ANNOTATION Disease_Progression AS LIST {"Early Stage","Late Stage"}
DEFINE ANNOTATION Half_life AS LIST {"30 min", "29 min", "70 min"}


########################################################################################################################################################################################
#######################################################################TAU MODIFICATIONS################################################################################

###################################start recuration Sandra###################################

SET Citation = {"PubMed", "25974414"}
SET Evidence = "While several N and C-terminally truncated Tau species are observed in AD brains, only a limited number of specific Tau cleavage sites, after residues Asp13, Asp25,
Asn368, Glu391 and Asp421, have been identified so far in situ. The species generated by these cleavages are found in neurofibrillary tangles, and their occurrence is correlated
with the severity of the disease."

SET Disease = "Alzheimer's disease"
SET Confidence = "High"
p(HGNC:MAPT, trunc(Asp13)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, trunc(Asp25)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, trunc(Asp368)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, trunc(Glu391)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, trunc(Asp421)) partOf a(GO:"neurofibrillary tangle")

p(HGNC:MAPT, trunc(Asp13)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, trunc(Asp25)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, trunc(Asp368)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, trunc(Glu391)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, trunc(Asp421)) pos path(MESH:"Alzheimer Disease")
UNSET Disease
UNSET Confidence

SET Method = {"Western Blot","Immunoprecipitation","Liquid Chromatography","Mass Spectrometry"}
SET Anatomy = "cerebral cortex"
SET Evidence = "In order to pinpoint new N-terminal truncation sites of Tau, we optimized a proteomic approach (Fig. 1C) in brain samples. The whole range of Tau species was
immunoprecipitated (IP) from protein extracts with the Tau-5 antibody, which recognizes amino acid residues 218–225. As shown by WB analysis (Fig. S1),
Tau-5 IP allows the purification of full-length Tau (FL-Tau) as well as N- and C-terminally truncated Tau and aggregated species, which display lower and higher molecular
weights, respectively. These new N-terminal sites were scattered across the Tau sequence (Fig. 1D), and except for Ala2, have not been described before."
# biochemical coding without mentioning the effect of these truncations
SET Confidence = "High"
SET Tau_Antibody = "Tau-5"
SET Tau_Structure = "projection domain"
p(HGNC:MAPT, trunc(Ala2)) isA p(HGNC:MAPT)
UNSET Tau_Antibody
p(HGNC:MAPT, pmod(HBP:polyamination, Gln, 6)) isA p(HGNC:MAPT)

p(HGNC:MAPT, trunc(Ala103)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Gln124)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Met127)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Pro172)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys174)) isA p(HGNC:MAPT)
UNSET Tau_Structure
SET Tau_Domain = "proline-rich domain"
p(HGNC:MAPT, trunc(Lys224)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Ser238)) isA p(HGNC:MAPT)
UNSET Tau_Domain
SET Tau_Structure = "microtubule-binding region"
p(HGNC:MAPT, trunc(Lys240)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys259)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Gly261)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys280)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Val306)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Ile308)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Val309)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys311)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys331)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Glu391)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Lys395)) isA p(HGNC:MAPT)
UNSET Tau_Structure
SET Tau_Antibody = {"Tau-12", "Tau-13"}
p(HGNC:MAPT, trunc(Met11)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Glu12)) isA p(HGNC:MAPT)
p(HGNC:MAPT, trunc(Asp13)) isA p(HGNC:MAPT)
UNSET Tau_Antibody
UNSET Confidence

SET Evidence = "Regarding the effect of N-terminally truncated Tau, the Met11-Tau fragment showed the same properties as FL-Tau while
Gln124-Tau was associated with a markedly increased level of acetylated tubulin compared to FL-Tau."
SET Confidence = "High"
p(HGNC:MAPT, trunc(Gln124)) -> p(FPLX:Tubulin, pmod(Ac))
UNSET Confidence

SET Evidence = "In agreement with this possibility, the investigation of another posttranslational
modification of tubulin, detyrosination, which is also representative of a stable population of microtubules, revealed that
it was significantly increased with Gln124-Tau when compared to FL-Tau"
SET Confidence = "Medium"
p(HGNC:MAPT, trunc(Gln124)) -> p(INTERPRO:"Alpha tubulin", pmod(HBP:detyrosination))
p(HGNC:MAPT, trunc(Gln124)) pos act(p(HGNC:VASH1))
p(HGNC:MAPT, trunc(Gln124)) pos act(p(HGNC:VASH2))
act(p(HGNC:VASH1)) -> p(INTERPRO:"Alpha tubulin", pmod(HBP:detyrosination))
act(p(HGNC:VASH2)) -> p(INTERPRO:"Alpha tubulin", pmod(HBP:detyrosination))
UNSET Confidence
UNSET Anatomy
UNSET Method


SET Evidence = "Hyperphosphorylation with Prostate-derived sterile 20-like kinase 1 alpha/beta (PSK1/TAOK2), Prostate-derived sterile 20-like kinase 2 (PSK2/TAOK1), CK1."
SET Confidence = "Medium"
SET Tau_Antibody = {"Tau-12", "Tau-13"}
kin(p(HGNC:TAOK1)) => p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
kin(p(HGNC:TAOK2)) => p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
kin(p(HGNC:CSNK1A1)) => p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Tau_Antibody
UNSET Confidence

SET Citation = {"PubMed", "16566606"}

SET Evidence = "Previously, we showed that peroxynitrite (ONOO-) induces the oxidative 3,3¢-
dityrosine (3,3¢-DT) cross-linking and site-selective nitration of tau monomers [Reynolds et al. (2005)"
SET Confidence = "High"
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:nitration))
UNSET Confidence

SET Evidence = "Further, select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50
conformation [Reynolds et al. (2005) Biochemistry 44, 13997-14009], inhibits the ability of monomeric tau to promote tubulin assembly."
# Alz-50 conformation refers to a misfolded conformation of tau
SET Confidence = "Medium"
SET Tau_Antibody = {"9G3", "pY18", "Tau-12", "Tau-13"}
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) -| bp(GO:"tubulin complex assembly")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) -- p(HGNC:MAPT,pmod(HBP:misfolded))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -| bp(GO:"tubulin complex assembly")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -- p(HGNC:MAPT,pmod(HBP:misfolded))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) -| bp(GO:"tubulin complex assembly")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) -- p(HGNC:MAPT,pmod(HBP:misfolded))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 394)) -| bp(GO:"tubulin complex assembly")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 394)) -- p(HGNC:MAPT,pmod(HBP:misfolded))
p(HGNC:MAPT) -> bp(GO:"tubulin complex assembly")
p(HGNC:MAPT,pmod(HBP:misfolded))
UNSET Tau_Antibody
UNSET Confidence


##################################################################################Tau Methylation#############################################################################################

SET Citation = {"PubMed", "26671985"}
SET Evidence = "Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction
of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD)."
SET Confidence = "Medium"
act(a(HBP:"Tau oligomers")) -> path(HBP:neurotoxicity)
act(a(HBP:"Tau oligomers")) -| act(complex(GO:axon))
p(HBP:"phosphatase-activating domain") eq p(HGNC:MAPT, frag(2_18))
p(HGNC:MAPT, frag(2_18)) partOf p(HGNC:MAPT, frag(1_151))
#p(HGNC:MAPT, frag(1_151)) corresponds to the NTD
p(HBP:"phosphatase-activating domain") neg act(complex(GO:axon))
act(complex(GO:axon)) neg a(HBP:"neurotoxicity")
UNSET Confidence

SET Evidence = "We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of
PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of
9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each).
These 4 markers are particularly useful in understanding potential posttraumatic events in CTE because PAD exposure impairs axonal transport (24),
oligomers confer toxicity (28, 38–40), pS422 correlates with cognitive decline (15), and D421 truncated tau may be related to cell toxicity (41, 42).
All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed
extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE."
SET Confidence = "Medium"
SET Method = {"Immunohistochemistry","Immunofluorescence","ELISA"}
SET Tau_Antibody = {"TN1","TOC1","Anti-pS422","TauC3"}
SET MeSHDisease = "Chronic Traumatic Encephalopathy"
SET MeSHAnatomy = "Brain"
p(HBP:"phosphatase-activating domain") biomarkerFor path(MESH:"Chronic Traumatic Encephalopathy")
p(HGNC:MAPT, trunc(Asp421)) biomarkerFor path(MESH:"Chronic Traumatic Encephalopathy")
p(HGNC:MAPT, pmod(Ph, Ser, 422)) biomarkerFor path(MESH:"Chronic Traumatic Encephalopathy")
a(HBP:"Tau oligomers") biomarkerFor path(MESH:"Chronic Traumatic Encephalopathy")
p(HBP:"phosphatase-activating domain") -| bp(GO:"axonal transport")
a(HBP:"Tau oligomers") pos path(HBP:neurotoxicity)
p(HGNC:MAPT, trunc(Asp421)) -- path(HBP:neurotoxicity)
p(HGNC:MAPT, pmod(Ph, Ser, 422)) -> path(MESH:"Cognitive Dysfunction")
UNSET MeSHDisease
UNSET Tau_Antibody
UNSET Method
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "24869773"}
SET Evidence = "An example of a spectrum identifying K311 as a site of dimethylation at 2.2 ppm mass accuracy is shown in Fig. 2B. This residue was reported as a possible methylation
site in AD-brain derived tau protein on the basis of Edman degradation years ago [36]. It resides within the “PHF6” motif of the MTBR, which has been reported to mediate the
aggregation propensity of recombinant monomeric tau in vitro [6, 37]. Other methylation sites within the MTBR include K259, K290, and K353, each of which lies in a
KXGS motif associated with AMP-activated protein kinase mediated regulation of microtubule binding [38]. Within the N-terminal projection domain, Lys methylation was detected at K24, K44, K67, and K190 (Fig. 1)."
SET Confidence = "Medium"
SET Method = {"Tubulin polymerization assay, light scattering method", "Liquid Chromatography", "Mass Spectrometry", "Tau aggregation assay", "CD Spectroscopy"}
SET MeSHAnatomy = "Brain"
p(HGNC:MAPT, pmod(Me, Lys, 311)) -- path(MESH:"Alzheimer Disease")

SET Tau_Structure = "microtubule-binding region"
SET Tau_Motif = "PHF6"
p(HGNC:MAPT, pmod(Me, Lys, 311)) -- p(HBP:"Tau aggregates")
UNSET Tau_Motif
SET Tau_Motif = "KXGS"
p(HGNC:MAPT, pmod(Me, Lys, 259)) reg complex(p(HGNC:MAPT),a(GO:microtubule))
p(HGNC:MAPT, pmod(Me, Lys, 290)) reg complex(p(HGNC:MAPT),a(GO:microtubule))
p(HGNC:MAPT, pmod(Me, Lys, 353)) reg complex(p(HGNC:MAPT),a(GO:microtubule))
p(FPLX:AMPK) reg complex(p(HGNC:MAPT),a(GO:microtubule))
UNSET Tau_Motif
SET Tau_Structure = "projection domain"
p(HGNC:MAPT, pmod(Me, Lys, 24)) -- p(HGNC:MAPT)
p(HGNC:MAPT, pmod(Me, Lys, 44)) -- p(HGNC:MAPT)
p(HGNC:MAPT, pmod(Me, Lys, 67)) -- p(HGNC:MAPT)
p(HGNC:MAPT, pmod(Me, Lys, 190)) -- p(HGNC:MAPT)
UNSET Tau_Structure
SET MeSHAnatomy

p(HGNC:MAPT, pmod(Me, Lys, 24)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 44)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 67)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 190)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 259)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 290)) isA p(HGNC:MAPT, pmod(Me,Lys))
p(HGNC:MAPT, pmod(Me, Lys, 353)) isA p(HGNC:MAPT, pmod(Me,Lys))
UNSET Confidence

SET Evidence = "These data indicate that Lys methylation depressed the intrinsic aggregation propensity of tau, and did so in part by increasing the concentration of tau
needed to support fibril formation."
# fibril formation refers to Tau fibrils
SET Confidence = "Medium"
p(HGNC:MAPT, pmod(Me,Lys)) -| a(HBP:"Tau aggregates")
p(HGNC:MAPT) -- a(HBP:"Tau fibrils")
UNSET Confidence

UNSET Method


SET Citation = {"PubMed", "22033876"}
SET Evidence = "However, robust monomethylation was identified at seven sites distributed throughout the tau sequence (Table 1). Three of the sites (K163, K174, and K180)
reside within the proline-rich region of the tau N-terminal projection domain, which mediates interactions with microtubule-associated proteins such as actin [27] and the
Src homology three domain of plasma membrane-associated proteins including Src family kinases [37] and  phospholipase Cγ [54]. In contrast, K254, K267, and K290
are part of the first and second repeats of the microtubule binding domain. Although no Lys acetylation was detected at these sites in our datasets, it was possible to quantify relative
methylation and ubiquitylation of K254."
SET Confidence == "Medium"
SET Method = {"Liquid Chromatography", "Mass Spectrometry","Immunohistochemistry", "Chromatography, Immunoaffinity", "Fluorescence Microscopy, Confocal"}
SET Disease = "Alzheimer's disease"
SET Anatomy = "hippocampal formation"
SET Tau_State = "Paired Helical Filament"
SET Tau_Structure = "projection domain"
p(HGNC:MAPT, pmod(Me, Lys, 163)) partOf a(HBP:"proline-rich domain")
p(HGNC:MAPT, pmod(Me, Lys, 174)) partOf a(HBP:"proline-rich domain")
p(HGNC:MAPT, pmod(Me, Lys, 180)) partOf a(HBP:"proline-rich domain")
a(HBP:"proline-rich domain") reg complex(p(FPLX:Actin),p(HGNC:MAPT))
a(HBP:"proline-rich domain") reg complex(p(INTERPRO:"SH3 domain"),p(HGNC:MAPT))
a(HBP:"proline-rich domain") reg complex(p(HGNCGENEFAMILY:"Src family tyrosine kinases"),p(HGNC:MAPT))
a(HBP:"proline-rich domain") reg complex(p(HGNC:PLCG1),p(HGNC:MAPT))

SET Tau_Structure = "microtubule-binding region"
p(HGNC:MAPT, pmod(Me, Lys, 254)) partOf p(HBP:"tubulin-binding repeat 1")
p(HGNC:MAPT, pmod(Me, Lys, 267)) partOf p(HBP:"tubulin-binding repeat 1")
p(HGNC:MAPT, pmod(Me, Lys, 290)) partOf p(HBP:"tubulin-binding repeat 2")
UNSET Tau_Structure
UNSET Tau_State
UNSET Anatomy
UNSET Disease
UNSET Method
UNSET Confidence

SET Citation = {"PubMed", "23943618"}
SET Evidence = "Notably, methylation of PP2A catalytic C subunit on the Leu- 309 residue by leucine carboxyl methyltransferase 1 (LCMT1)
promotes the biogenesis and stabilization of PP2A/B  enzymes (20). We have shown that decreased LCMT1 activity and/or expression levels correlate with down-regulation of PP2A
methylation and PP2A/Bα expression levels and with concomitant accumulation of phospho-Tau in AD-affected brain regions (21), in cultured N2a neuroblastoma cells and in vivo"
SET Confidence = "Medium"
SET Disease = "Alzheimer's disease"
SET Cell_Line = "N2a"
SET Method = {"Western Blot"}
SET MeSHAnatomy = "Brain"
p(HGNC:LCMT1) -> p(HGNC:PPP2CA, pmod(Me, Leu, 309))
p(HGNC:PPP2CA, pmod(Me, Leu, 309)) -> act(p(FPLX:PPP2))
act(p(FPLX:PPP2)) pos complex(p(FPLX:PPP2), p(HGNC:MAPT))
complex(p(FPLX:PPP2), p(HGNC:MAPT)) neg p(HGNC:MAPT, pmod(Ph))
UNSET MeSHAnatomy
UNSET Method
UNSET Cell_Line
UNSET Disease
UNSET Confidence

SET Citation = {"PubMed", "22764226"}
SET Evidence = "Incubation of human SH-SY5Y neuroblastoma cells for 2 h with L-dopa induced a dose-dependent
decrease in both soluble and insoluble methylated PP2A C subunit levels, and concomitant accumulation of demethylated PP2A enzymes"
SET Confidence = "High"
SET Method = {"Western Blot", "Confocal Microscopy"}
SET Cell_Line = "SH-SY5Y"
act(a(CHEBI:"L-dopa")) -| p(HGNC:PPP2CA, pmod(Me))
UNSET Cell_Line
UNSET Confidence

SET Evidence = "Significantly, we found similar effects in human dopaminergic neurons
(Fig. 2F). Treatment of neurons with L-Dopa induced a 40–49% decrease in methylated
PP2A and concomitant 168–179% increase in endogenous p-Tau (PHF-1) levels (Fig. 2G)."
SET Confidence = "Medium"
SET Anatomy = "dopaminergic cell groups"
act(a(CHEBI:"L-dopa")) -| p(HGNC:PPP2CA, pmod(Me))
act(a(CHEBI:"L-dopa")) -> p(HGNC:MAPT,pmod(Ph,Ser,396)
act(a(CHEBI:"L-dopa")) -> p(HGNC:MAPT,pmod(Ph,Ser,404)
UNSET Confidence

SET Evidence = "Folate starvation in the presence of L-dopa resulted in a 200–210% increase in demethylated PP2A levels,
and 235–250% increase in p-Tau levels in the dopaminergic neurons, relative to untreated controls maintained in NF medium."
SET Confidence = "Medium"
SET Anatomy = "dopaminergic cell groups"
act(a(CHEBI:"L-dopa")) -| p(HGNC:PPP2CA, pmod(Me))
act(a(CHEBI:"L-dopa")) -> p(HGNC:MAPT,pmod(Ph))
UNSET Anatomy
UNSET Confidence

SET Evidence = "Here, we found that administration of L-dopa led to a significant 5-fold increase in plasma tHcy concentrations, when compared to saline treated mice (Table 1).
This L-dopa induced increase in plasma tHcy was significantly greater in mice that had been reared on either low folate (LF) or FD diets (Table 1)."
SET Confidence = "Medium"
SET Species = "10090"
SET Anatomy = "blood plasma"
act(a(CHEBI:"L-dopa")) -> a(CHEBI:homocysteine)
UNSET Anatomy
UNSET Confidence

SET Evidence = "Reductions in PP2A methylation were associated with a concomitant increase in each brain region of p-Tau at the PHF-1 epitope (Fig. 6A,B)."
# reductions via L-dopa
SET Confidence = "Medium"
SET MeSHAnatomy = "Brain"
act(a(CHEBI:"L-dopa")) -| p(MGI:Ppp2ca, pmod(Me))
p(MGI:Ppp2ca, pmod(Me)) neg p(HGNC:MAPT,pmod(Ph,Ser,396)
p(MGI:Ppp2ca, pmod(Me)) neg p(HGNC:MAPT,pmod(Ph,Ser,404)
UNSET MeSHAnatomy
UNSET Species
UNSET Method
UNSET Confidence


###################################################################################Tau Glycation########################################################################################


SET Citation = {"PubMed", "25681682"}
SET Evidence = "The levels of sRAGE consistently decreased with age (R = −0.264, p = <0.001) and with the indices of obesity, such as BMI.
However, of special interest was the highly significant and previ-ously not reported independent correlation with fat free mass (p < 0.001)."
SET Confidence = "Medium"
SET Anatomy = "blood plasma"
p(HGNC:AGER) neg bp(GO:aging)
p(HGNC:AGER) neg bp(MESH:"Body Mass Index")
UNSET Anatomy
p(HGNC:AGER) -- act(p(HGNC:AGER))
SET Confidence


SET Citation = {"PubMed", "24183963"}
SET Evidence = "Recently, Li et al. (2012b) have demonstrated in their study that AGEs can induce tau
hyperphosphorylation through receptor for advanced glycation end product (RAGE)-mediated glycogen synthase kinase 3 (GSK-3) activation and targeting
RAGE/GSK-3 pathway can improve AD-like changes."
SET Confidence = "Medium"
a(CHEBI:"advanced glycation end-product") => act(p(HGNC:AGER))
act(p(HGNC:AGER)) -> kin(p(HGNC:GSK3B))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
a(CHEBI:"advanced glycation end-product") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
SET Confidence

SET Anatomy = "hippocampal formation"
SET Method = {"Cell Viability Assay, MTT", "Western Blot", "Confocal Laser Microscopy"}
SET Evidence = "Primary hippocampal neuron cells at different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA
were incubated together for 24 h, and then thr205- phosphorylated tau was estimated by the western immunoblotting method. Western blot analysis of each
experimental group showed that glucose–BSA promoted tau thr205-phosphorylation in a concentration-dependent manner (Fig. 3(a)).
In the present study, it was also shown that 100 nM GLP-1 or Ex-4 treatment reduced tau hyperphosphorylation induced by glucose–BSA (Fig. 3(b, c))."
SET Confidence = "Medium"
composite(a(CHEBI:glucose),a(PUBCHEM:16132389)) -> p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HGNC:GLP1R) -| p(HGNC:MAPT, pmod(Ph, Thr, 205))
a(CHEBI:"exendin-4") -| p(HGNC:MAPT, pmod(Ph, Thr, 205))
UNSET Confidence

SET Evidence = "Western blot analysis of different experimental groups, primary hippocampal neuron cells concurrent treatment
with different concentrations (0, 50, 100, 200 lg/ml) of glucose–BSA for 24 h, also showed that glucose–BSA
inhibited the phosphorylation of GSK-3b in a concentration-dependent manner (Fig. 4(a)). And 100 nM GLP-1 or Ex-4 can up-regulate phosphorylation
of GSK-3b at Ser9, which was decreased by treatment with glucose–BSA (Fig. 4(b, c))."
SET Confidence = "Medium"
composite(a(CHEBI:glucose),a(PUBCHEM:16132389)) -| p(HGNC:GSK3B, pmod(Ph, Ser, 9))
p(HGNC:GLP1R) -> p(HGNC:GSK3B, pmod(Ph, Ser, 9))
a(CHEBI:"exendin-4") -> p(HGNC:GSK3B, pmod(Ph, Ser, 9))
p(HGNC:GSK3B, pmod(Ph, Ser, 9)) -| kin(p(HGNC:GSK3B))
UNSET Method
UNSET Anatomy
UNSET Confidence


SET Citation = {"PubMed", "23531502"}
SET Evidence = "CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro due to their interaction with the two cysteine residues in tau.
A synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox which necessitates of cysteine for aggregation inhibition by CA."
# CA: cinnamaldehyde
# EC: epicatechin
SET Confidence = "Medium"
SET Method = {"Electron Microscopy, Transmission", "Mass Spectrometry"}
SET ExpMethod = {"in vitro"}
complex(p(HGNC:MAPT),a(CHEBI:cinnamaldehyde)) -| a(HBP:"Tau aggregates")
complex(p(HGNC:MAPT),a(CHEBI:"(-)-epicatechin")) -| a(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "The data (Fig. 8B) shows that no significant difference in the extent of tubulin assembly could
be observed with normal tau or tau incubated with CA. These results also indicate that once assembled, the microtubules remained stable to the same extent in the
presence or in the absence of CA."
SET Confidence = "Medium"
composite(p(HGNC:MAPT),a(CHEBI:cinnamaldehyde)) cnc bp(GO:"microtubule polymerization")
UNSET Confidence

SET Evidence = "We found that CA (lane 4) and EC (lane 6) substantially prevented the H2O2 induced formation of the high molecular weight species."
SET Confidence = "Medium"
a(CHEBI:cinnamaldehyde) -| act(a(CHEBI:"hydrogen peroxide"))
a(CHEBI:"(-)-epicatechin") -| act(a(CHEBI:"hydrogen peroxide"))
act(a(CHEBI:"hydrogen peroxide")) -> a(HBP:"Tau aggregates")
a(CHEBI:cinnamaldehyde) -| a(HBP:"Tau aggregates")
a(CHEBI:"(-)-epicatechin") -| a(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "We were prompted to carry out this study because Acr is mainly localized in the neurons [54], is found in association
with NFTs and dystrophic neurites surrounding senile plaques [55], is highly toxic to neurons, is found elevated 2–5 fold in affected regions of AD brain [33],
and has been shown to increase tau phosphorylation at pathological sites, attributed to activation of both
GSK3beta and the stress activated kinase p38 [56], which possibly promotes tau aggregation [57]."
# Acr: acrolein
SET Confidence = "Medium"
act(a(CHEBI:acrolein)) -- a(GO:"neurofibrillary tangle")
act(a(CHEBI:acrolein)) -- path(MESH:"Plaque, Amyloid")
act(a(CHEBI:acrolein)) -- a(HBP:"dystrophic neurite")
act(a(CHEBI:acrolein)) -> bp(GO:"neuron death")
act(a(CHEBI:acrolein)) -> p(HGNC:MAPT,pmod(Ph))
act(a(CHEBI:acrolein)) -> act(p(HGNC:GSK3B))
act(p(HGNC:GSK3B)) -- a(HBP:"Tau aggregates")
act(a(CHEBI:acrolein)) -> act(p(HGNC:MAPK14))
act(p(HGNC:MAPK14)) -- a(HBP:"Tau aggregates")
SET MeSHAnatomy = "Brain"
act(a(CHEBI:acrolein)) pos path(MESH:"Alzheimer Disease")
UNSET MeSHAnatomy
UNSET Confidence
UNSET ExpMethod
UNSET Method

SET Evidence = "Finally, we observed that EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein"
SET Confidence = "Medium"
a(CHEBI:"(-)-epicatechin") -| a(CHEBI:acrolein)
UNSET Confidence

SET Citation = {"PubMed", "26655600"}
SET Evidence = "However, granule cells of the dentate gyrus mainly express 3R isoforms, which resist Tau aggregation in AD, but accumulate 3R aggregates in
Pick's disease [14]. 3R Tau is a major Tau isoform in laser microdissected Pick bodies [15]."
SET Confidence = "Medium"
SET Anatomy = "dentate gyrus granule cell layer"
SET Disease = "Alzheimer's disease"
p(HBP:"3R tau") cnc a(HBP:"Tau aggregates")
UNSET Disease
SET Disease = "Pick's disease"
p(HBP:"3R tau",loc(GO:"Pick body")) pos path(MESH:"Pick's disease")
UNSET Disease
UNSET Anatomy
UNSET Confidence

SET Method = {"Thioflavin T Fluorescence Assay", "Liquid Chromatography", "Mass Spectrometry"}
SET Evidence = "The results show that 4R2N and 3R2N Tau increase their aggregation extent with
glycation while 3R1N decreases aggregation properties with glycation"
SET Confidence = "Medium"
p(HBP:"Tau isoform F (441 aa)", pmod(HBP:glycation)) -> a(HBP:"Tau aggregates")
p(HBP:"Tau isoform C (410 aa)", pmod(HBP:glycation)) -> a(HBP:"Tau aggregates")
p(HBP:"Tau isoform B (381 aa)", pmod(HBP:glycation)) -| a(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "On the other hand, the MS analysis shows that in the combined reaction of 4R2N Tau the level of phosphorylation is increased and the level of glycation is decreased."
SET Confidence = "High"
p(HBP:"Tau isoform F (441 aa)", pmod(HBP:glycation)) neg p(HBP:"Tau isoform F (441 aa)", pmod(Ph))
UNSET Confidence

SET Evidence = "Glycation and phosphorylation of both 4R1N and 4R0N Tau reduce its aggregation."
SET Confidence = "Medium"
p(HBP:"Tau isoform D (383 aa)", pmod(HBP:glycation)) -| a(HBP:"Tau aggregates")
p(HBP:"Tau isoform D (383 aa)", pmod(Ph)) -| a(HBP:"Tau aggregates")
p(HBP:"Tau isoform E (412 aa)", pmod(HBP:glycation)) -| a(HBP:"Tau aggregates")
p(HBP:"Tau isoform E (412 aa)", pmod(Ph)) -| a(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "Despite 4R1N having no significant change, the same modified 4R2N Tau promotes its aggregation significantly (Fig. 6A, C, E)."
SET Confidence = "Medium"
p(HBP:"Tau isoform B (381 aa)", pmod(Ph)) -> a(HBP:"Tau aggregates")
p(HBP:"Tau isoform B (381 aa)", pmod(HBP:glycation)) -> a(HBP:"Tau aggregates")
UNSET Confidence
UNSET Method


SET Citation = {"PubMed", "26304819"}
SET Cell_Line = "SH-SY5Y"
SET Method = {"RT-PCR", "Immunoblotting", "Bradford Assay", "Fluorescence Microscopy"}

SET Evidence = "A relationship has recently been reported between the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and apoptotic
events14. Real-time RT-PCR experiments showed that the expression of GAPDH was significantly increased by the addition of GA (Fig. 2a).
These results suggested that GA caused cell toxicity concomitant with increases in the gene expression of GAPDH in SH-SY5Y cells."
SET Confidence = "Medium"
a(CHEBI:glyceraldehyde) -> r(HGNC:GAPDH)
a(CHEBI:glyceraldehyde) -> bp(GO:"apoptotic process")
r(HGNC:GAPDH) -- bp(GO:"apoptotic process")
UNSET Confidence

SET Evidence = "GA dose-dependently increased the production of GA-AGEs in SH-SY5Y cells."
SET Confidence = "High"
a(CHEBI:glyceraldehyde) -> a(HBP:"GA-AGE")
a(HBP:"GA-AGE") isA a(CHEBI:"advanced glycation end-product")
UNSET Confidence

SET Evidence = "Aβ 42 in the medium decreased in a GA dose-dependent manner (Fig. 3a). In contrast, GA significantly increased tau and its phosphorylated form, p-tauT181 (Fig. 3b,c) in the medium.
In addition, VEGF (Fig. 3e) and TGF-β (Fig. 3f), which are also AD biomarkers,  were increased when the concentration of GA added was greater than 0.7 mM."
SET Confidence = "Medium"
a(CHEBI:glyceraldehyde) -| a(CHEBI:"amyloid-beta polypeptide 42")
a(CHEBI:glyceraldehyde) -> p(HGNC:MAPT)
a(CHEBI:glyceraldehyde) -> p(HGNC:MAPT, pmod(Ph, Thr ,181))
a(CHEBI:glyceraldehyde) -> p(HGNC:VEGFA)
a(CHEBI:glyceraldehyde) -> p(HGNC:TGFB1)
p(HGNC:VEGFA) biomarkerFor path(MESH:"Alzheimer Disease")
p(HGNC:TGFB1) biomarkerFor path(MESH:"Alzheimer Disease")
UNSET Method
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "26095350"}
SET Species = "10090"
SET Method = {"Immunohistochemistry", "Immunofluorescence", "Western Blot"}
SET Evidence = "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides, produces high levels of
advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells."
SET Confidence = "Medium"
SET Anatomy = "brain"
a(CHEBI:"D-ribose") -> a(CHEBI:"advanced glycation end-product")
a(CHEBI:"D-ribose") -> p(MGI:Mapt, pmod(Ph, Ser, 214))
a(CHEBI:"D-ribose") -> p(MGI:Mapt, pmod(Ph, Ser, 396))
a(CHEBI:"D-ribose") -> p(MGI:Mapt, pmod(Ph, Ser, 214), pmod(Ph, Ser, 396))
a(CHEBI:"D-ribose") -> p(MGI:Mapt,pmod(HBP:hyperphosphorylation))
UNSET Anatomy
SET Cell_Line = "N2a"
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Ser, 214))
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Thr, 181))
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Confidence

SET Evidence = "The treatment of 10 mM D-ribose for 24 h resulted in a significant increase in active form of CaMKII (p-Thr286/287), yet simultaneously
in a decrease in inactive form of CaMKII (p-Thr305/306) phosphorylation (Fig. 4e). The enzyme activity assay supported this result."
SET Confidence = "Medium"
a(CHEBI:"D-ribose") -> p(MGI:Camk2b, pmod(Ph, Thr, 287),pmod(Ph,Thr,286))
p(MGI:Camk2b, pmod(Ph, Thr, 287),pmod(Ph,Thr,286)) -> act(p(MGI:Camk2b))
a(CHEBI:"D-ribose") -| p(MGI:Camk2b, pmod(Ph, Thr, 306),pmod(Ph,Thr,305))
p(MGI:Camk2b, pmod(Ph, Thr, 306),pmod(Ph,Thr,305)) -| act(p(MGI:Camk2b))
UNSET Confidence

SET Evidence = "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose."
SET Confidence = "Medium"
a(CHEBI:"advanced glycation end-product") -> p(MGI:Mapt, pmod(Ph, Ser, 214))
a(CHEBI:"advanced glycation end-product") -> p(MGI:Mapt, pmod(Ph, Ser, 396))
a(CHEBI:"advanced glycation end-product") -> p(MGI:Mapt,pmod(HBP:hyperphosphorylation))
UNSET Cell_Line
UNSET Method
UNSET Confidence

SET Citation = {"PubMed", "22798221"}
SET Cell_Line = "N2a"
SET Method = {"ELISA", "Immunofluorescence", "Western Blot", "Dot Blot"}
SET Evidence = "Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability.
MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE)."
SET Confidence = "Medium"
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Ser, 404))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Ser, 198))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Ser, 199))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Ser, 202))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Thr, 231))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Ser, 396))
a(CHEBI:methylglyoxal) -> p(MGI:Mapt, pmod(Ph, Thr, 205))

a(CHEBI:methylglyoxal) -> a(CHEBI:"advanced glycation end-product")
a(CHEBI:methylglyoxal) -> p(HGNC:AGER)

UNSET Confidence

SET Evidence = "Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation."
SET Confidence = "Medium"
a(CHEBI:methylglyoxal) -> kin(p(MGI:Gsk3b))
a(CHEBI:methylglyoxal) -> kin(p(MGI:Mapk14))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Ser, 404))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Ser, 198))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Ser, 199))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Ser, 202))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Thr, 231))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Ser, 396))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph, Thr, 205))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Ser, 404))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Ser, 198))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Ser, 199))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Ser, 202))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Thr, 231))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Ser, 396))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(Ph, Thr, 205))
kin(p(MGI:Mapk14)) => p(MGI:Mapt, pmod(HBP:hyperphosphorylati
  NSET Method
UNSET Cell_Line
UNSET Confidence

SET Citation = {"PubMed", "19517062"}
SET Method = {"NBT colorimetric fructosamine assay", "Fluorescence Spectrophotometry", "Cell Viability Assay, MTT", "Atomic Force Microscopy", "Flow Cytometry"}
SET Cell_Line = "SH-SY5Y"
SET Evidence = "Tau is rapidly glycated in the presence of D-ribose, resulting in oligomerization and polymerization with Glycated derivatives appearing after 24 h.
Advanced glycation end-products (AGEs) were formed during initial stages of glycation. Thioflavin T-positive (ThT-positive) aggregations (day 4) indicated the globular-like features.
Atomic force microscopy revealed that the surface morphology of ribosylated Tau40 was globular-like."
SET Confidence = "Medium"
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(HBP:glycation))
p(HGNC:MAPT, pmod(HBP:glycation)) -> a(CHEBI:"advanced glycation end-product")
p(HGNC:MAPT, pmod(HBP:glycation)) partOf p(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(HBP:glycation)) -> a(HBP:"Tau oligomers")
p(HGNC:MAPT, pmod(HBP:glycation)) -> complex(a(CHEBI:"advanced glycation end-product"),p(HGNC:MAPT, pmod(HBP:glycation))
UNSET Confidence

SET Evidence = "D-ribosylated Tau aggregates were highly toxic to SHSY5Y cells and resulted in both apoptosis and necrosis"
SET Confidence = "High"
p(HBP:"Tau aggregates") -> bp(GO:"apoptotic process")
p(HBP:"Tau aggregates") -> bp(GO:"necrotic cell death")
UNSET Cell_Line
UNSET Method
UNSET Confidence


SET Citation = {"PubMed", "19251756"}
SET Method = {"Atomic Force Microscopy", "Electron Microscopy, Transmission", "Turbidometric Analysis", "Confocal Microscopy", "Western Blot", "Immunoprecipitation", "Immunohistochemistry", "Immunofluorescence"}
SET Evidence = "Triosephosphate isomerase (TPI) is a key enzyme in cell metabolism that controls the glycolytic flow and energy production through
the interconversion of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P) (Richard, 1993). Notably, TPI is the only glycolytic enzyme whose functional deficiency
is associated to neurodegeneration (Eber et al., 1991; Ovadi et al., 2004). In particular, inefficient glycolysis (Hoyer et al., 1988) and ATP depletion (Keil et al., 2004)
are characteristic in Alzheimer’s disease brains."
SET Confidence = "Medium"
act(p(INTERPRO:"Triosephosphate isomerase")) -> rxn(reactants(a(CHEBI:"dihydroxyacetone phosphate"),a(CHEBI:"D-glyceraldehyde 3-phosphate")), products(a(CHEBI:ATP)))
p(INTERPRO:"Triosephosphate isomerase") partOf bp(GO:"canonical glycolysis")
act(p(INTERPRO:"Triosephosphate isomerase")) neg a(HBP:Neurodegeneration)
bp(GO:"canonical glycolysis") neg path(MESH:"Alzheimer Disease")
a(CHEBI:ATP) neg path(MESH:"Alzheimer Disease")
UNSET Confidence

SET Evidence = "Ab induced nitro-oxidative stress on human neuroblastoma cells, resulting in nitrotyrosination of TPI. Moreover, higher levels of nitro-TPI were also detected in
extracts from hippocampus (Fig. 1F) and frontal cortex (Fig. 1G) obtained from Alzheimer’s disease brains, compared with healthy subjects."
SET Confidence = "High"
a(CHEBI:"amyloid-beta") -> bp(MESH:"Nitrosative Stress")
bp(MESH:"Nitrosative Stress") -> p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 164))
bp(MESH:"Nitrosative Stress") -> p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 208))

SET Disease = "Alzheimer's disease"
SET Anatomy = {"hippocampal formation", "frontal cortex"}
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 164)) pos path(MESH:"Alzheimer Disease")
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 208)) pos path(MESH:"Alzheimer Disease")
UNSET Anatomy
UNSET Disease
UNSET Confidence

SET Evidence = "Nitration of Tyr164 and Tyr208 would destabilize the closed state of loop 6 because the interaction between Tyr208 and Ala176 through an H-bond would be compromised
(Fig. 2A and B; Supplementary Fig. S2). Indeed, purified TPI after nitrotyrosination with a peroxynitrite donor (SIN-1) displayed a significant decrease in isomerase activity in both directions of
the catalysis, i.e. using DHAP (Fig. 2C) or GAP (Fig. 2D) as substrate."
SET Confidence = "High"
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 164)) -| act(p(INTERPRO:"Triosephosphate isomerase"))
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 208)) -| act(p(INTERPRO:"Triosephosphate isomerase"))
UNSET Confidence


SET Evidence = "In accordance with the decreased efficiency of nitro-TPI we found a significant increase in methylglyoxal production (P50.05), independent of whether DHAP or
GAP was used as substrate (Fig. 2E). Thus, nitrotyrosination of TPI results in reduced catalytic activity and increased occupancy of the enzyme by the substrate, and consequently, a higher
production of the toxic methylglyoxal."
SET Confidence = "Medium"
act(p(INTERPRO:"Triosephosphate isomerase")) neg a(CHEBI:methylglyoxal)
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 164)) -| act(p(INTERPRO:"Triosephosphate isomerase"))
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 208)) -| act(p(INTERPRO:"Triosephosphate isomerase"))
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 164)) -> a(CHEBI:methylglyoxal)
p(INTERPRO:"Triosephosphate isomerase", pmod(NO, Tyr, 208)) -> a(CHEBI:methylglyoxal)
UNSET Confidence

SET Evidence = "Taupositive material was present in the immunoprecipitates indicating that tau becomes associated to nitroTPI in an Ab dose-dependent
pattern (Fig. 5A).TPI and nitro-TPI were incubated with tau protein and samples were analysed by Atomic Force Microscopy (Fig. 7A–D) and TEM (Fig. 7F and G).
Abundant paired helical filament-like structures were found in samples containing nitro-TPI plus tau"
SET Confidence = "High"
p(HGNC:MAPT) -- p(INTERPRO:"Triosephosphate isomerase", pmod(NO))
p(HGNC:MAPT) partOf complex(p(HGNC:MAPT), p(INTERPRO:"Triosephosphate isomerase", pmod(NO)))
p(INTERPRO:"Triosephosphate isomerase", pmod(NO)) partOf complex(p(HGNC:MAPT), p(INTERPRO:"Triosephosphate isomerase", pmod(NO)))
a(CHEBI:"amyloid-beta") pos complex(p(HGNC:MAPT), p(INTERPRO:"Triosephosphate isomerase", pmod(NO)))
complex(p(HGNC:MAPT), p(INTERPRO:"Triosephosphate isomerase", pmod(NO))) partOf a(GO:"neurofibrillary tangle")
UNSET Method
UNSET Confidence

SET Citation = {"PubMed", "18494933"}
SET Cell_Line = "neural stem cell"
SET Method = {"Western Blot", "Electrophoretic Mobility Shift Assay", "RT-PCR", "Immunofluorescence", "RNA Interference, siRNA"}
SET Evidence = "Collectively, these studies demonstrate that the soluble, astroglial-derived S100B protein interacts with RAGE leading to the JNK phosphorylation
and the pJNK-dependent up-regulation of c-Jun, a component of the AP-1 complex."
SET Confidence = "Medium"
complex(p(HGNC:AGER),p(HGNC:S100B)) -> p(FPLX:JNK, pmod(Ph))
p(FPLX:JNK, pmod(Ph)) -> act(p(HGNC:MAPK8))
p(HGNC:JUN) partOf p(FPLX:AP1)
UNSET Confidence

SET Evidence = "In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression
of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3-beta phosphorylation and beta-catenin degradation, causing canonical Wnt pathway disruption and tau protein hyperphosphorylation."
SET Confidence = "Medium"
p(HGNC:S100B) -> act(p(FPLX:JNK))
act(p(FPLX:JNK)) -> p(HGNC:DKK1)
p(HGNC:DKK1) -> kin(p(HGNC:GSK3B))
p(HGNC:DKK1) pos deg(p(HGNC:CTNNB1))
p(HGNC:S100B) -| bp(GO:"Wnt signaling pathway")
p(HGNC:S100B) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
kin(p(HGNC:GSK3B)) => p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
UNSET Confidence
UNSET Method
UNSET Cell_Line


SET Citation = {"PubMed", "17082178"}
SET Evidence = "Acrolein and methylglyoxal were the most reactive compounds followed by glyoxal and malondialdehyde in terms of formation of Tau dimers and higher molecular weight oligomers.
Analysis of the Tau aggregates by electron microscopy study showed that formation of fibrils using wild-type Tau and several Tau mutants could be observed
with acrolein and methylglyoxal but not with glyoxal and malondialdehyde."
SET Confidence = "Medium"
SET Method = {"Western Blot", "SDS-PAGE", "Thioflavin T Assay", "Electron Microscopy"}
a(CHEBI:acrolein) -> complex(p(HGNC:MAPT),p(HGNC:MAPT))
a(CHEBI:acrolein) -> a(HBP:"Tau oligomers")
a(CHEBI:acrolein) -> a(GO:"neurofibrillary tangle")
a(CHEBI:methylglyoxal) -> a(GO:"neurofibrillary tangle")
a(CHEBI:methylglyoxal) -> complex(p(HGNC:MAPT),p(HGNC:MAPT))
a(CHEBI:methylglyoxal) -> a(HBP:"Tau oligomers")
a(CHEBI:glyoxal) -> complex(p(HGNC:MAPT),p(HGNC:MAPT))
a(CHEBI:glyoxal) -> a(HBP:"Tau oligomers")
a(CHEBI:glyoxal) cnc a(GO:"neurofibrillary tangle")
a(CHEBI:malonaldehyde) -> complex(p(HGNC:MAPT),p(HGNC:MAPT))
a(CHEBI:malonaldehyde) -> a(HBP:"Tau oligomers")
a(CHEBI:malonaldehyde) cnc a(GO:"neurofibrillary tangle")
UNSET Method
UNSET Confidence


SET Citation = {"PubMed", "16630055"}
SET Evidence = "We recently discovered that the human brain tau is also modified by O-GlcNAcylation in addition to phosphorylation and that O-GlcNAcylation
modulates phosphorylation of tau inversely (Liu et al.,2004a). We found that fasting induced a time-dependent decrease in tau O-GlcNAcylation and
concurrent hyperphosphorylation of tau at most of the phosphorylation sites studied."
SET Confidence = "Medium"
SET MeSHAnatomy = "Brain"
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) neg p(HGNC:MAPT, pmod(Ph))
UNSET MeSHAnatomy
SET Species = "10090"
SET Method = {"Western Blot", "Immunohistochemistry"}
path(MESH:Fasting) -| p(MGI:Mapt, pmod(HBP:"O-GlcNAcylation"))
path(MESH:Fasting) -> p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
UNSET Method
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "8063802"}
SET Evidence = "Glycation by AGE (Advanced Glycation End products) decreases MT binding, promotes aggregation, activates RAGE"
SET Confidence = "Medium"
a(CHEBI:"advanced glycation end-product") -| complex(p(HGNC:MAPT),a(GO:microtubule))
a(CHEBI:"advanced glycation end-product") -> a(HBP:"Tau aggregates")
a(CHEBI:"advanced glycation end-product") -> act(p(HGNC:AGER))
UNSET Confidence

#####################################################################################Tau Polyamination##################################################################################


SET Citation = {"PubMed", "12578227"}
SET Evidence = "Protein and mRNA levels of transglutaminase 1 were increased in globus pallidus of PSP as compared to controls.
There were also significantly higher mRNA levels of the short form of transglutaminase 2 in globus pallidus of PSP (974% of control).
Transglutaminase 1 mRNA and the long isoform of transglutaminase 2 mRNA (2212% of control) were significantly higher in PSP in the dentate of cerebellum.
Together, these findings suggest that transglutaminase 1 and 2 enzymes may be involved in the formation and/or stabilization of neurofibrillary tangles in selectively vulnerable brain regions in PSP.
These transglutaminases may be potential targets for therapeutic intervention."
SET Confidence = "Medium"
SET Anatomy = "globus pallidus"
path(MESH:"Supranuclear Palsy, Progressive") -> p(HGNC:TGM1)
path(MESH:"Supranuclear Palsy, Progressive") -> r(HGNC:TGM1)
path(MESH:"Supranuclear Palsy, Progressive") -> r(HBP:"TGM2 Isoform 3 (349 aa)")
r(HBP:"TGM2 Isoform 3 (349 aa)") isA r(HGNC:TGM2)
SET Anatomy = "dentate nucleus"
path(MESH:"Supranuclear Palsy, Progressive") -> r(HGNC:TGM1)
path(MESH:"Supranuclear Palsy, Progressive") -> r(HGNC:TGM2)
UNSET Anatomy
SET MeSHDisease = "Supranuclear Palsy, Progressive"
p(HGNC:TGM1) pos a(GO:"neurofibrillary tangle")
p(HGNC:TGM2) pos a(GO:"neurofibrillary tangle")
p(HGNC:TGM1) isA p(ECCODE:"2.3.2.13")
p(HGNC:TGM2) isA p(ECCODE:"2.3.2.13")
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "11089576"}
SET Evidence = "There were significantly higher levels of epsilon-(gamma-glutamyl) lysine cross-linking of PHF-tau in globus pallidus and pons regions of PSP cases compared to barely detectable cross-links in controls.
The occipital cortex, an area spared from neurofibrillary pathology in PSP, showed no detectable cross-linking of PHF-tau protein in either PSP cases or control cases.
Double-label immunofluorescence demonstrated the colocalization of the cross-link and PHF-tau in NFT in pons of PSP
Previous studies and present data are consistent with the hypothesis that transglutaminase-induced cross-linking may be a factor contributing to the abnormal polymerization
and stabilization of tau in straight and PHFs leading to neurofibrillary tangle formation in neurodegenerative diseases, including PSP and AD."
SET Confidence = "Medium"
SET Anatomy = {"globus pallidus","pons"}
path(MESH:"Supranuclear Palsy, Progressive") pos act(p(ECCODE:"2.3.2.13"))
act(p(ECCODE:"2.3.2.13")) pos a(GO:"neurofibrillary tangle")
a(GO:"neurofibrillary tangle") pos path(MESH:"Supranuclear Palsy, Progressive")
a(GO:"neurofibrillary tangle") pos path(MESH:"Alzheimer Disease")
UNSET Anatomy
UNSET Confidence


SET Citation = {"PubMed", "11738469"}
SET Evidence = "The number of neurons that are immunoreactive with an antibody directed at the epsilon-(gamma-glutamyl)lysine bond was significantly higher in AD cortex
compared with age-matched controls and schizophrenics. PHF tau-directed antibodies AT8, MC-1 and PHF-1 co-localized with epsilon(gamma-glutamyl)lysine immunolabeling in AD NFT.
Immunoaffinity purification and immunoblotting experiments demonstrated that PHF tau contains epsilon(gamma-glutamyl)lysine bonds in parietal and frontal cortex in AD.
In control cases with NFT present in the entorhinal cortex and hippocampus, indicative of Braak and Braak stage II, epsilon(gamma-glutamyl)lysine bonds were present in PHF tau
in parietal and frontal cortex, despite the lack of microscopically detectable NFT or senile plaques in these cortical regions.
The presence of PHF tau with epsilon(gamma-glutamyl)lysine bonds in brain regions devoid of NFT in stage II (but regions, which would be expected to contain NFT in stage III)
suggests that these bonds occur early in the formation of NFT."
SET Confidence = "High"
SET Method = {"Immunoaffinity purification", "Immunoblotting", "Fluorescence Microscopy", "Confocal Microscopy"}
SET Disease = "Alzheimer's disease"
SET Anatomy = {"parietal cortex","frontal cortex"}
path(MESH:"Alzheimer Disease") pos act(p(ECCODE:"2.3.2.13"))
act(p(ECCODE:"2.3.2.13")) pos a(GO:"neurofibrillary tangle")
UNSET Disease
SET Braak_Stage = {"Stage I", "Stage II"}
SET Anatomy = {"entorhinal cortex", "hippocampal formation"}
act(p(ECCODE:"2.3.2.13")) pos a(GO:"neurofibrillary tangle")
UNSET Anatomy
UNSET Braak_Stage
UNSET Method
UNSET Confidence


SET Citation = {"PubMed", "9099822"}
SET Evidence = "Total transglutaminase activity was significantly higher in the Alzheimer's disease prefrontal cortex compared to control.
In addition the levels of tissue transglutaminase, as determined by quantitative immunoblotting, were elevated approximately 3-fold in Alzheimer's disease prefrontal cortex compared to control.
To our knowledge, this is the first demonstration that transglutaminase is increased in Alzheimer's disease brain.
There were no significant differences in transglutaminase activity or levels in the cerebellum between control and Alzheimer's disease cases.
Because the elevation of transglutaminase in the Alzheimer's disease samples occurred in the prefrontal cortex, where neurofibrillary pathology is usually abundant,
and not in the cerebellum, which is usually spared in Alzheimer's disease, it can be suggested that transglutaminase could be a contributing factor in neurofibrillary tangle formation."
SET Confidence = "Medium"
SET Method = {"Transglutaminase Assay", "Immunoblotting"}
SET Disease = "Alzheimer's disease"
SET Anatomy = "prefrontal cortex"
path(MESH:"Alzheimer Disease") -> act(p(HGNCGENEFAMILY:Transglutaminases))
act(p(HGNCGENEFAMILY:Transglutaminases)) pos a(GO:"neurofibrillary tangle")
UNSET Anatomy
UNSET Disease
UNSET Method
UNSET Confidence


SET Citation = {"PubMed", "8985134"}
SET Evidence = "Degenerating neurons from the AD hippocampus, compared to neurons from the normal aged hippocampus, exhibited increased immunoreactivity for TGase and demonstrated
co-labeling for PHF1 and anti-TGase. Our results suggest that TGase may be associated with the neurofibrillary degeneration observed in AD, thereby implicating TGase as a potential factor
in the pathogenesis of Alzheimer's disease."
SET Confidence = "High"
SET Disease = "Alzheimer's disease"
SET Anatomy = "hippocampal formation"
path(MESH:"Alzheimer Disease") pos act(p(ECCODE:"2.3.2.13"))
act(p(ECCODE:"2.3.2.13")) pos a(GO:"neurofibrillary tangle")
UNSET Anatomy
UNSET Disease
UNSET Confidence


SET Citation = {"PubMed", "10537045"}
SET Evidence = "For these studies, SH-SY5Y cells stably overexpressing tTG were used. tTG coimmunoprecipitated with tau, and elevating intracellular calcium levels with maitotoxin
resulted in a 52 +/- 4% increase in the amount of tTG that coimmunoprecipitated with tau. The increase in association of tTG with tau after treatment with maitotoxin corresponded
to a coimmunolocalization of tTG, tTG activity, and tau in the cells. Further, tau was modified by tTG in situ in response to maitotoxin treatment.
In vitro polyaminated tau was significantly less susceptible to micro-calpain proteolysis; however, tTG-mediated polyamination of tau did not significantly alter the microtubule-binding capacity of tau."
SET Confidence = "High"
SET Cell_Line = "SH-SY5Y"
p(HGNC:TGM2) pos p(HGNC:MAPT)
p(HGNC:TGM2) partOf complex(p(HGNC:TGM2), p(HGNC:MAPT))
p(HGNC:MAPT) partOf complex(p(HGNC:TGM2), p(HGNC:MAPT))
a(HBP:maitotoxin) -> a(CHEBI:"calcium(2+)")
a(CHEBI:"calcium(2+)") pos complex(p(HGNC:TGM2), p(HGNC:MAPT))
a(HBP:maitotoxin) -> act(p(HGNC:TGM2))
act(p(HGNC:TGM2)) -- a(HBP:"microtubule-binding region")
a(HBP:"microtubule-binding region") partOf p(HGNC:MAPT)
UNSET Cell_Line
UNSET Confidence

####################################################################################Tau Nitration#######################################################################################


SET Citation = {"PubMed", "22057784"}
SET Evidence = "Tau-nY18 did not label the classical pathological lesions of CBD or PSP but did label the neuronal lesions associated with PiD. Tau-nY29 revealed some, but not all classes of tau inclusions associated with both CBD and PSP but did label numerous Pick body inclusions in PiD.
Tau-nY197 was restricted to the neuropil threads in both CBD and PSP; however, similar to Tau-nY29, extensive Pick body pathology was clearly labeled. Tau-nY394 did not detect any of the lesions associated with these disorders."
SET Confidence = "High"
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) pos path(MESH:"Pick Disease of the Brain")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) pos path(MESH:"Pick Disease of the Brain")
SET Disease = "progressive supranuclear palsy"
SET HBP_Disease = "Corticobasal Degeneration"
SET Anatomy = "neuropil"
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) pos path(MESH:"Supranuclear Palsy, Progressive")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) pos path(HBP:"Corticobasal Degeneration")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) partOf a(MESH:"Neuropil Threads")
UNSET Anatomy
SET MeSHDisease = "Pick Disease of the Brain"
p(HGNC:MAPT, pmod(NO, Tyr, 29)) pos path(MESH:"Pick Disease of the Brain")
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "18562203"}
SET Evidence = "This antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls,
suggesting that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation"
SET Confidence = "Medium"
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) -- act(a(MESH:Astrocytes))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) pos path(MESH:"Plaque, Amyloid")
act(a(MESH:Astrocytes)) -- path(MESH:"Plaque, Amyloid")
UNSET Confidence

SET Citation = {"PubMed", "17050703"}
SET Evidence = "Tau-nY29 detects soluble tau and paired helical filament tau from severely affected Alzheimer's brain but fails to recognize tau from normal aged brain.
This observation suggests that nitration at Tyr29 is a disease-related event that may alter the intrinsic ability of tau to self-polymerize.
In Alzheimer's brain, Tau-nY29 labels the fibrillar triad of tau lesions, including neurofibrillary tangles, neuritic plaques, and, to a lesser extent, neuropil threads.
Intriguingly, although Tau-nY29 stains both the neuronal and glial tau pathology of Pick disease, it detects only the neuronal pathology in corticobasal degeneration and progressive supranuclear palsy without labeling the predominant glial pathology."
SET Confidence = "Medium"
SET Disease = "Alzheimer's disease"
SET MeSHAnatomy = "Brain"
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -- a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) pos bp(GO:"neurofibrillary tangle assembly")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) partOf path(MESH:"Plaque, Amyloid")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) partOf a(MESH:"Neuropil Threads")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -- path(HBP:"Corticobasal Degeneration")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -- path(MESH:"Supranuclear Palsy, Progressive")
UNSET MeSHAnatomy
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) isA p(HGNC:MAPT, pmod(HBP:nitration))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) isA p(HGNC:MAPT, pmod(HBP:nitration))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) isA p(HGNC:MAPT, pmod(HBP:nitration))
UNSET Confidence

SET Citation = {"PubMed", "21210655"}
SET Evidence = "PN-treated wild-type tau and 5XY→F tau consistently displayed lysine formylation throughout tau in a non-sequence specific
distribution. Lysine formylation likely results from reactive free radical exposure caused by PN treatment."
SET Confidence = "Medium"
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:formylation, Lys))
a(CHEBI:peroxynitrite) -> bp(MESH:"Nitrosative Stress")
bp(MESH:"Nitrosative Stress") -> p(HGNC:MAPT, pmod(HBP:formylation, Lys))
UNSET Confidence

SET Citation = {"PubMed", "17768677"}
SET Evidence = "It was possible to find nitrated Tyr 488 (numbers refer to mouse tau P10637 in the Swiss-Prot/ThEMBL data bank) which corresponds
to Tyr 507 in rat tau (Table 1) in accordance with the data reported above for tau in PC12 cells."
SET Confidence = "Medium"
SET ExpMethod = {"in vivo"}
SET Species = "10116"
p(RGD:Mapt, pmod(HBP:nitration, Tyr, 507)) partOf a(MESH:Brain)
UNSET Species
UNSET ExpMethod
UNSET Confidence

SET Citation = {"PubMed", "16816118"}
SET Evidence = "In the present study we injected bilaterally 3-morpholino-sydnonimine (SIN-1), a recognized and widely used peroxynitrite donor (25–30), into rat hippocampus,
and investigated whether or not peroxynitrite could induce simultaneously nitration and hyperphosphorylation of tau and the underlying mechanisms in vivo.
The level of nitrated and hyperphosphorylated tau was markedly increased in rat hippocampus 24 h, and prevented by preinjection of uric acid, a natural scavenger of
peroxynitrite. GSK-3beta and p38 MAPKs, including p38alpha, p38beta, and p38delta activity was increased, but no change in the activity of p38gamma, ERK, and c-Jun amino-terminal kinase (JNK).
Both nitrated tau and hyperphosphorylated tau were aggregated in the hippocampus, with activity of 20S proteasome significantly arrested in SIN-1-injected rats.
Hyperphosphorylated tau was degraded as efficiently as normal tau by 20S proteasome, but the nitrated tau with an unorderly secondary structure became more resistant to the proteolysis,
providing evidence that peroxynitrite simultaneously induces tau hyperphosphorylation, nitration, and accumulation, and that activation of GSK-3beta, p38alpha, p38beta, p38delta isoforms
and the inhibition of proteasome activity are respectively responsible for the peroxynitrite-induced tau hyperphosphorylation and accumulation."
SET Confidence = "Medium"
SET ExpMethod = {"in vivo"}
SET Species = "10116"
SET Anatomy = "hippocampal formation"
a(CHEBI:linsidomine) -> a(CHEBI:peroxynitrite)
a(CHEBI:peroxynitrite) -> p(RGD:Mapt, pmod(HBP:hyperphosphorylation))
a(CHEBI:peroxynitrite) -> p(RGD:Mapt, pmod(HBP:nitration))
a(CHEBI:"uric acid") -| p(RGD:Mapt, pmod(HBP:hyperphosphorylation))
a(CHEBI:"uric acid") -| p(RGD:Mapt, pmod(HBP:nitration))
a(CHEBI:"uric acid") -| act(a(CHEBI:peroxynitrite))
a(CHEBI:peroxynitrite) -> act(p(RGD:Gsk3b))
a(CHEBI:peroxynitrite) -> act(p(RGD:Mapk14))
a(CHEBI:peroxynitrite) -> act(p(RGD:Mapk11))
a(CHEBI:peroxynitrite) -> act(p(RGD:Mapk13))
a(CHEBI:peroxynitrite) cnc act(p(RGD:Mapk12))
a(CHEBI:peroxynitrite) cnc act(p(FPLX:ERK))
a(CHEBI:peroxynitrite) cnc act(p(FPLX:JNK))
p(RGD:Mapt, pmod(HBP:hyperphosphorylation)) -> a(HBP:"Tau aggregates")
p(RGD:Mapt, pmod(HBP:nitration)) -> a(HBP:"Tau aggregates")
a(CHEBI:linsidomine) -| act(p(HBP:"20 S Proteasome"))
act(p(HBP:"20 S Proteasome")) -> deg(p(RGD:Mapt, pmod(HBP:hyperphosphorylation)))
act(p(HBP:"20 S Proteasome")) -> deg(p(RGD:Mapt))
a(CHEBI:peroxynitrite) -> a(HBP:"Tau aggregates")
UNSET Anatomy
UNSET Species
UNSET ExpMethod
UNSET Confidence

SET Citation = {"PubMed", "16566606"}
SET Evidence = "During Abeta-associated inflammation, reactive nitrogen and oxygen species are generated that can cause neuronal dysfunction and death (34-37).
Prevalent among these species is peroxynitrite (ONOO-)"
SET Confidence = "Medium"
a(CHEBI:"amyloid-beta") -> bp(GO:"inflammatory response")
a(CHEBI:"amyloid-beta") -> a(CHEBI:"reactive nitrogen species")
bp(GO:"inflammatory response") -> a(CHEBI:"reactive nitrogen species")
a(CHEBI:"reactive nitrogen species") -| act(a(MESH:Neurons))
a(CHEBI:"reactive nitrogen species") -> bp(GO:"neuron death")
a(CHEBI:"amyloid-beta") -> a(CHEBI:"reactive oxygen species")
bp(GO:"inflammatory response") -> a(CHEBI:"reactive oxygen species")
a(CHEBI:"reactive oxygen species") -| act(a(MESH:Neurons))
a(CHEBI:"reactive oxygen species") -> bp(GO:"neuron death")
bp(GO:"inflammatory response") -> a(CHEBI:peroxynitrite)
UNSET Confidence

SET Evidence = "Select nitration of residues Tyr18, Tyr29, Tyr197, and Tyr394, events known to stabilize the pathological Alz-50 conformation inhibits the ability of monomeric tau
to promote tubulin assembly, effect specific for the 3-NT modification, as mutant tau proteins pseudophosphorylated at each Tyr residue are fully competent to stabilize MTs,
suggesting that ONOO(-)-mediated modifications stabilize tau filaments via 3,3'-DT bonding and destabilize MTs by site-selective nitration of tau monomers."
SET Confidence = "Medium"
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) -| bp(GO:"microtubule polymerization")
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) -| bp(GO:"microtubule polymerization")
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) -| bp(GO:"microtubule polymerization")
a(CHEBI:peroxynitrite) -> p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 394))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 394)) -| bp(GO:"microtubule polymerization")
p(HGNC:MAPT) -> bp(GO:"microtubule polymerization")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 394)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 18)) neg act(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 29)) neg act(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(HBP:nitration, Tyr, 197)) neg act(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(Ph, Tyr, 394)) neg act(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(Ph, Tyr, 18)) pos a(GO:microtubule)
p(HGNC:MAPT, pmod(Ph, Tyr, 29)) pos a(GO:microtubule)
p(HGNC:MAPT, pmod(Ph, Tyr, 197)) pos a(GO:microtubule)
p(HGNC:MAPT, pmod(Ph, Tyr, 394)) pos a(GO:microtubule)
a(CHEBI:peroxynitrite) -> a(HBP:"3-3' dityrosine cross-linking")
a(HBP:"3-3' dityrosine cross-linking") pos a(HBP:"paired helical filaments")
UNSET Confidence

####################################################################################Tau Hyperphosphorylation############################################################################

SET Citation = {"PubMed", "27796283"}
SET Evidence = "Rac1 and RhoA are the best-studied members that regulate spine dynamics; their activation facilitates and prevents dendritic spine formation, respectively"
SET Confidence = "Medium"
act(p(HGNC:RHOA)) reg bp(GO:"dendritic spine development")
act(p(HGNC:RAC1)) reg bp(GO:"dendritic spine development")
bp(GO:"dendritic spine development") pos a(MESH:"Dendritic Spines")
UNSET Confidence

SET Evidence = "CaMKs functionally link NMDA (N-methyl-d-aspartate) receptors to Rac1 activation via the phosphorylation of specific guanine nucleotide exchange factors (GEFs)
such as Kalirin-7, TIAM1 and β-PIX"
SET Confidence = "High"
a(MESH:"Receptors, N-Methyl-D-Aspartate") -> act(p(HGNC:RAC1))
a(MESH:"Receptors, N-Methyl-D-Aspartate") -> p(HGNC:TIAM1, pmod(Ph))
p(HGNC:TIAM1, pmod(Ph)) -> act(p(HGNC:RAC1))
p(HGNC:CAMK2B) -> p(HBP:"Kalirin 7", pmod(Ph, Thr, 95))
p(HBP:"Kalirin 7", pmod(Ph, Thr, 95)) -> act(p(HBP:"Kalirin 7"))
act(p(HBP:"Kalirin 7")) -> act(p(HGNC:RAC1))
p(HGNC:CAMK1) -> p(HGNC:ARHGEF7, pmod(Ph, Ser, 516))
p(HGNC:ARHGEF7, pmod(Ph, Ser, 516)) -> act(p(HGNC:ARHGEF7))
act(p(HGNC:ARHGEF7)) -> act(p(HGNC:RAC1))
UNSET Confidence

SET Evidence = "In contrast, much less is known about how RhoA is regulated by excitatory glutamate receptors. The Rho-GEF Lfc (also known as GEF-H1) is one notable link between
RhoA activity and glutamate receptors18. Lfc is inhibited by AMPA receptors; Lfc and RhoA inhibition is implicated in spine maintenance10. RhoA hyperactivity can lead
to spine loss and impaired synaptic function."
SET Confidence = "Medium"
complex(GO:"AMPA glutamate receptor complex") -| act(p(HGNC:ARHGEF2))
act(p(HGNC:ARHGEF2)) -- act(p(HGNC:RHOA))
act(p(HGNC:ARHGEF2)) -- complex(GO:"AMPA glutamate receptor complex")
complex(GO:"AMPA glutamate receptor complex") reg act(p(HGNC:RHOA))
act(p(HGNC:ARHGEF2)) reg a(MESH:"Dendritic Spines")
act(p(HGNC:RHOA)) neg a(MESH:"Dendritic Spines")
act(p(HGNC:RHOA)) neg act(a(GO:synapse))
UNSET Confidence

SET Evidence = "These observations suggest that CaMKv blocks RhoA activity by preventing its interaction with Lfc. These results demonstrate that CaMKv regulates spine maintenance through RhoA inhibition.
The suppression of the Lfc/RhoA pathway by AMPA receptors is implicated in dendritic spine maintenance10. Given that CaMKv expression is upregulated by synaptic activity,
CaMKv may be a key signalling protein that transduces the signals from AMPA receptors to suppress RhoA during activity-dependent spine maintenance.
Corroborating this, the AMPA receptor blocker NBQX attenuated CaMKv expression in neurons (Fig. 3i,j).
Importantly, CaMKv overexpression completely rescued NBQX-induced spine loss (Fig. 3k,l).
These findings collectively reveal that activity-dependent CaMKv expression and the subsequent inhibition of Lfc/RhoA are required to mediate AMPA receptor function in spine maintenance."
SET Confidence = "Medium"
act(p(HGNC:CAMKV)) -| complex(p(HGNC:RHOA), p(HGNC:ARHGEF2))
complex(p(HGNC:RHOA), p(HGNC:ARHGEF2)) pos act(p(HGNC:RHOA))
act(p(HGNC:CAMKV)) -| act(p(HGNC:RHOA))
a(GO:synapse) reg p(HGNC:CAMKV)
p(HGNC:CAMKV) pos a(MESH:"Dendritic Spines")
act(p(HGNC:CAMKV)) reg a(MESH:"Dendritic Spines")
act(p(HGNC:ARHGEF2)) reg a(MESH:"Dendritic Spines")
act(p(HGNC:RHOA)) reg a(MESH:"Dendritic Spines")
UNSET Confidence

SET Evidence = "However, co-expression of the phospho-mimetic T345E failed to restore the defects in spine density after CaMKv depletion (Fig. 4l,m),
suggesting that CaMKv phosphorylation by Cdk5 at Thr345 inhibits its function."
SET Confidence = "High"
p(HGNC:CDK5) -> p(HGNC:CAMKV, pmod(Ph, Thr, 345))
p(HGNC:CAMKV, pmod(Ph, Thr, 345)) -| act(p(HGNC:CAMKV))
UNSET Confidence

SET Evidence = "These findings suggest that CaMKv is required for both synaptic transmission and protein synthesis-dependent LTP in the hippocampus."
SET Confidence = "Medium"
SET MeSHAnatomy = "Hippocampus"
p(HGNC:CAMKV) reg bp(GO:"neuron-neuron synaptic transmission")
p(HGNC:CAMKV) -- bp(MESH:"Long-Term Potentiation")
UNSET MeSHAnatomy
UNSET Confidence

SET Citation = {"PubMed", "29121589"}
SET Evidence = "NRF2 is regulated principally by two different mechanisms. The best established mechanism is the control of protein stability by Kelch-like ECH-associated protein 1 (KEAP1).
KEAP1 is an ubiquitin E3 ligase substrate adapter for a Cullin3/Rbx1-dependent E3 ubiquitin ligase complex; henceforth binding of KEAP1 to NRF2 mediates ubiquitination and subsequent
proteasomal degradation of NRF2 [7]."
SET Confidence = "Medium"
p(HGNC:KEAP1) -> complex(p(HGNC:KEAP1), p(HGNC:NFE2L2), p(HGNC:CUL3))
p(HGNC:NFE2L2) partOf complex(p(HGNC:KEAP1), p(HGNC:NFE2L2), p(HGNC:CUL3))
p(HGNC:CUL3) partOf complex(p(HGNC:KEAP1), p(HGNC:NFE2L2), p(HGNC:CUL3))
complex(p(HGNC:KEAP1), p(HGNC:NFE2L2), p(HGNC:CUL3)) reg p(HGNC:NFE2L2, pmod(Ub))
p(HGNC:NFE2L2, pmod(Ub)) reg deg(p(HGNC:NFE2L2))
complex(p(HGNC:KEAP1), p(HGNC:NFE2L2), p(HGNC:CUL3)) reg deg(p(HGNC:NFE2L2))
UNSET Confidence

SET Evidence = "The second mechanism is related to GSK-3, which phosphorylates NRF2 creating a recognition site for β-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (β-TrCP).
β-TrCP leads to Cullin-1/Rbx1-mediated NRF2 ubiquitination and its subsequent degradation [8]. Since GSK-3β is inhibited by phosphorylation at Ser9 by Ser/Thr protein kinases such as AKT,
it has been suggested that NRF2 might be up-regulated through activation of AKT and permanent inactivation of GSK-3 [9], [10]."
SET Confidence = "Medium"
p(HGNC:GSK3B) -> p(HGNC:NFE2L2, pmod(Ph))
p(HGNC:BTRC) -> complex(p(HGNC:NFE2L2, pmod(Ph)), p(HGNC:BTRC), p(HGNC:CUL1))
p(HGNC:NFE2L2, pmod(Ph)) partOf complex(p(HGNC:NFE2L2, pmod(Ph)), p(HGNC:BTRC), p(HGNC:CUL1))
p(HGNC:CUL1) partOf complex(p(HGNC:NFE2L2, pmod(Ph)), p(HGNC:BTRC), p(HGNC:CUL1))
complex(p(HGNC:NFE2L2, pmod(Ph)), p(HGNC:BTRC), p(HGNC:CUL1)) -> p(HGNC:NFE2L2, pmod(Ub))
complex(p(HGNC:NFE2L2, pmod(Ph)), p(HGNC:BTRC), p(HGNC:CUL1)) deg(p(HGNC:NFE2L2))
p(FPLX:AKT) -> p(HGNC:GSK3B, pmod(Ph, Ser, 9))
p(HGNC:GSK3B, pmod(Ph, Ser, 9)) -| kin(p(HGNC:GSK3B))
p(FPLX:AKT) pos p(HGNC:NFE2L2)
act(p(HGNC:GSK3B)) neg p(HGNC:NFE2L2)

p(HGNC:BTRC) isA p(ECCODE:"2.3.2.27")
p(HGNC:KEAP1) isA p(ECCODE:"2.3.2.27")
UNSET Confidence

SET Species = "10090"
SET Evidence = "Wild-type MEFs treated with DMF (20 μM) showed a time-dependent response effect activating phosphorylation of ERK (Fig. 2A, B) and p38 (Fig. 2A, C), that was maximal within 5 min.
The Ser/Thr protein kinase AKT, an upstream regulator of GSK-3β, was also activated after 5 min as determined by increased phosphorylation of S473 (Fig. 2A, D)"
SET Confidence = "Medium"
a(CHEBI:"dimethyl fumarate") -> p(FPLX:ERK,pmod(Ph))
p(FPLX:ERK,pmod(Ph)) -> act(p(FPLX:ERK))
a(CHEBI:"dimethyl fumarate") -> p(FPLX:p38,pmod(Ph))
p(FPLX:p38,pmod(Ph)) -> act(p(FPLX:p38))
a(CHEBI:"dimethyl fumarate") pos p(FPLX:AKT, pmod(Ph, S, 473))
p(FPLX:AKT, pmod(Ph, S, 473)) -> act(p(FPLX:AKT))
p(FPLX:AKT) reg act(p(MGI:Gsk3b))
UNSET Confidence

SET Anatomy = "hippocampal formation"
SET Evidence = "DMF increased the phosphorylation levels of GSK-3βSer9 in both genotypes, indicating that this effect is upstream of NRF2 as shown in Fig. 3A."
SET Confidence = "Medium"
a(CHEBI:"dimethyl fumarate") -> p(MGI:Gsk3b, pmod(Ph, Ser, 9))
UNSET Anatomy
UNSET Confidence

SET Evidence = "Taken together, our results show that DMF reduces GSK-3 activity in vivo as determined by a significant and subtle reduction in the phosphorylation levels of its two substrates TAU and CRMP2 respectively."
SET Confidence = "Medium"
a(CHEBI:"dimethyl fumarate") -| act(p(MGI:Gsk3b))
a(CHEBI:"dimethyl fumarate") -| p(MGI:Mapt, pmod(Ph))
a(CHEBI:"dimethyl fumarate") -| p(MGI:Dpysl2, pmod(Ph))
kin(p(MGI:Gsk3b)) => p(MGI:Dpysl2, pmod(Ph))
kin(p(MGI:Gsk3b)) => p(MGI:Mapt, pmod(Ph))
UNSET Confidence

SET Evidence = "Astrocytes displayed enlarged bodies and ramifications (Type B morphology), consistent with a reactive state after TAUP301L expression in Nrf2+/+ and Nrf2−/− mice (Fig. 6A left panels). However, only astrocytes from Nrf2+/+ mice treated with DMF were maintained in a resting morphology (Type A) (Fig. 6A right panels).
Concerning microglia, TAUP301L expression induced a very significant increase in IBA1+ microglia at the ipsilateral hippocampal side of Nrf2+/+ and Nrf2−/− mice  (Fig. 7A), which was confirmed by stereological quantification (Fig. 7B).
DMF treatment reduced significantly this microgliosis in Nrf2+/+ but not in Nrf2−/− mice, reinforcing the idea of NRF2-dependent anti-inflammatory effect"
SET Confidence = "Medium"
p(MGI:Mapt, var("p.Pro301Leu")) -> a(HBP:Astrogliosis)
p(MGI:Mapt, var("p.Pro301Leu")) -> a(HBP:"Microgliosis")
a(CHEBI:"dimethyl fumarate") -| a(HBP:Astrogliosis)
a(CHEBI:"dimethyl fumarate") -| a(HBP:"Microgliosis")
p(MGI:Nfe2l2) -| bp(GO:"inflammatory response")
UNSET Confidence

SET Evidence = "Messenger RNA analysis of two pro-inflammatory markers such as IL-1β and inducible nitric oxide synthase (iNOS)
indicate that TAUP301L expression induce Il-1β (Fig. 6D) and iNOS (Fig. 7D) mRNA expression in both genotypes and DMF treatment
decreased this expression only in Nrf2+/+ mice."
SET Confidence = "High"
a(CHEBI:"dimethyl fumarate") -| r(MGI:Il1b)
a(CHEBI:"dimethyl fumarate") -| r(MGI:Nos2)
p(HGNC:MAPT, var("p.Pro301Leu")) -> r(MGI:Il1b)
p(HGNC:MAPT, var("p.Pro301Leu")) -> r(MGI:Nos2)
r(MGI:Il1b) biomarkerFor bp(GO:"inflammatory response")
r(MGI:Nos2) biomarkerFor bp(GO:"inflammatory response")
a(CHEBI:"dimethyl fumarate") -| bp(GO:"inflammatory response")
UNSET Confidence
UNSET Species


SET Citation = {"PubMed", "27807169"}
SET Evidence = "p39, but not p35, is selectively upregulated by histone acetylation-mediated transcription, underlying the robust increase
of Cdk5 activity during rat and mouse neuronal differentiation. Loss of p39 attenuates Cdk5 activity in neurons and preferentially affects
phosphorylation of specific Cdk5 targets, leading to aberrant axonal growth and impaired dendritic spine and synapse formation."
SET Confidence = "Medium"
SET Species = "10116"
bp(GO:"histone acetylation") -> p(RGD:Cdk5r2)
bp(GO:"neuron differentiation") pos act(p(RGD:Cdk5))
SET MeSHAnatomy = "Neurons"
p(RGD:Cdk5r2) => act(p(RGD:Cdk5))
UNSET MeSHAnatomy
p(RGD:Cdk5r2) pos a(GO:"dendritic spine")
p(RGD:Cdk5r2) pos a(GO:axon)
p(RGD:Cdk5r2) pos bp(GO:"synapse assembly")
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "7514173"}
SET Evidence = "Vm (nM/min/mg) is 2400, 80, 106, 650, and 140; Km is 200, 59, 114, 16 (all uM) and 5mg/ml for phospho-CREB peptide, myelin basic protein, k-casein, phosphatase Inhibitor-2 and phosvitin"
SET Confidence = "High"
SET Vmax = "2400 nM/min/mg"
SET Km = "200 μM"
kin(p(HGNC:GSK3B)) -> p(FPLX:CREB, pmod(Ph))
SET Vmax = "80 nM/min/mg"
SET Km = "59 μM"
kin(p(HGNC:GSK3B)) -> p(HGNC:MBP, pmod(Ph))
SET Vmax = "106 nM/min/mg"
SET Km = "114 μM"
kin(p(HGNC:GSK3B)) -> p(HGNC:CSN3, pmod(Ph))
SET Vmax = "140 nM/min/mg"
SET Km = "5 μM"
kin(p(HGNC:GSK3B)) -> p(HGNC:PPP1R2, pmod(Ph))
SET Vmax = "650 nM/min/mg"
SET Km = "16 μM"
kin(p(HGNC:GSK3B)) -> p(HGNC:CSNK2B, pmod(Ph))
UNSET Vmax
UNSET Km

SET IC50 = "50 mM"
a(CHEBI:"glycerol 2-phosphate") -| kin(p(HGNC:GSK3B))
SET IC50 = "0.2 mM"
a(CHEBI:"diethyl pyrocarbonate") -| kin(p(HGNC:GSK3B))
SET IC50 = "0.6 mM"
a(CHEBI:"pyridoxal 5'-phosphate") -| kin(p(HGNC:GSK3B))
SET IC50 = "2 mM"
a(CHEBI:"Phenylglyoxal") -| kin(p(HGNC:GSK3B))
SET IC50 = "0.4 mg/ml"
a(CHEBI:"poly(lysine) polymer") -| kin(p(HGNC:GSK3B))
SET IC50 = "160 mM"
a(CHEBI:"sodium chloride") -| kin(p(HGNC:GSK3B))
SET IC50 = "35 mM"
a(CHEBI:"sodium fluoride") -| kin(p(HGNC:GSK3B))
SET IC50 = "0.4 mM"
a(CHEBI:"manganese(II) chloride") -| kin(p(HGNC:GSK3B))
SET IC50 = "4.5 mM"
a(CHEBI:"calcium dichloride") -| kin(p(HGNC:GSK3B))
UNSET IC50
UNSET Confidence


SET Citation = {"PubMed", "17078951"}
SET Evidence = "Here, we found that prephosphorylation by PKA promotes GSK-3beta-catalyzed tau phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422,
but inhibits its phosphorylation at Thr212 and Ser404. In contrast, the prephosphorylation had no significant effect on its subsequent phosphorylation by cdk5 at Thr181, Ser199, Thr205, Thr231 and Ser422;
inhibited it at Ser202, Thr212, Thr217 and Ser404; and slightly promoted it at Ser396."
SET Confidence = "Medium"
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 181))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 205))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 217))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 422))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 404))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 212))

p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Thr, 181))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Ser, 199))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Thr, 217))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Thr, 231))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Ser, 396))
p(FPLX:PKA) pos p(HGNC:MAPT, pmod(Ph, Ser, 422))

p(FPLX:PKA) neg p(HGNC:MAPT, pmod(Ph, Ser, 404))
p(FPLX:PKA) neg p(HGNC:MAPT, pmod(Ph, Thr, 212))


act(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(Ph, Thr, 181))
act(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
act(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(Ph, Thr, 205))
act(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
act(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(Ph, Ser, 422))

p(FPLX:PKA) -| p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(FPLX:PKA) -| p(HGNC:MAPT, pmod(Ph, Thr, 212))
p(FPLX:PKA) -| p(HGNC:MAPT, pmod(Ph, Thr, 217))
p(FPLX:PKA) -| p(HGNC:MAPT, pmod(Ph, Ser, 404))

p(FPLX:PKA) -> p(HGNC:MAPT, pmod(Ph, Ser, 396))

p(FPLX:PKA) reg act(p(HGNC:GSK3B))
p(FPLX:PKA) reg act(p(HGNC:CDK5))
UNSET Confidence


SET Citation = {"PubMed", "9089387"}
SET Evidence = "By using a yeast two hybrid system, TPKI was found to interact with pyruvate dehydrogenase (PDH), which is a key enzyme in the glycolytic pathway.
PDH was phosphorylated in vitro by TPKI to reduce the activity converting pyruvate into acetyl-CoA, which is required for acetylcholine synthesis."
#TPKI referes to Tau Protein Kinase (Family) I, which corresponds to GSK3B
SET Confidence = "Medium"
kin(p(HGNC:GSK3B)) -> p(FPLX:PDH, pmod(Ph))
p(FPLX:PDH, pmod(Ph)) neg act(p(FPLX:PDH, pmod(Ph)))
p(FPLX:PDH) partOf bp(GO:"canonical glycolysis")
p(HGNC:GSK3B) isA p(ECCODE:"2.7.11.26")
complex(p(HGNC:GSK3B),p(FPLX:PDH))
p(FPLX:PDH, pmod(Ph)) -| rxn(reactants(a(CHEBI:pyruvate)),products(a(CHEBI:"acetyl-CoA")))
a(CHEBI:"acetyl-CoA") -> a(CHEBI:acetylcholine)
UNSET Confidence


SET Citation = {"PubMed", "22102280"}
SET Evidence = "We report here that tideglusib inhibits GSK-3β irreversibly, as demonstrated by the lack of recovery in enzyme function after the unbound drug has been removed from
the reaction medium and the fact that its dissociation rate constant is non-significantly different from zero."
SET Confidence = "High"
SET Ki = "5 nM"
a(HBP:tideglusib) -| kin(p(HGNC:GSK3B))
UNSET Ki
UNSET Confidence

SET Evidence = "Inhibition caused by hypothemycin and tideglusib on a panel of selected human recombinant kinases"
SET Confidence = "High"
SET Ki = "210 nM"
a(CHEBI:hypothemycin) -| kin(p(HGNC:GSK3B))
UNSET Ki
UNSET Confidence

SET Evidence = "Alsterpaullone showed identical results with the wild-type and the mutant enzymes, demonstrating that its mechanism of inhibition is independent of the presence of the Cys-199 residue."
SET Confidence = "High"
SET Ki = "40 nM"
a(CHEBI:"alsterpaullone") -| kin(p(HGNC:GSK3B))
UNSET Ki
UNSET Confidence


SET Citation = {"PubMed", "11013232"}
SET Evidence = "We report here that indirubins are also powerful inhibitors (IC(50): 5-50 nm) of an evolutionarily related kinase, glycogen synthase kinase-3beta (GSK-3 beta)."
SET Confidence = "High"
SET IC50 = "5-50 nM"
a(HBP:indirubin) -| kin(p(HGNC:GSK3B))
UNSET IC50
UNSET Confidence


SET Citation = {"PubMed", "10998059"}
SET Evidence = "Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3beta.
Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3beta in Alzheimer's disease.
Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. "
SET Confidence = "Medium"
SET Ki = "4-80 nM"
a(CHEBI:"alsterpaullone") -| p(HGNC:MAPT, pmod(Ph))
a(CHEBI:"alsterpaullone") -| kin(p(HGNC:GSK3B))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph))
SET Species = "10090"
SET Anatomy = "striatum"
a(CHEBI:"alsterpaullone") -| kin(p(MGI:Cdk5))
a(CHEBI:"alsterpaullone") -| act(p(MGI:Cdk5r1))
kin(p(MGI:Cdk5)) -> p(MGI:Ppp1r1b, pmod(Ph))
act(p(MGI:Cdk5r1)) -> p(MGI:Ppp1r1b, pmod(Ph))
a(CHEBI:"alsterpaullone") -| p(MGI:Ppp1r1b, pmod(Ph))
UNSET Species
UNSET Ki
UNSET Confidence


SET Citation = {"PubMed", "8702879"}
SET Evidence = "The phosphorylation sites were determined to be Ser551 and Ser553 with Cdk5-p23, and Ser62, Ser67, and Ser551 with MAP kinase.
Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein
phosphorylated with Cdk5-p23."
SET Confidence = "Medium"
SET Duration = "2 hours"
SET Substrate_Concentration = "0.5 M"

act(p(HGNC:CDK5)) -> p(HGNC:SYN1, pmod(Ph, Ser, 551))
act(p(HGNC:CDK5)) -> p(HGNC:SYN1, pmod(Ph, Ser, 553))

UNSET Substrate_Concentration
UNSET Duration

act(p(FPLX:MAPK)) -> p(HGNC:SYN1, pmod(Ph, Ser, 62))
act(p(FPLX:MAPK)) -> p(HGNC:SYN1, pmod(Ph, Ser, 67))
act(p(FPLX:MAPK)) -> p(HGNC:SYN1, pmod(Ph, Ser, 551))

p(HGNC:SYN1, pmod(Ph, Ser, 62)) neg act(p(HGNC:SYN1))
p(HGNC:SYN1, pmod(Ph, Ser, 67)) neg act(p(HGNC:SYN1))
p(HGNC:SYN1, pmod(Ph, Ser, 551)) neg act(p(HGNC:SYN1))
act(p(HGNC:SYN1)) -> bp(GO:"actin filament bundle assembly")
UNSET Confidence

SET Citation = {"PubMed", "26400044"}
SET Species = "10090"
SET Evidence = "First, we verified the colocalization of p-WAVE1 and pCRMP2 with aggregated hyperphosphorylated tau in the hippocampus at 23 months of age. Biochemical analysis
revealed the inclusion of p-WAVE1, p-CRMP2, and tau in the sarkosyl-insoluble fractions of hippocampal homogenates"
SET Confidence = "Medium"
SET Anatomy = "hippocampal formation"
a(HBP:"Tau aggregates") -> complex(p(HBP:"Tau aggregates"), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
p(MGI:Mapt,pmod(HBP:hyperphosphorylation)) -> complex(p(MGI:Mapt,pmod(HBP:hyperphosphorylation)), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
p(MGI:Wasf1, pmod(Ph)) partOf complex(p(HBP:"Tau aggregates"), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
p(MGI:Wasf1, pmod(Ph)) partOf complex(p(MGI:Mapt,pmod(HBP:hyperphosphorylation), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
p(MGI:Dpysl2, pmod(Ph)) partOf complex(p(HBP:"Tau aggregates"), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
p(MGI:Dpysl2, pmod(Ph)) partOf complex(p(MGI:Mapt,pmod(HBP:hyperphosphorylation), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph)))
UNSET Anatomy
UNSET Confidence

SET Evidence = "We found that the immunoreactivities of p-WAVE1 and pCRMP2 colocalized with p-tau and were located near
peripheral amyloid plaques in the cerebral cortices of 23- month-old 33Tg (Fig. 3A) and 17-month-old APPswe/ PS1DE9 (Fig. 3B) mice."
SET Confidence = "Medium"
SET Anatomy = "cerebral cortex"
complex(p(MGI:Mapt,pmod(Ph)), p(MGI:Wasf1, pmod(Ph)), p(MGI:Dpysl2, pmod(Ph))) -- path(MESH:"Plaque, Amyloid")
UNSET Anatomy
UNSET Confidence

SET Evidence = "ATRA prevents the accumulation of amyloid plaques and APP processing into Ab through downregulation of Cdk5 in APP/PS1 mice.
These results suggested that the administration of ATRA inhibited activity of Cdk5 and GSK3b and attenuated the formation of p-tau aggregation,
including p-CRMP2 and p-WAVE1 in the 33Tg mouse brain."
SET Confidence = "Medium"
a(CHEBI:"all-trans-retinoic acid") -| path(MESH:"Plaque, Amyloid")
a(CHEBI:"all-trans-retinoic acid") -| bp(HBP:"APP processing")
a(CHEBI:"all-trans-retinoic acid") -| a(CHEBI:"amyloid-beta")
a(CHEBI:"all-trans-retinoic acid") -| kin(p(MGI:Cdk5))
a(CHEBI:"all-trans-retinoic acid") -| kin(p(MGI:Gsk3b))
a(CHEBI:"all-trans-retinoic acid") -| a(HBP:"Tau aggregates")
a(CHEBI:"all-trans-retinoic acid") -| p(MGI:Mapt,pmod(Ph))
UNSET Confidence

UNSET Species

SET Citation = {"PubMed", "8726973"}
SET Evidence = "The kinase activity was inhibited by staurosporine, isopentanyladenine and olomoucine in a dose dependent manner.
Kinetic studies indicated Ki values of 39 nM, 38 microM and 8 microM, respectively for staurosporine, isopentanyladenine and olomoucine."
SET Confidence = "High"
SET Ki = "39 nM"
a(CHEBI:staurosporine) -| act(p(HGNC:CDK5))
SET Ki = "38 μM"
a(HBP:isopentanyladenine) -| act(p(HGNC:CDK5))
SET Ki = "8 μM"
a(HBP:olomoucine) -| act(p(HGNC:CDK5))
UNSET Ki
UNSET Confidence


SET Citation = {"PubMed", "18239272"}
SET Evidence = "Tau-phosphorylation properties dependent on co-factors (Km 8 to 15 uM, Vmax 0.8 to 4 uM/min/mg protein) and Km for ATP is 2uM"
SET Confidence = "High"
SET Vmax = "0.8-4 μM/min/mg"
SET Km = "8-15 μM"
SET Km_ATP = "2 μM"
p(HGNC:CSNK1D) -> p(HGNC:MAPT, pmod(Ph))
UNSET Km_ATP
UNSET Km
UNSET Vmax
UNSET Confidence


SET Citation = {"PubMed", "23088643"}
SET Evidence = "TTBK1 has been shown, by partial phosphopeptide mapping, to phosphorylate tau at serine residues 198, 199, 202 and 422 and at tyrosine
197 in vitro, sites that are also phosphorylated in AD PHFs (7, 12)"
SET Confidence = "Medium"
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 198))
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Tyr, 197))
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 422))
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT, pmod(Ph, Ser, 198))
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT, pmod(Ph, Ser, 199))
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT, pmod(Ph, Tyr, 197))
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT, pmod(Ph, Ser, 422))

p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Ser, 199)) partOf p(HBP:"Tau epitope, AT8")

UNSET Confidence

SET Evidence = "The pSer422 antibody displayed an almost identical pattern to that of AT8, in that it stained NFTs (Figure 5A–D), neuropil threads and neuritic plaques (Figure 5E–H)"
SET Confidence = "High"
p(HBP:"Tau epitope, AT8") -- a(GO:"neurofibrillary tangle")
p(HBP:"Tau epitope, AT8") -- a(MESH:"Neuropil Threads")
p(HBP:"Tau epitope, AT8") -- path(MESH:"Plaque, Amyloid")

p(HGNC:MAPT, pmod(Ph, Ser, 422)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, pmod(Ph, Ser, 422)) partOf a(MESH:"Neuropil Threads")
p(HGNC:MAPT, pmod(Ph, Ser, 422)) partOf path(MESH:"Plaque, Amyloid")
UNSET Confidence

SET Evidence = "These data suggest a role for TTBK1 in pre-tangle formation prior to the formation of fibrillar tau and strengthen the idea that tau is phosphorylated at Ser422
at an early intermediate stage in NFT formation."
SET Confidence = "Medium"
p(HGNC:TTBK1) -- a(HBP:pretangles)
p(HGNC:TTBK1) -- a(HBP:"Tau fibrils")
a(HBP:"Tau fibrils") -> a(HBP:pretangles)
p(HGNC:MAPT, pmod(Ph, Ser, 422)) -- a(HBP:pretangles)
a(HBP:pretangles) isA a(GO:"neurofibrillary tangle")
a(GO:"neurofibrillary tangle") -- p(HGNC:MAPT, pmod(Ph, Ser, 422))
p(HGNC:TTBK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 422))
UNSET Confidence

SET Citation = {"PubMed", "20096481"}
SET Study_Group = "Spanish cohort"
SET Evidence = "Activates cdk5 and GSK3; genetic variation protects against AD in Spanish cohort"
SET Confidence = "High"
p(HGNC:TTBK1) -> act(p(HGNC:CDK5))
p(HGNC:TTBK1) -> kin(p(HGNC:GSK3B))
UNSET Confidence

SET Evidence = "Haplotype analysis of the block formed by rs2651206, rs10807287, and rs7764257 showed that the combination of the three frequent
alleles (CTA) was significantly (p = 0.02) overrepresented in the AD group (67%) compared to the control group (63%), and this result was still significant after multiple testing
corrections with 10,000 permutations (p = 0.05)."
SET Confidence = "Medium"
g(DBSNP:rs2651206) pos path(MESH:"Alzheimer Disease")
g(DBSNP:rs10807287) pos path(MESH:"Alzheimer Disease")
g(DBSNP:rs7764257) pos path(MESH:"Alzheimer Disease")

g(DBSNP:rs2651206) -- g(HGNC:TTBK1)
g(DBSNP:rs10807287) -- g(HGNC:TTBK1)
g(DBSNP:rs7764257) -- g(HGNC:TTBK1)
UNSET Confidence

UNSET Study_Group


SET Citation = {"PubMed", "17620722"}
SET Evidence = "Tau-tubulin kinase 2 (TTBK2) is a Ser/Thr kinase that putatively phosphorylates residues Ser208 and Ser210
(numbered according to a 441-residue human tau isoform) in tau protein."
SET Confidence = "High"
p(HGNC:TTBK2) -> p(HGNC:MAPT, pmod(Ph, Ser, 208))
p(HGNC:TTBK2) -> p(HGNC:MAPT, pmod(Ph, Ser, 210))
UNSET Confidence

SET Citation = {"PubMed", "2820993"}
SET Evidence = "The results provide a molecular basis to explain the synergistic action of casein kinase II and GSK-3 that is also observed with native glycogen synthase."
SET Confidence = "High"
act(p(FPLX:CSNK2)) -> kin(p(HGNC:GSK3B))
UNSET Confidence

SET Citation = {"PubMed", "21548880"}
SET Evidence = "SCA11 truncating mutations promote TTBK2 protein expression, suppress kinase activity and lead to enhanced nuclear localization.
Using a SCA11-mutation-carrying knockin mouse we show that this leads to inhibition of endogenous TTBK2 protein kinase activity."
SET Confidence = "High"
p(HGNC:TTBK2, trunc(Tyr448)) pos path(HBP:"Spinocerebellar Ataxia 11")
p(HGNC:TTBK2, trunc(Asp449)) pos path(HBP:"Spinocerebellar Ataxia 11")
p(HGNC:TTBK2, trunc(Glu450)) pos path(HBP:"Spinocerebellar Ataxia 11")

p(HGNC:TTBK2, trunc(Tyr448)) -> p(HGNC:TTBK2)
p(HGNC:TTBK2, trunc(Asp449)) -> p(HGNC:TTBK2)
p(HGNC:TTBK2, trunc(Glu450)) -> p(HGNC:TTBK2)

p(HGNC:TTBK2, trunc(Tyr448)) -| kin(p(HGNC:TTBK2))
p(HGNC:TTBK2, trunc(Asp449)) -| kin(p(HGNC:TTBK2))
p(HGNC:TTBK2, trunc(Glu450)) -| kin(p(HGNC:TTBK2))

p(HGNC:TTBK2, trunc(Tyr448)) -> p(HGNC:TTBK2), loc(GO:nucleus))
p(HGNC:TTBK2, trunc(Asp449)) -> p(HGNC:TTBK2), loc(GO:nucleus))
p(HGNC:TTBK2, trunc(Glu450)) -> p(HGNC:TTBK2), loc(GO:nucleus))
UNSET Confidence

SET Citation = {"PubMed", "19118186"}
SET Evidence = "TTBK1-Tg mice show significant age-dependent memory impairment as determined by radial arm water maze test, which is associated with enhancement of tau and
neurofilament phosphorylation, increased levels of p25 and p35, both activators of cyclin-dependent protein kinase 5 (CDK5), enhanced calpain I activity,
and reduced levels of hippocampal NMDA receptor types 2B (NR2B) and D. Enhanced CDK5/p35 complex formation is strongly correlated with dissociation of F-actin from p35,
suggesting the inhibitory mechanism of CDK5/p35 complex formation by F-actin."
SET Confidence = "Medium"
SET Species = "10090"
p(MGI:Ttbk1) -> p(MGI:Cdk5r1)
p(MGI:Cdk5r1) -> act(p(MGI:Cdk5))
p(MGI:Ttbk1) pos act(p(ECCODE:"3.4.22.52"))
p(MGI:Ttbk1) neg p(MGI:Grin2b)
p(MGI:Ttbk1) neg p(MGI:Grin2d)
bp(GO:memory) neg p(MGI:Mapt)
bp(GO:aging) -| bp(GO:memory)
p(MGI:Ttbk1) neg p(MGI:Capn1)
complex(p(MGI:Cdk5),p(MGI:Cdk5r1)) neg complex(a(GO:"filamentous actin"),p(MGI:Cdk5r1))
a(GO:"filamentous actin") neg complex(p(MGI:Cdk5),p(MGI:Cdk5r1))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "21548880"}
SET Evidence = "Significant association with a reduced risk of LOAD (odds ratio/OR=0.69).
rs2651206 polymorphism was strongly associated with LOAD (OR=0.72) (age, gender, and APOE adjusted). The TG haplotype, deriving from the two minor alleles,
decreases risk of LOAD (OR=0.78, P=0.037)."
SET Confidence = "High"
SET Study_Group = "Han chinese"
g(DBSNP:rs2651206) pos path(MESH:"Alzheimer Disease")
g(DBSNP:rs2651206) isA g(HGNC:TTBK1)
UNSET Study_Group
UNSET Confidence


SET Citation = {"PubMed", "25673844"}
SET Evidence = "The CK1 group of eukaryotic protein kinases are composed of seven CK1 isoforms (CK1α, CK1α2, CK1δ, CK1ε, CK1γ1, CK1γ2, and CK1γ3),
two Tau–tubulin kinase isoforms (TTBK1 and TTBK2), and three VRK isoforms (VRK1, VRK2, and VRK3)"
SET Confidence = "High"
p(HGNC:TTBK1) isA p(HBP:"CK1 superfamily")
p(HGNC:TTBK2) isA p(HBP:"CK1 superfamily")
p(HGNC:VRK1) isA p(HBP:"CK1 superfamily")
p(HGNC:VRK2) isA p(HBP:"CK1 superfamily")
p(HGNC:VRK3) isA p(HBP:"CK1 superfamily")

p(HGNC:CSNK1A1) isA p(FPLX:CSNK1)
p(HGNC:CSNK1A1L) isA p(FPLX:CSNK1)
p(HGNC:CSNK1D) isA p(FPLX:CSNK1)
p(HGNC:CSNK1E) isA p(FPLX:CSNK1)
p(HGNC:CSNK1G1) isA p(FPLX:CSNK1)
p(HGNC:CSNK1G2) isA p(FPLX:CSNK1)
p(HGNC:CSNK1G3) isA p(FPLX:CSNK1)

p(FPLX:CSNK1) isA p(HBP:"CK1 superfamily")
UNSET Confidence

SET Evidence = "We demonstrate that Casein kinase 1 family members, including isoforms of Tau-tubulin protein kinases (TTBK1 and TTBK2),
phosphorylate human SV2A at two constellations of residues, namely Cluster-1 (Ser42, Ser45, and Ser47) and Cluster-2 (Ser80, Ser81, and Thr84).
These residues are also phosphorylated in vivo, and the phosphorylation of Thr84 within Cluster-2 is essential for triggering binding to the C2B domain of human synaptotagmin-1"
SET Confidence = "Medium"
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 42))
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 45))
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 47))
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 80))
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 81))
p(FPLX:CSNK1) -> p(HGNC:SV2A, pmod(Ph, Thr, 84))

p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 42))
p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 45))
p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 47))
p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 80))
p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Ser, 81))
p(HGNC:TTBK1) -> p(HGNC:SV2A, pmod(Ph, Thr, 84))

p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Ser, 42))
p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Ser, 45))
p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Ser, 47))
p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Ser, 80))
p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Ser, 81))
p(HGNC:TTBK2) -> p(HGNC:SV2A, pmod(Ph, Thr, 84))

p(HGNC:SV2A, pmod(Ph, Thr, 84)) -> complex(p(HGNC:SYT1),p(HGNC:SV2A))
UNSET Confidence

SET Citation = {"PubMed", "25473830"}
SET Evidence = "Using refined methodology, we demonstrate TTBK1 and TTBK2 directly phosphorylate TDP-43 in vitro and promote TDP-43 phosphorylation in mammalian cultured cells.
TTBK1/2 overexpression drives phosphorylation and relocalization of TDP-43 from the nucleus to cytoplasmic inclusions reminiscent of neuropathologic changes in disease states."
SET Confidence = "High"
p(HGNC:TTBK1) => p(HGNC:TARDBP, pmod(Ph))
p(HGNC:TTBK2) => p(HGNC:TARDBP, pmod(Ph))
p(HGNC:TTBK1) -> tloc(p(HGNC:TARDBP, pmod(Ph)), fromLoc(GO:nucleus), toLoc(GO:cytoplasm))
p(HGNC:TTBK2) -> tloc(p(HGNC:TARDBP, pmod(Ph)), fromLoc(GO:nucleus), toLoc(GO:cytoplasm))
UNSET Confidence

SET Citation = {"PubMed", "27607061"}
SET Evidence = "TTBK2 down-regulates GluK2 activity by decreasing the receptor protein abundance in the cell membrane via RAB5-dependent endocytosis,
an effect that may protect against neuroexcitotoxicity."
SET Confidence = "Medium"
p(HGNC:TTBK2) -| surf(p(HGNC:GRIK2))
surf(p(HGNC:GRIK2)) pos act(p(HGNC:GRIK2))
act(p(HGNC:RAB5A)) neg surf(p(HGNC:GRIK2))
act(p(HGNC:RAB5A)) partOf bp(GO:"clathrin-dependent endocytosis")
SET MeSHAnatomy = "Neurons"
surf(p(HGNC:GRIK2)) neg path(HBP:Excitotoxicity)
UNSET MeSHAnatomy
UNSET Confidence

SET Citation = {"PubMed", "26323690"}
SET Evidence = "These findings indicate that TTBK2 with EB1/3 phosphorylates KIF2A and antagonizes KIF2A-induced depolymerization at MT plus ends for cell migration."
SET Confidence = "High"
complex(p(HGNC:MAPRE1),p(HGNC:TTBK2)) -> p(HGNC:KIF2A, pmod(Ph))
complex(p(HGNC:MAPRE3),p(HGNC:TTBK2)) -> p(HGNC:KIF2A, pmod(Ph))
p(HGNC:KIF2A, pmod(Ph)) neg bp(GO:"microtubule depolymerization")
UNSET Confidence

SET Citation = {"PubMed", "23942339"}
SET Evidence = "Upregulation of Na+Cl- coupled betaine/GABA transporter BGT1 for organic osmolytes"
SET Confidence = "High"
p(HGNC:TTBK2) -> act(p(HGNC:SLC6A12))
UNSET Confidence


SET Citation = {"PubMed", "22814243"}
SET Evidence = "Upregulation of SLC5A1 Na-copled Glucose transport"
SET Confidence = "High"
p(HGNC:TTBK2) -> act(p(HGNC:SLC5A1))
act(p(HGNC:SLC5A1)) pos bp(GO:"glucose transmembrane transport")
UNSET Confidence


SET Citation = {"PubMed", "25297623"}
SET Evidence = "TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively.
Using TTBK2 variants that contained mutations in the SxIP or proline-rich motifs, we obtained evidence that Cep164, but not EB1, is essential for centriolar localization of TTBK2.
Therefore, Cep164 binding is essential for the function of TTBK2 in promoting CP110 removal and ciliogenesis.
We also provide evidence that TTBK2 has the potential to effectively phosphorylate Cep164 and Cep97 and inhibits the interaction between Cep164 and its binding partner Dishevelled-3 (an important regulator of ciliogenesis) in a kinase activity-dependent manner."
SET Confidence = "Medium"
p(HGNC:TTBK2) -- p(HGNC:CEP164)
p(HGNC:TTBK2) -- p(HGNC:MAPRE1)
complex(p(HGNC:TTBK2),p(HGNC:CEP164)) -> act(p(HGNC:TTBK2))
act(p(HGNC:TTBK2)) -> deg(p(HGNC:CCP110))
act(p(HGNC:TTBK2)) -> p(HGNC:CEP164, pmod(Ph))
act(p(HGNC:TTBK2)) -> p(HGNC:CEP97, pmod(Ph))
p(HGNC:CEP164, pmod(Ph)) neg complex(p(HGNC:CEP164), p(HGNC:DVL3))
p(HGNC:CEP164) partOf complex(p(HGNC:CEP164), p(HGNC:DVL3))
p(HGNC:DVL3) partOf complex(p(HGNC:CEP164), p(HGNC:DVL3))
p(HGNC:CEP164) partOf complex(p(HGNC:TTBK2),p(HGNC:CEP164))
p(HGNC:CEP164) -> p(HGNC:TTBK2,loc(GO:centriole))
p(HGNC:MAPRE1) partOf complex(p(HGNC:TTBK2),p(HGNC:MAPRE1))
act(p(HGNC:TTBK2)) -> bp(GO:"cytosolic ciliogenesis")
p(HGNC:DVL3) reg bp(GO:"cytosolic ciliogenesis")
UNSET Confidence

SET Citation = {"PubMed", "24808823"}
SET Evidence = "Overexpression of TTBK1 was sufficient in inducing spatial learning impairment in mice, which is associated
with enhanced Cdk5 activity and reduction in cell surface level of NR2B. Over-expressionof TTBK1 transgene in JNPL3 mice resulted in accumulation of pre-tangle forms of tau.
Inaddition, TTBK1 expression plays a unique role in accelerating motor neuron degeneration and neuroinflammation in JNPL3mice."
SET Confidence = "Medium"
SET Species = "10090"
p(MGI:Ttbk1) neg path(MESH:"Spatial Learning")
p(MGI:Cdk5) neg path(MESH:"Spatial Learning")
surf(p(MGI:Grin2b)) pos path(MESH:"Spatial Learning")
p(MGI:Ttbk1) -> a(HBP:pretangles)
p(MGI:Ttbk1) -> deg(a(MESH:"Motor Neurons"))
p(MGI:Ttbk1) -> bp(GO:"neuroinflammatory response")
p(MGI:Ttbk1) pos act(p(MGI:Cdk5))
UNSET Confidence


SET Citation = {"PubMed", "11943212"}
SET Enzyme_Acitvity = "1 U/ml"
SET Evidence = "All five SAP kinases generated the AT270 epitope, indicative of phosphorylation of T181 in tau."
SET Confidence = "High"
p(HGNC:MAPK14) -> p(HGNC:MAPT, pmod(Ph, T, 181))
p(HGNC:MAPK11) -> p(HGNC:MAPT, pmod(Ph, T, 181))
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, T, 181))
p(HGNC:MAPK13) -> p(HGNC:MAPT, pmod(Ph, T, 181))
p(HGNC:MAPK8) -> p(HGNC:MAPT, pmod(Ph, T, 181))

p(HGNC:MAPT, pmod(Ph, T, 181)) partOf p(HBP:"Tau epitope, AT270")
UNSET Confidence

SET Evidence = "For AT8, which recognises phosphorylated S202 and T205 in tau, SAPK3/p38gamma gave the strongest labelling"
SET Confidence = "High"
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, T, 205))
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, S, 202))
UNSET Confidence

SET Evidence = "The AD2 epitope, which corresponds to phosphorylated S396 and S404 in tau, was generated most effectively by SAPK3/p38gamma and SAPK4/p38delta"
SET Confidence = "High"
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, T, 396))
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, S, 404))
p(HGNC:MAPK13) -> p(HGNC:MAPT, pmod(Ph, T, 396))
p(HGNC:MAPK13) -> p(HGNC:MAPT, pmod(Ph, S, 404))

p(HGNC:MAPT, pmod(Ph, T, 396)) partOf p(HBP:"Tau epitope, AD2")
p(HGNC:MAPT, pmod(Ph, S, 404)) partOf p(HBP:"Tau epitope, AD2")
UNSET Confidence

SET Evidence = "Finally, phosphorylation of S422 in tau, as recognisedby antibody AP422, was generated most effciently by SAPK3/p38gamma, SAPK4/p38delta and SAPK2b/p38beta"
SET Confidence = "High"
p(HGNC:MAPK12) -> p(HGNC:MAPT, pmod(Ph, S, 422))
p(HGNC:MAPK13) -> p(HGNC:MAPT, pmod(Ph, S, 422))
p(HGNC:MAPK11) -> p(HGNC:MAPT, pmod(Ph, S, 422))

p(HGNC:MAPT, pmod(Ph, S, 422)) partOf p(HBP:"Tau epitope, AP422")
UNSET Confidence

#######################################################################################################################################################################################

SET Citation = {"PubMed", "28784767"}
SET Method = {"NMR Spectroscopy", "Electron Microscopy, Transmission", "Thioflavin T Assay"}
SET Evidence = "Only very recently has the crystal structure of its fragment antigen body (Fab) with different
phosphorylated peptides suggested that a third phosphorylation event at position Ser208 might lead to an epitope with an even better affinity (15)."
SET Confidence = "High"
p(HGNC:MAPT, pmod(Ph, Ser, 208)) partOf p(HBP:"Tau epitope, AT8")
UNSET Confidence

SET Evidence = "When combined with ERK2 catalyzed phosphorylation, the turn-like
disrupting G207V mutation in TauF8 hence leads to fast aggregation that already occurs during the phosphorylation reaction."
SET Confidence = "Medium"
act(p(HGNC:MAPK1)) -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
act(p(HGNC:MAPK1)) -> p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, var("pGly207Val")) -> bp(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(Ph, Ser, 202),  pmod(Ph, Thr, 205)) -> a(HBP:"Tau Protein Secondary Structure, Turn")
p(HGNC:MAPT, var("p.Gly207Val")) -| a(HBP:"Tau Protein Secondary Structure, Turn")
p(HGNC:MAPT, pmod(Ph, Ser, 202)) -> bp(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) -> bp(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "Our finding that the resulting Tau species with phosphorylation at Ser202/Th205, but with a disrupted turn-like structure,
forms abundant fibers detectable by thioflavin fluorescence or electron microscopy (Figs. 2 and 4) suggests the initial
turn-like structure induced by the phosphorylation of only Ser202 and Thr205 is protective against aggregation."
SET Confidence = "High"
a(HBP:"Tau Protein Secondary Structure, Turn") -| bp(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "Phosphorylation at Ser208 might be catalyzed by Casein kinase 1 (44), and its identification as a potential
site for O-GlcNacylation (45) points to the important role of this residue."
SET Confidence = "High"
kin(p(FPLX:CSNK1)) -> p(HGNC:MAPT, pmod(Ph, Ser, 208))
UNSET Confidence

SET Evidence = "Indeed, Tau phosphorylation at the three positions, Ser202/Thr205/Ser208, while not at Ser262, is
sufficient to induce aggregation without the addition of any exogenous aggregation inducer."
SET Confidence = "High"
p(HGNC:MAPT, pmod(Ph, Ser, 202),  pmod(Ph, Thr, 205), pmod(Ph, Thr, 208)) eq p(HBP:"Tau epitope, AT8")
p(HBP:"Tau epitope, AT8") -> bp(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(Ph, Ser, 208)) -| a(HBP:"Tau Protein Secondary Structure, Turn")
a(HBP:"Tau Protein Secondary Structure, Turn") -| bp(HBP:"Tau aggregates")
UNSET Confidence
UNSET Method


SET Citation = {"PubMed", "26751493"}
SET Evidence = "Using the same tau-1 monoclonal antibody and electron microscopy with colloidal gold-labeled secondary antibodies, tau was also found in very low amounts in astrocytes [16]
and oligodendrocytes [17], and this was confirmed by tau mRNA expression analysis in the mouse brain [18]."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHAnatomy = "Brain"
r(MGI:Mapt) partOf a(CL:"0000127")
r(MGI:Mapt) partOf a(CL:"0000128")
UNSET Species
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "3. Putative phosphorylation sites on tau protein and epitopes specific for major tau
antibodies. Red color denotes amino acids phosphorylation in AD brain."
SET Confidence = "Medium"
SET MeSHDisease = "Alzheimer Disease"
SET MeSHAnatomy = "Brain"
p(HGNC:MAPT, pmod(Ph, Y, 18)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 68)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 69)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 71)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 113)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 123)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 153)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 175)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 184)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 185)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 191)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, Y, 197)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 208)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 210)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 214)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 237)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 238)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 258)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 262)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 289)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 356)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, Y, 394)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 403)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 409)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 435)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, T, 427)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 433)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ph, S, 422)) pos path(MESH:"Alzheimer Disease")
UNSET MeSHDisease
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "Apart from binding to MT, the repeat domains of tau also bind to tubulin deacetylase, histone deacetylase 6 (HDAC6) [68] and apolipoprotein E (apoE)
more with the "3 than the "4 isovariant [69])."
SET Confidence = "High"
a(HBP:"microtubule-binding region") -- p(HGNC:HDAC6)
p(HBP:"tubulin-binding repeat 1") -- p(HBP:"APOE e3")

p(HBP:"tubulin-binding repeat 1") partOf a(HBP:"microtubule-binding region")
a(HBP:"microtubule-binding region") partOf p(HGNC:MAPT)
UNSET Confidence

SET Evidence = "The projection domain of tau may be involved in cell signaling that occurs through the interaction with Lck, Fgr and cSrc (Src-family kinases),
growth factor receptor-bound protein 2 (Grb2), phospholipase C- [70], phosphatidylinositol and phosphatidylinositol bisphosphate [71,72], peptidyl-prolyl cis/trans isomerase Pin 1,
and many others (for review see [73]), making them potential therapeutic targets in tauopathies [74]."
SET Confidence = "Medium"
complex(p(HGNC:LCK),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(p(HGNC:FGR),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(p(HGNC:SRC),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(p(HGNC:GRB2),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(p(FPLX:PLC),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(a(CHEBI:phosphatidylinositol),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(a(CHEBI:"phosphatidylinositol bisphosphate"),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")
complex(p(HGNC:PIN1),a(HBP:"projection domain")) -- bp(GO:"cell-cell signaling")

a(HBP:"projection domain")  partOf p(HGNC:MAPT)
UNSET Confidence

SET Evidence = "In synapses, the projection domain of tau interacts with protein kinase Fyn (plays an important role during myelination [75]),
postsynaptic density protein 95 (PSD-95) [76], and N-methyl-D-aspartate receptors (NMDAR)."
SET Confidence = "Medium"
SET MeSHAnatomy = "Synapses"
a(HBP:"projection domain") -- p(HGNC:FYN)
p(HGNC:FYN) -- bp(GO:myelination)
a(HBP:"projection domain") -- p(HGNC:DLG4)
a(HBP:"projection domain") -- p(MESH:"Receptors, N-Methyl-D-Aspartate")
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "An additional “knot” of tau being entangled in epigenetic landscape of neurodegeneration comes from
the finding that by acting as a HDAC6 inhibitor, tau is being indirectly involved in both (dys)regulation
of transcriptional activity and impairment of autophagic clearance by the ubiquitin proteasome system [81,82]."
SET Confidence = "High"
p(HGNC:MAPT) -| act(p(HGNC:HDAC6))
p(HGNC:MAPT) -| bp(GO:autophagy)
p(HGNC:MAPT) neg act(complex(GO:"proteasome complex"))
UNSET Confidence

SET Evidence = "On the other side, sarkosyl extracts from the filaments of PSP [129], corticobasal
degeneration (CBD; [130]), argyrophilic grain disease (AgD; [131]), and some cases of FTDP-17, contain
tau protein that separates as doublets of 64 and 69 kDa and are predominantly composed of tau
isoforms with 4R (class II tauopathies), whereas sarkosyl extracts from filaments of Pick’s disease
are characterized by the presence of pathological tau doublets of 60 and 64 kDa and contain mainly
3R tau isoforms (class III tauopathy)."
SET Confidence = "High"
p(HBP:"4R tau") pos path(HBP:"Corticobasal Degeneration")
p(HBP:"4R tau") pos path(HBP:"Argyrophilic Grain Disease")
p(HBP:"4R tau") pos path(MESH:"Supranuclear Palsy, Progressive")

p(HBP:"3R tau") pos path(MESH:"Niemann-Pick Diseases")
UNSET Confidence

SET Evidence = "Poorkaj et al. reported two exonic mutations (P301L and
V337M) in two families with FTDP-17 [139], while Hutton et al. reported six different mutations in
10 families: three of these mutations (G272V, P301L and R406W) were missense mutations in exons,
while the other three were in the 5' splice site of exon 10 [140]."
SET Confidence = "High"
p(HGNC:MAPT, var("p.Pro301Leu")) pos path(MESH:"Frontotemporal Dementia")
p(HGNC:MAPT, var("p.Val337Met")) pos path(MESH:"Frontotemporal Dementia")
p(HGNC:MAPT, var("p.Gly272Val")) pos path(MESH:"Frontotemporal Dementia")
p(HGNC:MAPT, var("p.Arg406Trp")) pos path(MESH:"Frontotemporal Dementia")
UNSET Confidence

SET Evidence = "A PSEN1 mutation causes a Pick’s disease phenotype including FTD tau pathology
without deposition of Abeta [145]; some MAPT single nucleotide polymorphisms have also been linked to
sporadic Parkinson’s disease (PD, [146]);"
SET Confidence = "High"
p(HGNC:PSEN1, var("p.Gly183Val")) pos path(MESH:"Frontotemporal Dementia")
p(HGNC:PSEN1, var("p.Gly183Val")) pos path(MESH:"Niemann-Pick Diseases")
p(HGNC:PSEN1, var("p.Gly183Val")) cnc a(CHEBI:"amyloid-beta")

g(DBSNP:rs2471738) -- path(MESH:"Parkinson Disease")
g(DBSNP:rs242557) -- path(MESH:"Parkinson Disease")
UNSET Confidence

SET Evidence = "The tau fragment first isolated from the PHF core is approximately 100 amino acids in length.
Its N-terminus was defined by sequence analysis [30,56], and its C-terminus was defined by epitope
mapping of MN423. Immunoreactivity was shown to depend on a specific C-terminal trunctation at Glu391 [33,150]."
SET Confidence = "High"
p(HGNC:MAPT, trunc(Glu391)) -- p(HBP:"paired helical filaments")
p(HBP:"paired helical filaments") partOf a(GO:"neurofibrillary tangle")
UNSET Confidence

SET Evidence = "In a prospective study three different synaptic protein (synaptophysin, SNAP-25 and syntaxin) were found
to be progressively decreased in neocortex at Braak stages III-VI [158], NFT-bearing neurons demonstrating, for example, a 35%–57% reduction in synaptophysin mRNA in AD brain [159]."
SET Confidence = "Medium"
SET Braak_Stage = {"Stage III", "Stage VI"}
SET MeSHAnatomy = "Neocortex"
r(HGNC:SYP) neg a(GO:"neurofibrillary tangle")
p(HGNC:SNAP25) neg a(GO:"neurofibrillary tangle")
p(INTERPRO:"Syntaxin, N-terminal domain") neg a(GO:"neurofibrillary tangle")
UNSET Braak_Stage
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "The most recent data obtained indicate that tau pathology indeed may be induced and propagated after the injection of tau oligomers or
aggregates in either wild-type or mutated MAPT transgenic mice [164], and that tau aggregates can be transferred from cell to cell in vitro [164,165] and in vivo [166,167]."
SET Confidence = "Medium"
a(HBP:"Tau aggregates") pos tloc(a(HBP:"Tau aggregates"), fromLoc(MESH:Neurons), toLoc(MESH:Neurons))
a(HBP:"Tau oligomers") -> a(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "In the case of soluble monomeric or small oligomeric tau protein, the endocytosis appears to be clathrin-dependent (reviewed in [169]).
In contrast, larger aggregates of tau could bind heparin in the extracellular matrix and be internalized through macropinocytosis [170].
As a result of exocytosis and endocytosis, the spreading of tau can occur in various neurodegenerative diseases (tauopathies) including AD.
Three plausible mechanisms of tau spreading are shown schematically in Figure 6. Additionally, it appears that
microglial cells may facilitate tau propagation by phagocytosis and exocytosis of tau protein [171]."
SET Confidence = "Medium"
p(HBP:"Tau oligomers") -- bp(GO:"clathrin-dependent endocytosis")
p(HBP:"Tau aggregates") partOf complex(p(HBP:"Tau aggregates"), a(CHEBI:heparin))
a(CHEBI:heparin) partOf complex(p(HBP:"Tau aggregates"), a(CHEBI:heparin))
complex(p(HBP:"Tau aggregates"), a(CHEBI:heparin)) -- bp(GO:macropinocytosis)

bp(GO:macropinocytosis) isA tloc(a(HBP:"Tau aggregates"), fromLoc(MESH:Neurons), toLoc(MESH:Neurons))
bp(GO:"clathrin-dependent endocytosis") isA tloc(a(HBP:"Tau aggregates"), fromLoc(MESH:Neurons), toLoc(MESH:Neurons))
bp(GO:"cell-cell signaling via exosome") isA tloc(a(HBP:"Tau aggregates"), fromLoc(MESH:Neurons), toLoc(MESH:Neurons))
a(CL:"0000129") -> tloc(a(HBP:"Tau aggregates"), fromLoc(MESH:Neurons), toLoc(MESH:Neurons))
UNSET Confidence

SET Evidence = "Green coffee, a non-toxic small molecule, found to be an inhibitor of protein
phosphatase 2A methylesterase, was shown to improve cognitive and motor performance in mouse models with tau pathology"
SET Confidence = "Medium"
SET Species = "10090"
a(CHEBI:"trans-5-O-caffeoyl-D-quinic acid") -| act(p(MGI:Ppme1))
a(CHEBI:"trans-5-O-caffeoyl-D-quinic acid") -> bp(GO:cognition)
a(CHEBI:"trans-5-O-caffeoyl-D-quinic acid") -> bp(GO:"motor behavior")
UNSET Species
UNSET Confidence

SET Evidence = "A quite different strategy is to target tau clearance—e.g., by rapamycin that induces
macroautophagy [175], inhibitors of Hsp90 chaperone protein that binds to misfolded proteins or by
immunotherapeutic approaches [176]."
SET Confidence = "High"
a(CHEBI:sirolimus) -> bp(GO:macroautophagy)
bp(GO:macroautophagy) -| p(HGNC:MAPT)
p(HBP:"Tau antibody, RG7345") -| p(HGNC:MAPT, pmod(Ph, S, 422))
p(HGNC:MAPT, pmod(Ph, S, 422)) partOf p(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "MB is a phenothiazine that crosses the blood brain barrier and acts as a redox cycler. Moreover, besides its beneficial properties as being able to improve
energy metabolism and to act as an antioxidant, it is also able to reduce tau protein aggregation"
SET Confidence = "Medium"
a(CHEBI:"methylene blue") -| p(HBP:"Tau aggregates")
a(CHEBI:"methylene blue") -> bp(GO:"energy reserve metabolic process")
a(CHEBI:"methylene blue") isA a(CHEBI:antioxidant)
UNSET Confidence

SET Evidence = "Recently, it has been proposed that tau protein acetylation may be responsible for tau aggregation in AD. Grinberg and collaborators
detected tau acetylation at Lys274 in all tauopathies (both primary and secondary), except in AgD"
SET Confidence = "Medium"
SET MeSHDisease = "Tauopathies"
p(HGNC:MAPT, pmod(Ac, Lys, 274)) pos p(HBP:"Tau aggregates")
UNSET MeSHDisease
UNSET Confidence

SET Evidence = "Other possible inhibitors of tau aggregation are rhodanine-based inhibitors, phenylthiazolyl-hydrazide inhibitors, N-phenylamines, phenothiazines
and benzothiazoles, and polyphenols and anthraquinones"
SET Confidence = "High"
a(CHEBI:rhodanine) -| p(HBP:"Tau aggregates")
a(HBP:thiohydantoin) -| p(HBP:"Tau aggregates")
a(HBP:oxazolidinedione) -| p(HBP:"Tau aggregates")
a(HBP:thioxooxazolidine) -| p(HBP:"Tau aggregates")

a(CHEBI:thiostrepton) -| p(HBP:"Tau aggregates")
a(HBP:sudoxicam) -| p(HBP:"Tau aggregates")
a(CHEBI:isoniazide) -| p(HBP:"Tau aggregates")
a(CHEBI:Iproniazid) -| p(HBP:"Tau aggregates")
a(CHEBI:iproclozide) -| p(HBP:"Tau aggregates")
a(HBP:isocarboxazide) -| p(HBP:"Tau aggregates")

a(CHEBI:myricetin) -| p(HBP:"Tau aggregates")

a(CHEBI:emodin) -| p(HBP:"Tau aggregates")
a(CHEBI:daunorubicin) -| p(HBP:"Tau aggregates")
a(CHEBI:doxorubicin) -| p(HBP:"Tau aggregates")
a(CHEBI:quinalizarin) -| p(HBP:"Tau aggregates")
UNSET Confidence

#######################################################################################################################################################################################


SET Citation = {"PubMed", "11943212"}
SET Evidence = "Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated form colocalizes with p-tau Ser262 in
granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD."
SET Confidence = "Medium"
SET Disease = "Alzheimer's disease"
p(HGNC:MARK4, pmod(Ph)) -- p(HGNC:MAPT, pmod(Ph, Ser, 262))
complex(p(HGNC:MAPT, pmod(Ph, Ser, 262)),p(HGNC:MARK4, pmod(Ph))) -- a(HBP:"granulovacuolar degeneration")
path(MESH:"Alzheimer's disease") pos a(HBP:"granulovacuolar degeneration")
UNSET Disease
UNSET Confidence

SET Citation = {"PubMed", "22692785"}
SET Evidence = "It has been reported that serine 262 in tau, which is specifically phosphorylated by MARK, is in a hyperphosphorylated form in the neurofibrillary deposits found in Alzheimer’s disease brains (15)."
SET Confidence = "Medium"
SET Disease = "Alzheimer's disease"
SET MeSHAnatomy = "Brain"
p(HGNC:MAPT, pmod(Ph, Ser, 262)) partOf a(GO:"neurofibrillary tangle")
a(MESH:"Microtubule-Associated Proteins") -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
UNSET Disease
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "MARK4 was extremely decreased in the brain regions with a mass of PrPSc in a G114V gCJD patient, but was clearly observable in the regions with a minimum amount
of PrPSc or without detectable PrPSc in a D178N FFI patient."
SET Confidence = "High"
SET MeSHDisease = {"Creutzfeldt-Jakob Syndrome", "Insomnia, Fatal Familial"}
p(HGNC:MARK4) neg p(HBP:PrPSc)
UNSET MeSHDisease
UNSET Confidence

SET Evidence = "These finding highlight that treatment of PrP106-126 in cultured cells does not alter the level of total tau, but induces a reduction of p-tau262."
SET Confidence = "High"
SET Cell_Line = {"PC12", "SK-N-SH"}
p(HBP:"PrP106-126") -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "22156579"}
SET Evidence = "To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of Aβ, we employed a peptide inhibitor capable of effectively and
specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses as assayed
at the morphological and electrophysiological levels."
SET Confidence = "Medium"
a(MESH:"Microtubule-Associated Proteins") pos act(a(HBP:"amyloid-beta oligomers"))
UNSET Confidence

SET Evidence = "We first confirmed that expression of an MKI-GFP fusion protein in rat hippocampal neurons effectively attenuated MARK4-mediated phosphorylation of both endogenous
tau (Fig. 3A) and transfected human tau at the 12E8 sites (Fig. 3B). Phosphorylation of tau at the PHF-1 site was also reduced by MKI (Fig. 3A).
It is possible that the PHF-1 site is also targeted by PAR-1/MARKs in vivo, or that the phosphorylation of tau at the 12E8 sites is a prerequisite for PHF-1 site phosphorylation,
as the 12E8 sites were previously shown to be required for tau phosphorylation at other sites"
# MKI refers to MARK kinases inhibitors
SET Confidence = "Medium"
SET Tau_Motif = "KXGS"
p(HGNC:MARK4) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MARK4) -> p(HGNC:MAPT, pmod(Ph, Ser, 356))
p(HGNC:MAPT, pmod(Ph, Ser, 262)) partOf a(HBP:"Tau epitope, 12E8")
p(HGNC:MAPT, pmod(Ph, Ser, 356)) partOf a(HBP:"Tau epitope, 12E8")
UNSET Tau_Motif
a(HBP:"Tau epitope, 12E8") pos a(HBP:"Tau epitope, PHF1")
p(HGNC:MAPT, pmod(Ph, Ser, 396)) pos a(HBP:"Tau epitope, PHF1")
p(HGNC:MAPT, pmod(Ph, Ser, 404)) pos a(HBP:"Tau epitope, PHF1")
UNSET Confidence


SET Citation = {"PubMed", "16973293"}
SET Evidence = "Human microtubule affinity-regulating kinase 4S (hMARK4S),undetectable in human neural progenitor cells (HNPCs) and NTera2 (NT2) cells,
is up-regulated in both cell systems from the very early stages of neuronal differentiation, suggesting euronal commitment is marked by MARK4S up-regulation."
SET Confidence = "High"
SET Cell_Line = {"HNPC", "NT2"}
p(HBP:"MARK4 isoform 2 (688 aa)") pos bp(GO:"neuron development")
p(HBP:"MARK4 isoform 2 (688 aa)") isA p(HGNC:MARK4)
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "27623715"}
SET Evidence = "Only middle-aged Tet-mev-1 mice showed JNK/MARK activation and Ca2+ overload, particularly in astrocytes with decreased hippocampal GFAP and S100ß,
but without pathological features such as apoptosis, amyloidosis, and lactic acidosis in neurons and astrocytes. This led to decreasing levels of glial fibrillary acidic protein and S100β in the hippocampal area."
SET Confidence = "Medium"
SET Species = "10090"
SET Study_Group = "Tet-mev-1 mice"
SET Anatomy = "hippocampal formation"
SET Cell = "astrocyte"
bp(MESH:"Oxidative Stress") -> act(p(FPLX:JNK))
bp(MESH:"Oxidative Stress") -> act(a(MESH:"Microtubule-Associated Proteins"))
bp(MESH:"Oxidative Stress") -> a(CHEBI:"calcium(2+)")
bp(MESH:"Oxidative Stress") -| p(HGNC:S100B)
SET Cell = {"astrocyte", "neuron"}
bp(MESH:"Oxidative Stress") cnc bp(GO:"apoptotic process")
bp(MESH:"Oxidative Stress") cnc path(MESH:"Acidosis, Lactic")
bp(MESH:"Oxidative Stress") cnc bp(GO:"amyloid fibril formation")
UNSET Cell
UNSET Anatomy
UNSET Study_Group
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23666762"}
SET Evidence = "In parallel, phosphorylation of tau at Ser262 in MARK-transfected cells was investigated using a rabbit antibody recognizing
phosphorylated Ser262 of tau (AGG5759) and a mouse anti-tau antibody (SC-21796) (Fig. S1a3). Tau was shown to interact with each of the transfected MARK
isoforms (Fig. 1) and to be phosphorylated at Ser262 (Fig. 2). Staurosporine, a non-selective kinase inhibitor, significantly inhibited interactions between tau and each of
the four MARK isoforms after treatment with 20 lM staurosporine for 1 h (Fig. 1; p = 0.02 for MARK1–, MARK2– and MARK3–tau interactions and p = 3 9 10-6 for MARK4–tau interaction).
Treatment with staurosporine also significantly reduced PLA signals for tau phosphorylation at Ser262 (Fig. 2; p = 0.04 for MARK1- and p = 0.02 for MARK2- and MARK3- and p = 1 9 10-5
for MARK4-mediated tau phosphorylation)"
# MARK isoforms: MARK1, MARK2, MARK3 or MARK4.
SET Confidence = "Medium"
complex(p(HBP:"Tau antibody, AGG5759"),p(HGNC:MAPT, pmod(Ph, Ser, 262)))
complex(p(HBP:"Tau antibody, Tau-13"),p(HGNC:MAPT, pmod(Ph, Ser, 262)))
complex(p(HGNC:MAPT),p(HGNC:MARK1)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
complex(p(HGNC:MAPT),p(HGNC:MARK2)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
complex(p(HGNC:MAPT),p(HGNC:MARK3)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
complex(p(HGNC:MAPT),p(HGNC:MARK4)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
a(CHEBI:staurosporine) -| complex(p(HGNC:MAPT),p(HGNC:MARK1))
a(CHEBI:staurosporine) -| complex(p(HGNC:MAPT),p(HGNC:MARK2))
a(CHEBI:staurosporine) -| complex(p(HGNC:MAPT),p(HGNC:MARK3))
a(CHEBI:staurosporine) -| complex(p(HGNC:MAPT),p(HGNC:MARK4))
UNSET Confidence

SET Evidence = "In cells, a CagA peptide inhibited tau phosphorylation at Ser²6² mediated by MARK4 but not other MARK isoforms. A strong and significant elevation of MARK4 expression and MARK4-tau interactions in AD brains correlated with the Braak stages of the disease."
SET Confidence = "Medium"
p(HBP:"CagA peptide") -| kin(p(HGNC:MARK4))
p(HBP:"CagA peptide") -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MARK4) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MARK4) pos path(MESH:"Alzheimer Disease")
complex(p(HGNC:MAPT),p(HGNC:MARK4)) pos path(MESH:"Alzheimer Disease")
UNSET Confidence

SET Citation = {"PubMed", "27708431"}
SET Evidence = "In 293T culture, MB decreased MARK4-mediated Tau phosphorylation in a dose dependent manner. MB down-regulates MARK4 protein level through ubiquitin-proteasome
pathway and inhibition of MARK4 kinase activity in vitro."
#  Tau phosphorylation at the MARK4 site serine 262
SET Confidence = "Medium"
SET Cell_Line = "HEK293T"
a(CHEBI:"methylene blue") -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MARK4) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
a(CHEBI:"methylene blue") -| kin(p(HGNC:MARK4))
a(CHEBI:"methylene blue") -> deg(p(HGNC:MARK4))
a(CHEBI:"methylene blue") -> bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process") -> deg(p(HGNC:MARK4))
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "27798139"}
SET Evidence = "Inhibition of DAPK1 by deleting a catalytic domain or a death domain of DAPK1 rescues the ECIIPN-CA1PV synaptic loss and improves spatial learning and memory in AD mice.
This study demonstrates that activation of DAPK1 in ECIIPN contributes to a memory loss in AD and hence warrants a promising target for the treatment of AD."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHAnatomy = "Brain"
act(p(MGI:Dapk1)) -> a(GO:synapse)
SET MeSHDisease = "Alzheimer's Disease"
act(p(MGI:Dapk1)) -| path(MESH:"Spatial Learning")
act(p(MGI:Dapk1)) -| bp(GO:memory)
UNSET MeSHDisease
UNSET Species
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "27094130"}
SET Evidence = "DAPK1, but not its kinase deficient mutant (K42A), significantly increased human Aβ secretion in neuronal cell culture models.
Moreover, knockdown of DAPK1 expression or inhibition of DAPK1 catalytic activity significantly decreased Aβ secretion. Furthermore, DAPK1, but not K42A,
triggered Thr668 phosphorylation of APP, which may initiate and facilitate amyloidogenic APP processing leading to the generation of Aβ."
SET Confidence = "Medium"
SET MeSHAnatomy = "Neurons"
p(HGNC:DAPK1) -> sec(p(HGNC:APP, frag(672_713)))
kin(p(HGNC:DAPK1)) pos sec(p(HGNC:APP, frag(672_713)))
kin(p(HGNC:DAPK1)) -> p(HGNC:APP,pmod(Ph,Thr,668))
p(HGNC:APP,pmod(Ph,Thr,668)) -- bp(HBP:"APP processing")
bp(HBP:"APP processing") -> a(CHEBI:"amyloid-beta")
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "In contrast, the DAPK1 fragments from 1 to 1423, from 637 to 1423 and from 848 to 1423 efficiently bound to APP,
suggesting that the death domain (1271–1423, DD) is likely bound to APP (Fig. 4F)."
SET Confidence = "Medium"
complex(p(HGNC:DAPK1),p(HGNC:APP))
complex(p(HGNC:DAPK1, frag(637_1423)),p(HGNC:APP))
complex(p(HGNC:DAPK1, frag(848_1423)),p(HGNC:APP))
complex(p(HGNC:DAPK1, frag(1271_1423)),p(HGNC:APP))
p(HGNC:DAPK1, frag(1271_1423)) eq p(INTERPRO:"Death domain")
p(INTERPRO:"Death domain") partOf p(HGNC:DAPK1)
p(HGNC:DAPK1, frag(848_1423)) partOf p(HGNC:DAPK1)
p(HGNC:DAPK1, frag(637_1423)) partOf p(HGNC:DAPK1)
UNSET Confidence

SET Evidence = "Furthermore, DAPK1-induced APP phosphorylation was suppressed when DAPK1 ΔDD was introduced (Fig. 4G), indicating that DAPK1 regulates Aβ secretion through APP Thr668 phosphorylation."
SET Confidence = "High"
kin(p(HGNC:DAPK1)) -> p(HGNC:APP, pmod(Ph, Thr, 668))
p(HGNC:APP, pmod(Ph, Thr, 668)) reg sec(p(HGNC:APP, frag(672_711)))
p(HGNC:APP, pmod(Ph, Thr, 668)) reg sec(p(HGNC:APP, frag(672_713)))
UNSET Confidence


SET Citation = {"PubMed", "27068745"}
SET Evidence = "Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase 2A-mediated dephosphorylation of DAPK1 (20)."
SET Confidence = "Medium"
p(HGNC:UNC5B) -> act(p(HGNC:DAPK1))
p(HGNC:UNC5B) pos phos(p(FPLX:PPP2))
phos(p(FPLX:PPP2)) -| act(p(HGNC:DAPK1,pmod(Ph)))
act(p(HGNC:DAPK1,pmod(Ph))) -| act(p(HGNC:DAPK1))
act(p(HGNC:DAPK1)) -> bp(GO:"neuron apoptotic process")
UNSET Confidence

SET Evidence = "Overexpression of wild-type UNC5C causes low-grade death, intensified by an AD-linked mutation T835M inhibited by a AD-linked survival factor,
calmodulin-like skin protein (CLSP), and a natural ligand of UNC5C, netrin1. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade,
consisting of DAPK1/protein kinase D/apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade,
mediated by amyloid ß precursor protein (APP)."
SET Confidence = "Medium"
p(HGNC:UNC5C) pos bp(GO:"neuron apoptotic process")
p(HGNC:UNC5C, var("p.Thr835Met")) -> bp(GO:"neuron apoptotic process")
p(HGNC:CALML5) -| bp(GO:"neuron apoptotic process")
p(HGNC:NTN1) -| bp(GO:"neuron apoptotic process")
p(HGNC:UNC5C, var("p.Thr835Met")) pos act(p(HGNC:PRKD1))
act(p(HGNC:PRKD1)) pos act(p(HGNC:MAP3K5))
act(p(HGNC:MAP3K5)) -> act(p(FPLX:JNK))
act(p(FPLX:JNK)) pos p(ECCODE:"1.6.3.1")
act(p(FPLX:JNK)) -- p(HGNC:CASP3)
act(p(HGNC:MAP3K5)) -- p(HGNC:CASP3)
p(HGNC:CASP3) -> bp(GO:"neuron apoptotic process")
UNSET Confidence


SET Citation = {"PubMed", "25899010"}
SET Evidence = "In contrast, Pin1/PINN-1 (a DAPK interaction-partner and a peptidyl-prolyl isomerase involved in chronic neurodegenerative conditions)
suppresses neurodegeneration in our excitotoxicity model."
SET Confidence = "Medium"
SET Species = "6239"
p(HGNC:PIN1) -| a(HBP:Excitotoxicity)
p(HGNC:PIN1) -| path(HBP:Neurodegeneration)
complex(p(HGNC:DAPK1),p(HGNC:PIN1))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "27795443"}
SET Evidence = "In this report, we describe a novel mechanism of action determined by the JunD component of AP-1, a factor enhancing cell survival in v-Src-transformed cells.
We show that the loss of JunD results in the aberrant activation of a genetic program leading to cell death.
This program requires the activation of the tumor suppressor death-associated protein kinase 1 (DAPK1).
Since DAPK1 is phosphorylated and inhibited by v-Src, these results highlight the importance of this kinase and the multiple mechanisms controlled by v-Src
to antagonize the tumor suppressor function of DAPK1."
SET Confidence = "Medium"
SET Cell_Line = "Chicken embryo fibroblasts"
act(p(HGNC:JUND)) -| bp(GO:"apoptotic process")
act(p(HGNC:JUND)) neg act(p(HGNC:DAPK1))
act(p(HGNC:DAPK1)) -> bp(GO:"apoptotic process")
kin(p(HGNC:CSK)) -> p(HGNC:DAPK1,pmod(Ph))
kin(p(HGNC:CSK)) -| act(p(HGNC:DAPK1))
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "27133022"}
SET Evidence = "Unexpectedly, impairment of the basic loop interaction site completely abolishes calcium/calmodulin binding and DAPK2 activity is reduced to a residual level,
indicative of coupled binding to the two sites."
SET Confidence = "Medium"
p(HBP:"DAPK, basic loop (BL) motif") partOf p(HGNC:DAPK2)
p(HBP:"DAPK, basic loop (BL) motif") pos act(p(HGNC:DAPK2))
p(HBP:"DAPK, basic loop (BL) motif") pos complex(p(FPLX:CALM),p(HGNC:DAPK2))
p(HBP:"DAPK, basic loop (BL) motif") pos complex(a(CHEBI:"calcium(2+)"),p(HGNC:DAPK2))
UNSET Confidence


SET Citation = {"PubMed", "25995053"}
SET Evidence = "Direct interaction of DAPK1 with Tau causes spine loss and subsequently neuronal death. DAPK1 phosphorylates Tau protein at Ser262 (pS(262)) in cortical neurons of stroke mice."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHDisease = "Stroke"
complex(p(MGI:Dapk1), p(MGI:Mapt)) -| a(GO:"dendritic spine")
complex(p(MGI:Dapk1), p(MGI:Mapt)) -> bp(GO:"neuron apoptotic process")
SET Anatomy = "cerebral cortex"
kin(p(MGI:Dapk1)) => p(MGI:Mapt, pmod(Ph, Ser, 262))
p(MGI:Mapt, pmod(Ph, Ser, 262)) -| a(GO:"dendritic spine")
UNSET Anatomy
UNSET MeSHDisease
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "24853415"}
SET Evidence = "We showed previously that DAPK1 phosphorylates Ser71 in the catalytic active site of Pin1, thereby inhibiting its cellular function."
SET Confidence = "High"
p(HGNC:DAPK1) -> p(HGNC:PIN1, pmod(Ph, Ser, 71))
p(HGNC:PIN1, pmod(Ph, Ser, 71)) -| act(p(HGNC:PIN1))
UNSET Confidence

SET Evidence = "As shown in Figure 7a, compared with the vector control, DAPK1, but not DAPK1K42A, increased the phosphorylation of exogenous tau protein in HeLa cells,
as detected by Thr231-specific (AT180), Ser262-specific, and Ser396-specific (PHF-13) antibodies that recognize specific tau phosphoepitopes and/or abnormal conformations
specific to AD NFT."
SET Confidence = "High"
SET Cell_Line = "HeLa"
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
UNSET Cell_Line
UNSET Confidence

SET Evidence = "DAPK1-mediated increase in tau protein expression and stability were accompanied by increased Pin1 Ser71 phosphorylation."
SET Confidence = "High"
p(HGNC:DAPK1) pos p(HGNC:MAPT)
p(HGNC:PIN1, pmod(Ph, Ser, 71)) pos p(HGNC:MAPT)
UNSET Confidence


SET Citation = {"PubMed", "23948915"}
SET Evidence = "These data suggest that tau hyperphosphorylation at Thr231, Ser262, and Ser396 by DAPK1 renders the cells more resistant to the kinase-induced apoptotic cell death,
providing new insights into the tau-involved apoptotic abortion in the course of chronic neurodegeneration."
SET Confidence = "High"
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
p(HGNC:DAPK1) -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
p(HGNC:MAPT, pmod(Ph, Ser, 262)) neg bp(GO:"apoptotic process")
p(HGNC:MAPT, pmod(Ph, Ser, 396)) neg bp(GO:"apoptotic process")
p(HGNC:MAPT, pmod(Ph, Thr, 231)) neg bp(GO:"apoptotic process")
UNSET Confidence


SET Citation = {"PubMed", "21311567"}
SET Evidence = "Furthermore, silencing of both MARK1 and MARK2 blocked DAPK-induced tau S262 phosphorylation (Figure 3e). More importantly, a decrease of pS262 tau,
but not total tau, was observed in brain extracts derived from DAPK−/− mice, compared with that from DAPK+/+ mice (Figure 3f).
These results strongly suggest a role of endogenous DAPK in stimulating the activity of endogenous MARK, which in turn phosphorylates tau in neurons."
SET Confidence = "Medium"
SET MeSHAnatomy = "Neurons"
p(HGNC:DAPK1) => act(p(HGNC:MARK1))
p(HGNC:DAPK1) => act(p(HGNC:MARK2))
act(p(HGNC:MARK2)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
act(p(HGNC:MARK1)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
kin(p(HGNC:DAPK1)) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "Importantly, depletion of MARK1/2 reversed the inhibitory effect of DAPK on MT regrowth (Figure 5c, right panel).
These results indicate that the DAPK–MARK signaling axis inhibits MT assembly and stability."
SET Confidence = "High"
p(HGNC:DAPK1) -| bp(GO:"microtubule polymerization")
act(p(HGNC:MARK2)) -| bp(GO:"microtubule polymerization")
act(p(HGNC:MARK1)) -| bp(GO:"microtubule polymerization")
UNSET Confidence

###################################start recuration Esther############################################

SET Citation = {"PubMed", "28137862"}
SET Evidence = "Moreover, we found that Hap1 bound Dcaf7 competitively in cytoplasm with dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A),
a protein implicated in Down syndrome (DS). Depleting Hap1 promoted the DYRK1A-Dcaf7 interaction and increased the DYRK1A protein level."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHAnatomy = "Cytosol"
p(MGI:Dcaf1) -- p(MGI:Dyrk1a)
p(MGI:Dcaf1) partOf complex(p(MGI:Dcaf1), p(MGI:Dyrk1a))
p(MGI:Dyrk1a) partOf complex(p(MGI:Dcaf1), p(MGI:Dyrk1a))
p(MGI:Hap1) -- p(MGI:Dcaf1)
p(MGI:Hap1) neg p(MGI:Dyrk1a)
p(MGI:Hap1) neg complex(p(MGI:Dcaf1), p(MGI:Dyrk1a))
UNSET Species
UNSET MeSHAnatomy
p(HGNC:DYRK1A) -- path(MESH:"Down Syndrome")
UNSET Confidence


SET Citation = {"PubMed", "29221819"}
SET Evidence = "The normalization of the Dyrk1A gene dosage did not rescue the reduced cerebellar volume but increased the size of the granular and molecular layers,
the densities of granular and Purkinje cells, and dendritic arborization."
SET Confidence = "Medium"
#normalization: reduced overexpression
SET Species = "10090"
SET Research_Model = "Ts65Dn mice"
SET MeSHDisease = {"Alzheimer Disease", "Down Syndrome"}
p(MGI:Dyrk1a) neg a(HBP:"granular layer of cerebellar cortex")
p(MGI:Dyrk1a) neg a(HBP:"molecular layer of cerebellar cortex")
p(MGI:Dyrk1a) neg a(HBP:"Purkinje cell layer of cerebellar cortex")
p(MGI:Dyrk1a) neg bp(GO:"dendrite arborization")

SET Evidence = "Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum,
prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aß load in the cortex and hippocampus,
the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum."
SET Confidence = "Medium"
#normalization: reduced overexpression
SET Anatomy = {"cingulate cortex", "hippocampal formation", "septum"}
p(MGI:Dyrk1a) pos bp(GO:"cellular senescence")
UNSET Anatomy
SET Cell = "cholinergic neuron"
p(MGI:Dyrk1a) pos path(HP:Neurodegeneration)
UNSET Cell
SET Anatomy = "hippocampal formation"
p(MGI:Dyrk1a) pos p(MGI:App)
UNSET Anatomy
SET Anatomy = {"hippocampal formation", "cerebral cortex"}
p(MGI:Dyrk1a) pos a(CHEBI:"amyloid-beta")
UNSET Anatomy
SET Anatomy = {"hippocampal formation", "cerebellum"}
p(MGI:Dyrk1a) pos p(MGI:Mapt, pmod(Ph, Ser, 202))
UNSET Anatomy
SET Anatomy = {"hippocampal formation", "cerebral cortex", "cerebellum"}
p(MGI:Dyrk1a) pos p(MGI:Mapt)
UNSET Anatomy
UNSET MeSHDisease
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "28884684"}
SET Evidence = "ID-8 indeed showed selectivity against the CMGC kinase family, with DYRK1B, GSK3B and DYRK1A being the top three kinase targets.
Although a biotinylated derivative of ID-8 bound DYRK2 and DYRK4 in affinity chromatography pull down assays (Hasegawa et al., 2012),
ID-8 itself showed little activity against these kinases, or against DYRK3. Next we determined IC50 values for a subset of these kinase targets,
using the same 33P incorporation assay (Table 1)."
SET Confidence = "High"
SET IC50 = "54 nM"
a(HBP:"ID-8") -| kin(p(HGNC:DYRK1B))
UNSET IC50
SET IC50 = "450 nM"
a(HBP:"ID-8") -| kin(p(HGNC:GSK3B))
UNSET IC50
SET IC50 = "78 nM"
a(HBP:"ID-8") -| kin(p(HGNC:DYRK1A))
UNSET IC50
UNSET Confidence

SET Evidence = "Here we present evidence that the indole compound ID-8 and a series of related molecules act to inhibit the neural specification of hESC through inhibition of DYRK1A."
SET Confidence = "High"
kin(p(HGNC:DYRK1A)) pos bp(GO:"neuron differentiation")
a(HBP:"ID-8") -| bp(GO:"neuron differentiation")
UNSET Confidence


SET Citation = {"PubMed", "28540658"}
SET Evidence = "DYRK1A overexpression induced dramatic deficits in the serotonin contents of the four brain areas tested and major deficits in dopamine and adrenaline contents
especially in the hypothalamus."
SET Confidence = "High"
SET Species = "10090"
SET Anatomy = {"dorsal plus ventral thalamus", "hypothalamus", "hippocampal formation", "striatum"}
p(MGI:Dyrk1a) -| a(CHEBI:serotonin)
UNSET Anatomy
SET Anatomy = "hypothalamus"
p(MGI:Dyrk1a) -| a(CHEBI:dopamine)
p(MGI:Dyrk1a) -| a(CHEBI:adrenaline)
UNSET Anatomy
UNSET Confidence


SET Citation = {"PubMed", "28250274"}
SET Evidence = "Neprilysin, a major Aß-degrading enzyme, was downregulated in DS patient-derived fibroblasts.
Treatment with harmine, a DYRK1A inhibitor and gene knockdown of DYRK1A, upregulated neprilysin in fibroblasts."
SET Confidence = "Medium"
p(HGNC:MME) -> deg(a(CHEBI:"amyloid-beta"))
SET Cell_Line = "Human fibroblasts"
p(HGNC:MME) neg path(MESH:"Down Syndrome")
SET MeSHDisease = "Down Syndrome"
a(CHEBI:harmine) -| p(HGNC:DYRK1A)
p(HGNC:DYRK1A) neg p(HGNC:MME)
a(CHEBI:harmine) -> p(HGNC:MME)
UNSET Cell_Line
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "28775333"}
SET Evidence = "Here we demonstrated that MEF2D could upregulate DYRK1A gene expression through specific activation of DYRK1A isoform 5 gene transcription.
The coordinated expression of DYRK1A and MEF2D in mouse brain development indicated a possibility of the cross-interaction of these two genes during neurodevelopment.
The DYRK1A kinase activity was also affected by MEF2D's transcriptional regulation of DYRK1A."
SET Confidence = "High"
SET Species = "10090"
p(MGI:Mef2d) -> r(MGI:Dyrk1a)
p(MGI:Mef2d) -> kin(p(MGI:Dyrk1a))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "28775333"}
SET Evidence = "Inhibition of Dyrk1A enhanced tau exon 10 inclusion, leading to an increase in 4R-tau/3R-tau ratio in differentiated-human neuronal progenitors and in the neonatal rat brains.
Accompanied with overexpression of Dyrk1A, 3R-tau was increased and 4R-tau was decreased in the neonatal brains of Ts65Dn mice, a model of Down syndrome."
SET Confidence = "High"
SET Species = "10090"
SET Research_Model = "Ts65Dn mice"
SET MeSHDisease = {"Alzheimer Disease", "Down Syndrome"}
p(MGI:Dyrk1a) pos p(HBP:"3R tau")
p(MGI:Dyrk1a) neg p(HBP:"4R tau")
UNSET Confidence

SET Evidence = "Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression
and rescued anxiety and memory deficits in Ts65Dn mouse brains."
SET Confidence = "Medium"
SET MeSHAnatomy = "Brain"
a(CHEBI:"(-)-epigallocatechin 3-gallate") -| p(MGI:Dyrk1a)
a(CHEBI:"(-)-epigallocatechin 3-gallate") -| p(HBP:"3R tau")
a(CHEBI:"(-)-epigallocatechin 3-gallate") -| path(MESH:Anxiety)
a(CHEBI:"(-)-epigallocatechin 3-gallate") pos bp(GO:memory)
p(MGI:Dyrk1a) pos path(MESH:Anxiety)
p(MGI:Dyrk1a) neg bp(GO:memory)
UNSET Species
UNSET MeSHDisease
UNSET Research_Model
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "28632203"}
SET Evidence = "Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952,
a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile.
Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers."
SET Confidence = "High"
SET MeSHDisease = "Alzheimer Disease"
SET Anatomy = "blood plasma"
p(HGNC:DYRK1A) biomarkerFor path(MESH:"Alzheimer Disease")
p(HGNC:BDNF) biomarkerFor path(MESH:"Alzheimer Disease")
a(CHEBI:homocysteine) biomarkerFor path(MESH:"Alzheimer Disease")
composite(p(HGNC:DYRK1A), p(HGNC:BDNF), a(CHEBI:homocysteine)) biomarkerFor path(MESH:"Alzheimer Disease")
UNSET Anatomy
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "28167836"}
SET Evidence = "We conclude that the Dyrk1a dosage is critical for proper neurite and axonal outgrowth and that the two nonsense mutations, R205X and E239X, are loss-of-function mutants."
SET Confidence = "Medium"
SET HBP_Disease = "Autism Spectrum Disorder (ASD)"
act(p(HGNC:DYRK1A)) reg a(HBP:Neurites)
act(p(HGNC:DYRK1A)) reg a(GO:axon)

p(HGNC:DYRK1A, var("p.Arg205del")) -| act(p(HGNC:DYRK1A))
p(HGNC:DYRK1A, var("p.Glu239del")) -| act(p(HGNC:DYRK1A))
UNSET HBP_Disease
UNSET Confidence


SET Citation = {"PubMed", "29077046"}
SET Evidence = "DNA binding and stabilising"
SET Confidence = "Low"
#not in evidence or citation
a(CHEBI:harmine) -> complex(a(CHEBI:harmine), g(HGNC:DYRK1A))
UNSET Confidence


SET Citation = {"PubMed", "28877763"}
SET Evidence = "Additionally, we show that Syk overexpression leads to increased tau accumulation and promotes tau hyperphosphorylation at multiple epitopes in human neuron-like SH-SY5Y cells,
further supporting a role of Syk in the formation of tau pathogenic species. Collectively, our data show that Syk activation occurs following Aβ deposition and the formation of tau pathological species."
SET Confidence = "Medium"
SET Species = "9606"
SET CellLine = "SH-SY5Y"
p(HGNC:SYK) -> a(HBP:"Tau aggregates")
p(HGNC:SYK) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Species
UNSET CellLine
a(CHEBI:"amyloid-beta") -> act(p(HGNC:SYK))
a(HBP:"Tau aggregates") -> act(p(HGNC:SYK))
UNSET Confidence

SET Evidence = "The upregulation of Syk activation observed in the brains of Tg APPsw and Tg PS1/APPsw is mainly attributable to pSyk accumulations in dystrophic neurites
that are associated with Aβ plaques and increase with age and Aβ burden."
SET Confidence = "Medium"
SET Research_Model = "APPPS1 mice"
SET MeSHAnatomy = "Brain"
path(MESH:"Plaque, Amyloid")
p(MGI:Syk, pmod(Ph)) partOf a(HBP:"dystrophic neurite")
p(MGI:Syk, pmod(Ph)) -> act(p(MGI:Syk))
path(MESH:"Plaque, Amyloid") -- a(HBP:"dystrophic neurite")
a(CHEBI:"amyloid-beta") -> a(HBP:"dystrophic neurite")
bp(GO:aging) -> a(HBP:"dystrophic neurite")
UNSET Research_Model
UNSET MeSHAnatomy

SET Evidence = "Interestingly, Syk upregulation in SH-SY5Y cells leads to a significant increase (1.7-fold) in phosphorylated tau at Y18 (Fig. 14c, p < 0.01) and at S396/404
(Fig. 14d, 3-fold, p < 0.0001) compared to control cells. Total tau levels are also significantly increased following Syk overexpression (Fig. 14e, 4.2-fold, p < 0.0001)."
SET Confidence = "High"
SET Cell_Line = "SH-SY5Y"
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Tyr, 18))
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Ser, 396))
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Ser, 404))
p(MGI:Syk) pos p(MGI:Mapt)
UNSET Cell_Line
UNSET Confidence

SET Evidence = "We found an increase in Syk activation in DNs surrounding Aβ deposits as well as in neurons displaying an accumulation of phosphorylated Tau at Y18
and elevated levels of MC1 pathogenic tau conformers in AD brain sections whereas only weak immunoreactivity for pSyk was observed in brain sections from a non-demented control"
SET Confidence = "Medium"
p(HGNC:SYK, pmod(Ph)) pos path(MESH:"Plaque, Amyloid")
SET MeSHAnatomy = "Neurons"
p(HGNC:SYK, pmod(Ph)) pos p(HGNC:MAPT, pmod(Ph, Tyr, 18))
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "18070606"}
SET Evidence = "We report herein that Syk is also a tau kinase, phosphorylating tau in vitro and in CHO cells when both proteins are expressed exogenously.
In CHO cells, we have also demonstrated by co-immunoprecipitation that Syk binds to tau.
Finally, by site-directed mutagenesis substituting the tyrosine residues of tau with phenylalanine, we established that tyrosine 18 was the primary residue in tau phosphorylated by Syk."
SET Confidence = "High"
SET Species = "10029"
SET Cell_Line = "CHO"
p(RGD:Syk) -> p(RGD:Mapt, pmod(Ph,Tyr,18))
UNSET Cell_Line
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "26501932"}
SET Evidence = "Pretangles contained either paired helical filaments (PHFs) or PtdIns(4,5)P2-immunopositive small vesicles (approximately 1 µm in diameter) with nearly identical
topology to granulovacuolar degeneration (GVD) bodies. Various combinations of these vesicles and GVD bodies, the latter of which are pathological hallmarks observed within
the neurons of AD patients, were found concurrently in neurons.These vesicles and GVD bodies were both immunopositive not only for PtdIns(4,5)P2,
but also for several tau kinases such as glycogen synthase kinase-3ß and spleen tyrosine kinase."
SET Confidence = "Medium"
a(HBP:"paired helical filaments") partOf a(HBP:pretangles)
a(CHEBI:"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate") partOf a(GO:"synaptic vesicle")
p(HGNC:SYK) partOf a(HBP:pretangles)
a(CHEBI:"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate") partOf a(HBP:"GVD bodies")
a(CHEBI:"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate") partOf a(HBP:pretangles)
p(HGNC:SYK) partOf a(HBP:"GVD bodies")
p(HGNC:GSK3B) partOf a(HBP:"GVD bodies")
UNSET Confidence


SET Citation = {"PubMed", "25331948"}
SET Evidence = "We have previously shown that the L-type calcium channel (LCC) antagonist nilvadipine reduces brain amyloid-β (Aβ) accumulation by affecting both
Aβ production and Aβ clearance across the blood-brain barrier (BBB)."
SET Confidence = "Medium"
a(CHEBI:Nilvadipine) =| complex(GO:"L-type voltage-gated calcium channel complex")
SET MeSHAnatomy = "Brain"
a(CHEBI:Nilvadipine) -| a(CHEBI:"amyloid-beta")
a(CHEBI:Nilvadipine) -> deg(a(CHEBI:"amyloid-beta"))
SET MeSHAnatomy = "Blood-Brain Barrier"
a(CHEBI:Nilvadipine) -> tloc(a(CHEBI:"amyloid-beta"), fromLoc(MESH:Brain), toLoc(MESH:Blood))
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "Western blot analyses of brain homogenates show that (−)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205)
and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes"
SET Confidence = "Medium"
a(CHEBI:Nilvadipine) -| p(HGNC:MAPT, pmod(Ph, Ser, 199))
a(CHEBI:Nilvadipine) -| p(HGNC:MAPT, pmod(Ph, Ser, 202))
a(CHEBI:Nilvadipine) -| p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HGNC:MAPT, pmod(Ph,Ser, 199)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) partOf p(HBP:"Tau epitope, AT8")
a(CHEBI:Nilvadipine) -| p(HGNC:MAPT, pmod(Ph, Ser, 396))
a(CHEBI:Nilvadipine) -| p(HGNC:MAPT, pmod(Ph, Ser, 404))
p(HGNC:MAPT, pmod(Ph, Ser, 396)) partOf p(HBP:"Tau epitope, PHF1")
p(HGNC:MAPT, pmod(Ph, Ser, 404)) partOf p(HBP:"Tau epitope, PHF1")
UNSET Confidence

SET Evidence = "We further validated Syk as a target-regulating Aβ by showing that pharmacological inhibition of Syk or down-regulation of Syk expression reduces Aβ production
and increases the clearance of Aβ across the BBB mimicking (-)-nilvadipine effects. Moreover, treatment of transgenic mice overexpressing Aβ and transgenic Tau P301S mice with
a selective Syk inhibitor respectively decreased brain Aβ accumulation and Tau hyperphosphorylation at multiple AD relevant epitopes."
SET Confidence = "Medium"
SET Species = "10090"
p(MGI:Syk) -> a(CHEBI:"amyloid-beta")
p(MGI:Syk) -| deg(a(CHEBI:"amyloid-beta"))
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Tyr, 18))
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Ser, 396))
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Ser, 404))
kin(p(HGNC:GSK3B)) -> p(HBP:"Tau epitope, PHF1")
p(MGI:Syk) pos p(MGI:Mapt, pmod(Ph, Ser, 202))
p(HGNC:MAPT, pmod(Ph, Ser, 202)) eq p(HBP:"Tau epitope, CP13")
UNSET Species
UNSET Confidence

SET Evidence = "We observed that pharmacological inhibition of Syk with BAY61-3606 stimulates Ser-9 phosphorylation of GSK3β in SH-SY5Y cells (Fig. 9, A and B) suggesting that blocking Syk activity results in GSK3β inhibition."
SET Confidence = "Medium"
SET Cell_Line = "SH-SY5Y"
a(PUBCHEM:10200390) =| act(p(HGNC:SYK))
act(p(HGNC:SYK)) -| p(HGNC:GSK3B, pmod(Ph, Ser, 9))
act(p(HGNC:SYK)) -> kin(p(HGNC:GSK3B))
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "28176663"}
SET Evidence = "We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of
the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at
Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects."
SET Confidence = "Medium"
path(MESH:"Alzheimer Disease") -> r(HGNC:GSK3B)
SET MeSHDisease = "Alzheimer Disease"
SET MeSHAnatomy = "Cerebral Cortex"
a(HBP:"Braak_Stage I") pos kin(p(HGNC:GSK3B))
a(HBP:"Braak_Stage II") pos kin(p(HGNC:GSK3B))

a(HBP:"Braak_Stage V") neg kin(p(HGNC:GSK3B))
a(HBP:"Braak_Stage V") neg kin(p(HGNC:GSK3B))
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "28176663"}
SET Evidence = "Here, we show for the first time that the administration of D-ribose, the most active glycator among monosaccharides,
produces high levels of advanced glycation end products (AGEs) and, importantly, triggers hyperphosphorylation of Tau in the brain of C57BL/6 mouse and neuroblastoma N2a cells."
SET Confidence = "Medium"
a(CHEBI:"D-ribose") -> a(HBP:"advanced glycation end product")
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Thr, 181))
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Ser, 214))
a(CHEBI:"D-ribose") -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
UNSET Confidence

SET Evidence = "Thus, our results suggest that Tau hyperphosphorylation was a result of ribosylated AGEs, rather than due to a direct reaction involving D-ribose."
SET Confidence = "High"
a(HBP:"advanced glycation end product") -> p(HGNC:MAPT, pmod(Ph, Thr, 181))
a(HBP:"advanced glycation end product") -> p(HGNC:MAPT, pmod(Ph, Ser, 214))
a(HBP:"advanced glycation end product") -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
UNSET Confidence


SET Citation = {"PubMed", "26118667"}
SET Evidence = "To perform its function, Cdk5 must bind to the neuron-specific regulatory subunit protein p35, which is
beneficial for neuronal development (Tsai et al. 1994; Chae et al. 1997). However, truncation of p35 and conversion to p25 (Patrick et al. 1999) is found in the forebrain of rats after
focal cerebral ischemia and in AD patients, and these alterations are deleterious to the brain"
SET Confidence = "Medium"
p(HGNC:CDK5) -> complex(p(HGNC:CDK5), p(HGNC:CDK5R1))
p(HGNC:CDK5R1) -> bp(GO:"neuron maturation")
p(HGNC:CDK5R1) partOf complex(p(HGNC:CDK5), p(HGNC:CDK5R1))
complex(p(HGNC:CDK5), p(HGNC:CDK5R1)) -> act(p(HGNC:CDK5))
p(HGNC:CDK5R1) neg p(HBP:"CDK5R1 p25")
p(HGNC:CDK5R1, frag(99_307)) eq p(HBP:"CDK5R1 p25")
p(HBP:"CDK5R1 p25") pos path(MESH:"Alzheimer Disease")
UNSET Confidence

SET Evidence = "The accumulation of p25 involves neurofibrillary tangle (NFT) formation via regulation of tau phosphorylation (Wen et al. 2007; Su and Tsai 2011)"
SET Confidence = "Medium"
p(HBP:"CDK5R1 p25") pos a(GO:"neurofibrillary tangle")
p(HBP:"CDK5R1 p25") reg p(HGNC:MAPT, pmod(Ph))
UNSET Confidence

SET Evidence = "We observed that 2VO leads to tau hyperphosphorylation at Ser202/Thr205, Ser262, Thr231, and Ser422 and to the conversion
from cyclin-dependent kinase 5 (Cdk5)/p35 to Cdk5/p25 in rat hippocampi. "
SET Confidence = "High"
#2VO is bilateral common carotid artery occlusion
SET Species = "10116"
SET Anatomy = "hippocampal formation"
path(HBP:"Chronic cerebral hypoperfusion") -> p(RGD:Mapt, pmod(Ph, Ser, 202))
path(HBP:"Chronic cerebral hypoperfusion") -> p(RGD:Mapt, pmod(Ph, Thr, 205))
path(HBP:"Chronic cerebral hypoperfusion") -> p(RGD:Mapt, pmod(Ph, Ser, 262))
path(HBP:"Chronic cerebral hypoperfusion") -> p(RGD:Mapt, pmod(Ph, Thr, 231))
path(HBP:"Chronic cerebral hypoperfusion") -> p(RGD:Mapt, pmod(Ph, Ser, 422))
path(HBP:"Chronic cerebral hypoperfusion") -> p(HBP:"CDK5R1 p25")
UNSET Anatomy
UNSET Confidence

SET Evidence = "Endogenous miR-195 was knocked down using over-expression of its antisense molecule (pre-AMO-miR-195) via a lentivirus (lenti-pre-AMO-miR-195);
this knockdown increased the tau phosphorylation at Ser202/Thr205, Ser262, Thr231, Ser422, and the Cdk5/p25 activation, but over-expression of miR-195 using lenti-pre-miR-195
decreased the tau phosphorylation and Cdk5/p25 activation."
SET Confidence = "Medium"
m(MIRBASE:"rno-mir-195") -| p(HGNC:MAPT, pmod(Ph, Ser, 202))
m(MIRBASE:"rno-mir-195") -| p(HGNC:MAPT, pmod(Ph, Thr, 205))
m(MIRBASE:"rno-mir-195") -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
m(MIRBASE:"rno-mir-195") -| p(HGNC:MAPT, pmod(Ph, Thr, 231))
m(MIRBASE:"rno-mir-195") -| p(HGNC:MAPT, pmod(Ph, Ser, 422))
m(MIRBASE:"rno-mir-195") -| act(p(HBP:"CDK5R1 p25"))
UNSET Confidence

SET Evidence = "A dual luciferase reporter assay showed that miR-195 bound to the Cdk5r1 gene, which encodes p35 protein, in the 3'UTR and inhibited p35 expression."
SET Confidence = "High"
m(MIRBASE:"rno-mir-195") -> complex(m(MIRBASE:"rno-mir-195"), g(RGD:Cdk5r1))
complex(m(MIRBASE:"rno-mir-195"), g(RGD:Cdk5r1)) -| r(RGD:Cdk5r1)
UNSET Confidence

SET Evidence = "Chronic Brain hypoperfusion (CBH) elevates nuclear factor-kB (NF-kB), which binds with the promoter sequences of miR-195 and negatively regulates its expression.
Down-regulated miR-195 up-regulates APP and BACE1 and increases Aß levels. Some Aß then enter the intracellular space and activate calpain, promoting the conversion of Cdk5/p35 to
Cdk5/p25 and catalyzes the degradation of IkB (inhibitor of NF-?B)and directly phosphorylates Tau. Down-regulated miR-195 up-regulates p35, which provides the active substrates of p25"
SET Confidence = "Medium"
path(HBP:"Chronic cerebral hypoperfusion") -> p(FPLX:NFkappaB)
p(FPLX:NFkappaB) -> complex(p(FPLX:NFkappaB), g(MIRBASE:"rno-mir-195"))
complex(p(FPLX:NFkappaB), g(MIRBASE:"rno-mir-195")) -| m(MIRBASE:"rno-mir-195")
m(MIRBASE:"rno-mir-195") -| p(RGD:App)
m(MIRBASE:"rno-mir-195") -| p(RGD:Bace1)
m(MIRBASE:"rno-mir-195") -| a(CHEBI:"amyloid-beta")
a(CHEBI:"amyloid-beta", loc(MESH:"Intracellular Space")) -> act(p(FPLX:CAPN))
act(p(FPLX:CAPN)) pos reaction(reactants(p(RGD:Cdk5r1)),products(p(HBP:"CDK5R1 p25")))
act(p(FPLX:CAPN)) -> deg(p(HGNC:NFKBIA))
act(p(FPLX:CAPN)) -> p(HGNC:MAPT, pmod(Ph))
m(MIRBASE:"rno-mir-195") -| p(RGD:Cdk5r1)
UNSET Confidence
UNSET Species


SET Citation = {"PubMed", "27087442"}
SET Evidence = "The levels of CDK5, its regulatory subunits (p35 and p25) and calpain (including calpain1 and calpain2), but not GSK3ß, were significantly increased in E4FAD mice compared to E3FAD mice."
SET Confidence = "High"
SET Species = "10090"
SET Research_Model = "E4FAD mice"
g(HBP:"APOE e4") -> p(MGI:Cdk5)
g(HBP:"APOE e4") -> p(HBP:"CDK5R1 p25")
g(HBP:"APOE e4") -> p(MGI:Cdk5r1)
g(HBP:"APOE e4") -> p(MGI:Capn1)
g(HBP:"APOE e4") -> p(MGI:Capn2)
g(HBP:"APOE e4") cnc p(MGI:Gsk3b)
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "27087442"}
SET Evidence = "Our data showed that CDK5 knock down induced an increase in p35 protein levels and
Rac activity in triple transgenic Alzheimer's mice, which correlated with the recovery of cognitive function;
these findings confirm that increased p35 and active Rac are involved in neuroprotection.
In summary, our data suggest that p35 acts as a mediator of Rho GTPase activity and contributes to the neuroprotection induced by CDK5 RNAi."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHDisease = "Alzheimer Disease"
p(MGI:Cdk5) -| p(MGI:Cdk5r1)
p(MGI:Cdk5) -| act(p(HBP:RAC1b))
p(MGI:Cdk5) -| path(MESH:Cognition)
p(MGI:Cdk5r1) -| bp(GO:"neuron death")
act(p(HBP:RAC1b)) -| bp(GO:"neuron death")
p(MGI:Cdk5) -> bp(GO:"neuron death")
UNSET Confidence

SET Evidence = "We demonstrated that the treatment of cultured hippocampal neurons with 125 µM glutamate
for 20 min induced the cleavage of p35 to produce the p25 fragment 6 h after glutamate treatment,
and the maximal levels of p25 were detected at 12 h (Fig. 1A), which is consistent with a peak in tau hyperphosphorylation (AT8)."
SET Confidence = "Medium"
SET Cell = "hippocampal neuron"
a(CHEBI:"glutamate(1-)") -> p(HBP:"CDK5R1 p25")
p(HBP:"CDK5R1 p25") pos p(HBP:"Tau epitope, AT8")
UNSET Cell
UNSET Species


SET Citation = {"PubMed", "25987199"}
SET Evidence = "In this study, we demonstrated that GLP-1RA could inhibit oxidative stress and repair
mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with AGEs.
Importantly, we first observed AGEs in the circulatory system could induce tau hyperphosphorylation
after we injected AGEs (1μg/kg bodyweight) into the mice tail vein. We found GLP-1RA could promote
mitochondrial biogenesis and antioxidant system via regulating peroxisome proliferator-activated
receptor γ coactivator 1α (PGC-1α) signaling pathway in vivo besides down-regulating the activity of
glycogen synthase kinase 3β (GSK-3β) to reverse tau hyperphosphorylation directly."
SET Confidence = "Medium"
SET Cell_Line = "PC12"
p(HGNC:GLP1R) -| bp(MESH:"Oxidative Stress")
p(HGNC:GLP1R) -> act(a(GO:"mitochondrion"))
p(HGNC:GLP1R) -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Cell_Line
SET Species = "10090"
act(a(HBP:"advanced glycation end product")) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
act(p(MGI:Glp1r)) reg act(p(MGI:Ppargc1a))
act(p(MGI:Ppargc1a)) pos act(a(GO:"mitochondrion"))
act(p(MGI:Glp1r)) -| kin(p(MGI:Gsk3b))
act(p(MGI:Glp1r)) -| p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "25125464"}
SET Evidence = "CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422
sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites,
but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK)."
SET Confidence = "Medium"
# CRF-OE mice: CRF overexpressing
SET Species = "10090"
SET Anatomy = "hippocampal formation"
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, S, 202))
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, T, 204))
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, S, 396))
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, S, 404))
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, S, 262))
p(MGI:Crh) -> p(MGI:Mapt, pmod(Ph, S, 422))
a(PUBCHEM:9821250) -| p(MGI:Mapt, pmod(Ph, S, 202))
a(PUBCHEM:9821250) -| p(MGI:Mapt, pmod(Ph, T, 204))
a(PUBCHEM:9821250) -| p(MGI:Mapt, pmod(Ph, S, 396))
a(PUBCHEM:9821250) -| p(MGI:Mapt, pmod(Ph, S, 404))
a(PUBCHEM:9821250) cnc p(MGI:Mapt, pmod(Ph, S, 262))
a(PUBCHEM:9821250) cnc p(MGI:Mapt, pmod(Ph, S, 422))
a(PUBCHEM:9821250) -| p(FPLX:JNK, pmod(Ph, S, 404))
UNSET Anatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "25125464"}
SET Evidence = "Analysis of synaptosomes revealed that FynCA accumulated at high levels in the spine,
resulting in increased levels of the NMDA receptor subunit NR2b phosphorylated at residue Y1472.
Tau was strongly phosphorylated at the AT8 epitope S202/T205 as shown by Western blot and immunohistochemistry
indicating that an increased tyrosine kinase activity of Fyn has down-stream consequences for serine/threonine-directed phosphorylation."
SET Confidence = "Medium"
SET Species = "10090"
p(MGI:Fyn) pos a(GO:"neuron spine")
p(MGI:Fyn) -> p(MGI:Grin2b, pmod(Ph, Tyr, 1472))
act(p(MGI:Fyn)) -> p(MGI:Mapt, pmod(Ph, S, 202))
act(p(MGI:Fyn)) -> p(MGI:Mapt, pmod(Ph, T, 205))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23687953"}
SET Evidence = "The single kinase and sequential kinase-catalyzed Fc-phosphorylations points to dramatic changes
around the Fc group in the Fc-phosphorylated tau films. Additional surface characterization of the Fc-tau films
by time-of-flight secondary ion-mass spectrometry and X-ray photoelectron spectroscopy revealed that
Fc-phosphorylations influence the tau orientation and conformation on surfaces."
SET Confidence = "Low"
#not in evidence or citation
kin(p(HGNC:TTBK1)) => p(HGNC:MAPT, pmod(Ph, Tyr, 197))
kin(p(HGNC:ABL1)) => p(HGNC:MAPT, pmod(Ph, Tyr, 363))
UNSET Confidence


SET Citation = {"PubMed", "19459590"}
SET Evidence = "Because S199/S202/T205E, S396/S404E, 6-Phos and 7-Phos all demonstrated an AD-like shift in
mobility as a result of phosphorylation-like changes, we conclude that they have the characteristics of
hyperphosphorylated tau. These mutants will therefore be referred to as pseudo-hyperphosphorylated tau
throughout the manuscript. On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules
and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased
cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation."
SET Confidence = "Medium"
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Thr, 205))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
kin(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph, Ser, 404))
p(HGNC:MAPT, pmod(Ph, Ser, 199)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Ser, 202)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Thr, 205)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Ser, 396)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Ser, 404)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
UNSET Confidence


SET Citation = {"PubMed", "22833681"}
SET Evidence = "Hence, LTD-inducing NMDA receptor activation leads to an increase in tau phosphorylation at sites PHF-1, AT180, as well as AT8 and to a reduction at AT100."
SET Confidence = "Medium"
SET Species = "10116"
SET Anatomy = "hippocampal formation"
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) -> p(HBP:"Tau epitope, AT8")
#AT8:pSer202, pThr205, pSer208, pSer199
p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Ser, 208)) partOf p(HBP:"Tau epitope, AT8")
p(HGNC:MAPT, pmod(Ph, Ser, 199)) partOf p(HBP:"Tau epitope, AT8")
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) -> p(HBP:"Tau epitope, PHF1")
#PHF1: pSer396, pSer404
p(HGNC:MAPT, pmod(Ph, Ser, 396)) partOf p(HBP:"Tau epitope, PHF1")
p(HGNC:MAPT, pmod(Ph, Ser, 404)) partOf p(HBP:"Tau epitope, PHF1")
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) -> p(HBP:"Tau epitope, AT180")
p(HBP:"Tau epitope, AT180") eq p(HGNC:MAPT, pmod(Ph, Thr, 231))
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) -| p(HBP:"Tau epitope, AT100")
p(HGNC:MAPT, pmod(Ph, Thr, 214)) partOf p(HBP:"Tau epitope, AT100")
p(HGNC:MAPT, pmod(Ph, Ser, 212)) partOf p(HBP:"Tau epitope, AT100")
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) pos path(HBP:"Long-Term Depression")
UNSET Confidence

SET Evidence = "This result is supported by recent studies showing that the interaction between Fyn and tau
is regulated through tau phosphorylation at the AT8 site, increasing tau-Fyn interaction by 42-fold after tau
is phosphorylated or bearing a phosphomimetic mutation at the AT8 site (63).
In our experiments, tau phosphorylation at AT8 is strongly up-regulated through the activation of NMDA receptors (Fig. 3),
suggesting that NMDA receptor activation could massively enhance the interaction between tau and Fyn."
SET Confidence = "Medium"
p(HGNC:MAPT, pmod(Ph, Ser, 202)) -> complex(p(HGNC:MAPT), p(HGNC:FYN))
p(HGNC:MAPT, pmod(Ph, Thr, 205)) -> complex(p(HGNC:MAPT), p(HGNC:FYN))
p(HGNC:MAPT, pmod(Ph, Ser, 208)) -> complex(p(HGNC:MAPT), p(HGNC:FYN))
p(HGNC:MAPT, pmod(Ph, Ser, 199)) -> complex(p(HGNC:MAPT), p(HGNC:FYN))
act(a(MESH:"Receptors, N-Methyl-D-Aspartate")) -> complex(p(HGNC:MAPT), p(HGNC:FYN))
UNSET Confidence

UNSET Anatomy
UNSET Species

SET Citation = {"PubMed", "22833681"}
SET Evidence = "Acute treatment of rTg4510 mice with an O-GlcNAcase inhibitor transiently reduced tau phosphorylation
at epitopes implicated in tau pathology. More importantly, long-term inhibitor treatment strongly increased tau
O-GlcNAcylation, reduced the number of dystrophic neurons, and protected against the formation of pathological
tau species without altering the phosphorylation of non-pathological tau."
SET Confidence = "Medium"
SET Research_Model = "rTg4510 mice"
a(HBP:"Thiamet G") =| act(p(ECCODE:"3.2.1.169"))
act(p(ECCODE:"3.2.1.169")) -> p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation"))
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) pos p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) pos p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) pos p(HGNC:MAPT, pmod(Ph, Ser, 356))
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) pos p(HGNC:MAPT, pmod(Ph, Ser, 396))
UNSET Confidence

SET Evidence = "This indicates that O-GlcNAcylation prevents the aggregation of tau in a manner that does not affect its normal phosphorylation state."
SET Confidence = "High"
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) -| a(HBP:"Tau aggregates")
UNSET Research_Model
UNSET Confidence

SET Citation = {"PubMed", "24406748"}
SET Evidence = "We developed a transgenic mouse, named TPR50, harboring human P301S tau.
Tau phosphorylation in the hippocampus of TPR50 mice increased with age, particularly at S202/T205.
Therefore, cognitive dysfunction in TPR50 mice may result from early MT dysfunction and impaired axonal transport rather than accumulation of insoluble tau and neurodegeneration."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "TPR50 mice"
SET MeSHAnatomy = "Hippocampus"
p(HGNC:MAPT, var("p.Pro301Ser")) pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HGNC:MAPT, var("p.Pro301Ser")) pos p(HGNC:MAPT, pmod(Ph, Thr, 205))
UNSET MeSHAnatomy
p(HGNC:MAPT, var("p.Pro301Ser")) -| path(MESH:Cognition)
p(HGNC:MAPT, var("p.Pro301Ser")) -> path(HBP:"mitochondrial dysfunction")
p(HGNC:MAPT, var("p.Pro301Ser")) -| bp(GO:"axonal transport")
UNSET Research_Model
UNSET Species
UNSET Confidence

SET Citation = {"PubMed", "23294633"}
SET Evidence = "We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia.
In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes.
Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8
(phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with
fibrillar tau pathology."
SET Confidence = "Medium"
path(MESH:"Frontotemporal Dementia") pos p(HGNC:MAPT, var("p.Pro301Leu"))
SET Species = "10090"
SET Research_Model = "pR5 mice"
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(MGI:Gsk3b, pmod(Ph, Tyr, 279))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(MGI:Gsk3b, pmod(Ph, Tyr, 216))
p(MGI:Gsk3b, pmod(Ph, Tyr, 279)) -> kin(p(MGI:Gsk3b))
p(MGI:Gsk3b, pmod(Ph, Tyr, 216)) -> kin(p(MGI:Gsk3b))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HGNC:MAPT, pmod(Ph, Ser, 212))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HGNC:MAPT, pmod(Ph, Thr, 214))
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HGNC:MAPT, pmod(Ph, Ser, 422))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "14642273"}
SET Evidence = "Tau peptides containing phosphorylated S202, T205, and T396 were found only in Tg mice, supporting our results using AT8 and PHF1 antibodies"
SET Confidence = "Medium"
#tau peptides in p25 transgenic mice
#phosphorylation sites in p25 transgenic mice from table 1
SET Species = "10090"
SET Research_Model = "p25 transgenic mice"
p(HBP:"CDK5R1 p25") => kin(p(MGI:Cdk5))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 175))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 176))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 178))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 195))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 198))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 199))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 202))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 205))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 217))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 220))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 235))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 239))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 396))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Ser, 400))
kin(p(MGI:Cdk5)) => p(MGI:Mapt, pmod(Ph, Thr, 403))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "22002427"}
SET Evidence = "E391-3610 mice (higher expressers) exhibit robust somatodendritic distribution of phospho- Ser 202/Thr 205 tau throughout
the cortex, in hippocampal CA3 pyramidal neurons, CA1 apical dendrites and cell bodies and dentate granule cells."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "hTau E391 transgenic mice"
SET Anatomy = {"cerebral cortex", "CA3 field of hippocampus", "CA1 field of hippocampus", "dentate gyrus granule cell layer"}
p(HGNC:MAPT, trunc(Glu391)) pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HGNC:MAPT, trunc(Glu391)) pos p(HGNC:MAPT, pmod(Ph, Ser, 205))
UNSET Anatomy
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "24113872"}
SET Evidence = "Using mass spectrometry, we identified multiple sites on recombinant tau that are phosphorylated
by LRRK2 in vitro, including pT149 and pT153, which are phospho-epitopes that to date have been largely unexplored.
Importantly, we demonstrate that expression of transgenic LRRK2 in a mouse model of tauopathy increased
the aggregation of insoluble tau and its phosphorylation at T149, T153, T205, and S199/S202/T205 epitopes."
SET Confidence = "Medium"
p(HGNC:LRRK2) pos path(MESH:"Parkinson Disease")
SET Species = "10090"
SET Research_Model = "LRRK2 transgenic mice"
kin(p(HGNC:LRRK2)) => p(MGI:Mapt, pmod(Ph, Thr, 149))
kin(p(HGNC:LRRK2)) => p(MGI:Mapt, pmod(Ph, Thr, 153))
kin(p(HGNC:LRRK2)) => p(MGI:Mapt, pmod(Ph, Thr, 205))
kin(p(HGNC:LRRK2)) => p(HBP:"Tau aggregates")
kin(p(HGNC:LRRK2)) => p(MGI:Mapt, pmod(Ph, Ser, 199))
kin(p(HGNC:LRRK2)) => p(MGI:Mapt, pmod(Ph, Ser, 202))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "24033439"}
SET Evidence = "Finally, these data validate PHF-1 as an efficient marker for AD cytopathology following the progression of tau aggregation into NFT."
SET Confidence = "Medium"
p(HBP:"Tau epitope, PHF1") biomarkerFor path(MESH:"Alzheimer Disease")
p(HBP:"Tau epitope, PHF1") -> p(HBP:"Tau aggregates")
p(HBP:"Tau aggregates") -> a(GO:"neurofibrillary tangle")
UNSET Confidence


SET Citation = {"PubMed", "22253473"}
SET Evidence = "This sequence (Fig. 3G–N) is supported by Western blot analysis, phosphorylated Thr231 in three AD cases and their age-matched
controls, suggesting that tau phosphorylation at Thr231 occurs before the formation of oligomers (Fig. 3O)."
SET Confidence = "High"
SET MeSHDisease = "Alzheimer Disease"
SET Disease_Progression = "Early Stage"
p(HGNC:MAPT, pmod(Ph, Thr, 231)) pos path(MESH:"Alzheimer Disease")
UNSET Disease_Progression
UNSET Confidence

SET Evidence = "Phosphorylation at the epitope Ser202/Thr205 is regarded as a good marker for late-stage NFTs (5, 72). Hyman and colleagues (5)
demonstrated that AT8 immunoreactivity is present primarily in eNFTs and in certain cases in iNFTs. These investigators also found that AT8
revealed dense neuropil thread staining."
SET Confidence = "High"
SET Disease_Progression = "Late Stage"
p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf a(GO:"neurofibrillary tangle")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) partOf a(GO:"neurofibrillary tangle")
p(HBP:"Tau epitope, AT8") pos a(MESH:Neuropil)
UNSET Disease_Progression
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "22486774"}
SET Evidence = "Oligomers positive for pS202/pT205 accumulate at synapses in AD"
SET Confidence = "Medium"
SET MeSHDisease = "Alzheimer Disease"
SET MeSHAnatomy = "Synapses"
p(HGNC:MAPT, pmod(Ph, Ser, 202)) partOf a(HBP:"Tau oligomers")
p(HGNC:MAPT, pmod(Ph, Thr, 205)) partOf a(HBP:"Tau oligomers")
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "24251416"}
SET Evidence = "While residues Ser-262, Ser-324, and Ser-356 were completely phosphorylated,
Ser-293 in the second repeat was only 84% phosphorylated (Table 1).
Furthermore, four non-KXGS phosphorylation sites were detected, two within the repeat domain (Ser-305 in R2 and Ser-352 in R4)
and two more at the C-terminus (Ser-413 and Ser-416) (Figure 1B,C). Of these, Ser-305 was 66% phosphorylated and Ser-352,
Ser-413, and Ser-416 were ∼45−58% phosphorylated (Table 1). Using wild-type MARK2cat at 25 °C and pH 6.8, the same
phosphorylation sites were observed. The three primary sites, Ser-262, Ser-324, and Ser-356, were still completely phosphorylated."
SET Confidence = "High"
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 324))
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 356))
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 293))
p(HGNC:MAPT, pmod(Ph, Ser, 293)) partOf p(HBP:"tubulin-binding repeat 2")
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 305))
p(HGNC:MAPT, pmod(Ph, Ser, 305)) partOf p(HBP:"tubulin-binding repeat 2")
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 352))
p(HGNC:MAPT, pmod(Ph, Ser, 352)) partOf p(HBP:"tubulin-binding repeat 4")
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 413))
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 416))
UNSET Confidence


SET Citation = {"PubMed", "25031639"}
SET Evidence = "We demonstrate that elevated HDAC6 activity increases phosphorylation of tau at the 12E8 epitope (pS262/356),
a phospho-epitope present within the KXGS motifs of tau’s microtubule-binding domain. The phosphorylation of KXGS motifs within tau
by the kinase Par-1/MARK2 is required for tau proteotoxicity in Drosophila [29], observed at very early stages of NFT formation in AD brain [30],
and appears to prime tau for subsequent phosphorylation events"
SET Confidence = "Medium"
act(p(HGNC:HDAC6)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
act(p(HGNC:HDAC6)) -> p(HGNC:MAPT, pmod(Ph, Ser, 356))
p(HBP:"Tau epitope, 12E8") partOf p(HBP:"KXGS motif")
p(HBP:"KXGS motif", pmod(Ph)) -> a(GO:"neurofibrillary tangle")
UNSET Confidence

SET Evidence = "In particular, previous studies have demonstrated that the tau ubiquitin ligase, CHIP, is unable to bind and ubiquitinate tau
species phosphorylated by Par-1/MARK2 on the 12E8 epitope (S262/356) [33], a p-tau species that is also resistant to degradation upon treatment
with Hsp90 inhibitors [32,33]. Tau phosphorylated at the PHF1 epitope (S396/404) is still susceptible to degradation following Hsp90 inhibition
and actually exhibits an enhanced interaction with Hsp90"
SET Confidence = "Medium"
p(HGNC:MARK2) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MARK2) -> p(HGNC:MAPT, pmod(Ph, Ser, 356))
p(HGNC:MAPT, pmod(Ph, Ser, 262)) -| complex(p(HGNC:STUB1),p(HGNC:MAPT, pmod(Ph, Ser, 262)))
p(HGNC:MAPT, pmod(Ph, Ser, 356)) -| complex(p(HGNC:STUB1),p(HGNC:MAPT, pmod(Ph, Ser, 356)))
complex(p(HGNC:STUB1),p(HGNC:MAPT)) -> deg(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(Ph, Ser, 396)) -> complex(p(HGNC:STUB1),p(HGNC:MAPT, pmod(Ph, Ser, 396)))
p(HGNC:MAPT, pmod(Ph, Ser, 404)) -> complex(p(HGNC:STUB1),p(HGNC:MAPT, pmod(Ph, Ser, 404)))
UNSET Confidence


SET Citation = {"PubMed", "22156579"}
SET Evidence = "Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and
 synapses, phenotypes also observed after Aβ treatment."
SET Confidence = "Medium"
SET Species = "10116"
SET Anatomy = "hippocampal formation"
p(HGNC:MARK4) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
p(HGNC:MARK4) neg act(p(RGD:Dlg4))
p(HGNC:MARK4) neg p(RGD:Gria1)
p(HGNC:MARK4) neg a(GO:"dendritic spine")
p(HGNC:MARK4) neg a(GO:synapse)
UNSET Confidence

SET Evidence = "Consistent with previous reports (11,34), treatment of rat hippocampal neurons with synthetic Aβ,
prepared using a well-characterized procedure that enriches for Aβ oligomers (37),
resulted in increased tau phosphorylation at the 12E8 sites (Fig. 2A), suggesting that Aβ treatment had activated MARK kinases.
Increased phosphorylation of tau at a site recognized by the PHF-1 phospho-tau antibody was also observed (data not shown)."
SET Confidence = "Medium"
SET MeSHAnatomy = "Neurons"
#12E8:pSer262 and pSer356
a(CHEBI:"amyloid-beta") -> p(RGD:Mapt, pmod(Ph, Ser, 262))
a(CHEBI:"amyloid-beta") -> p(RGD:Mapt, pmod(Ph, Ser, 356))
a(CHEBI:"amyloid-beta") -> act(p(HGNC:MARK4))
a(CHEBI:"amyloid-beta") -> p(HBP:"Tau epitope, PHF1", pmod(Ph))
UNSET Anatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "22941973"}
SET Evidence = "When overexpressed in rat hippocampal primary neurons, 14-3-3z causes an increase in Ser(262) phosphorylation, a decrease in the amount of microtubule-bound tau,
a reduction in the amount of polymerized microtubules, as well as microtubule instability.
Downregulation of synaptophysin in 14-3-3z overexpressing neurons was mitigated by inhibiting the proteosome,
indicating that 14-3-3z promotes proteosomal degradation of synaptophysin.
When 14-3-3z overexpressing neurons were treated with the microtubule stabilizing drug taxol, tau Ser(262) phosphorylation decreased and synaptophysin level was restored."
SET Confidence = "Medium"
#14-3-3z is YWHAZ
SET Species = "10116"
SET Anatomy = "hippocampal formation"
act(p(HGNC:YWHAZ)) -> p(RGD:Mapt, pmod(Ph, Ser, 262))
act(p(HGNC:YWHAZ)) -| complex(p(RGD:Mapt), a(MESH:Microtubules))
act(p(HGNC:YWHAZ)) -| bp(GO:"microtubule polymerization")
act(p(HGNC:YWHAZ)) -> deg(p(RGD:Syp))
act(p(HGNC:YWHAZ)) -> act(p(FPLX:Proteasome))
act(p(FPLX:Proteasome)) -> deg(p(RGD:Syp))
a(CHEBI:paclitaxel) -| p(RGD:Mapt, pmod(Ph, Ser, 262))
a(CHEBI:paclitaxel) -> p(RGD:Syp)
UNSET Anatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23722080"}
SET Evidence = "Primary cortical neurons exposed to the mitochondrial toxin NaN3 (0.1-3 mM) were submitted to oxidative stress with H2O2 (30-150 μM), to mimic conditions observed in neurodegenerative disorders.
The effects of such treatment on a series of parameters useful in characterizing neuronal damage were investigated: (i) the basal release of glutamate, evaluated as (3)H-d-Aspartate efflux, was sharply, concentration-dependently,
increased; (ii) the phosphorylation status of intracellular markers known to be involved in the neurodegenerative processes, in particular in Alzheimer disease: tau and GSK3β were increased,
as well as the protein level of β-secretase (BACE1) and p35/25 evaluated by Western blotting, while (iii) the cell metabolic activity, measured with the MTT method, was reduced, in a concentration- and time-dependent manner.
The latter effect, as well as tau hyperphosphorylation, was prevented both by a mixture of antioxidant drugs (100 μM ascorbic acid, 10 μM trolox, 100 μM glutathione) and by the anti-Alzheimer drug, memantine, 20 μM."
SET Confidence = "Medium"
SET Species = "10116"
SET Anatomy = "cerebral cortex"
a(CHEBI:"sodium azide") =| a(GO:mitochondrion)
a(CHEBI:"hydrogen peroxide") -> bp(MESH:"Oxidative Stress")
bp(MESH:"Oxidative Stress") -| a(GO:mitochondrion)
a(CHEBI:"sodium azide") pos composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide"))
a(CHEBI:"hydrogen peroxide") pos composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide"))
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -> a(CHEBI:"glutamate(1-)")
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -> p(RGD:Gsk3b, pmod(Ph))
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -> p(RGD:Mapt, pmod(Ph))
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -> p(RGD:Bace1)
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -> p(HBP:"CDK5R1 p25")
composite(a(CHEBI:"sodium azide"), a(CHEBI:"hydrogen peroxide")) -| bp(GO:"cellular metabolic process")
composite(a(CHEBI:"L-ascorbic acid"), a(CHEBI:Trolox), a(CHEBI:glutathione)) -| p(RGD:Mapt, pmod(HBP:hyperphosphorylation))
composite(a(CHEBI:"L-ascorbic acid"), a(CHEBI:Trolox), a(CHEBI:glutathione)) -> bp(GO:"cellular metabolic process")
a(CHEBI:memantine) -| p(RGD:Mapt, pmod(Ph))
a(CHEBI:memantine) -> bp(GO:"cellular metabolic process")
UNSET Anatomy
UNSET Species
a(CHEBI:memantine) -| path(MESH:"Alzheimer Disease")
UNSET Confidence


SET Citation = {"PubMed", "22952452"}
SET Evidence = "Using transgenic Drosophila expressing human tau, we found that RNAi-mediated knockdown of milton or Miro,
an adaptor protein essential for axonal transport of mitochondria, enhanced human tau-induced neurodegeneration.
Tau phosphorylation at an AD-related site Ser262 increased with knockdown of milton or Miro; and partitioning defective-1 (PAR-1),
the Drosophila homolog of mammalian microtubule affinity-regulating kinase, mediated this increase of tau phosphorylation.
Tau phosphorylation at Ser262 has been reported to promote tau detachment from microtubules, and we found that the levels of microtubule-unbound free tau increased by milton knockdown.
Blocking tau phosphorylation at Ser262 site by PAR-1 knockdown or by mutating the Ser262 site to unphosphorylatable alanine suppressed the enhancement of tau-induced neurodegeneration caused by milton knockdown.
Furthermore, knockdown of milton or Miro increased the levels of active PAR-1."
SET Confidence = "Medium"
SET Species = "7227"
p(HGNC:TRAK1) -> bp(GO:"axonal transport of mitochondrion")
p(HGNC:TRAK1) -| path(HBP:Neurodegeneration)
p(HGNC:TRAK1) -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
kin(p(HGNC:MARK1)) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MAPT, pmod(Ph, Ser, 262)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Ser, 262)) pos path(HBP:Neurodegeneration)
p(HGNC:TRAK1) -| act(p(HGNC:MARK1))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23001711"}
SET Evidence = "Several kinases such as microtubule-affinity regulating kinase (MARK), protein kinase A, calcium calmodulin kinase II,
and checkpoint kinase 2 are known to phosphorylate tau on Ser(262) in vitro. In this study, we took advantage of the in situ proximity ligation assay
to investigate the role of MARK2, one of the four MARK isoforms, in AD. We demonstrate that MARK2 interacts with tau and phosphorylates tau at Ser(262)
in stably transfected NIH/3T3 cells expressing human recombinant tau. Staurosporine, a protein kinase inhibitor, significantly reduced the interaction between MARK2 and tau,
and also phosphorylation of tau at Ser(262)."
SET Confidence = "Medium"
p(HGNC:MARK1) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
kin(p(FPLX:PKA)) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(FPLX:"CAMK2_complex") -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:CHEK2) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
SET Cell_Line = "NIH/3T3"
kin(p(HGNC:MARK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 262))
a(CHEBI:staurosporine) -| kin(p(HGNC:MARK2))
a(CHEBI:staurosporine) -| complex(p(HGNC:MARK2),p(HGNC:MAPT))
a(CHEBI:staurosporine) -| p(HGNC:MAPT, pmod(Ph, Ser, 262))
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "22072628"}
SET Evidence = "In this study, we address the structural impact of phosphorylation of the Tau protein by Nuclear Magnetic Resonance (NMR) spectroscopy on a functional fragment of Tau (Tau[Ser208-Ser324] = TauF4).
TauF4 was phosphorylated by the proline-directed CDK2/CycA3 kinase on Thr231 (generating the AT180 epitope), Ser235, and equally on Thr212 and Thr217 in the Proline-rich region (Tau[Ser208-Gln244] or PRR).
These modifications strongly decrease the capacity of TauF4 to polymerize tubulin into microtubules. While all the NMR parameters are consistent with a globally disordered Tau protein fragment, local clusters of structuration can be defined.
The most salient result of our NMR analysis is that phosphorylation in the PRR stabilizes a short α-helix that runs from pSer235 till the very beginning of the microtubule-binding region (Tau[Thr245-Ser324] or MTBR of TauF4)."
SET Confidence = "High"
p(HGNC:CDK2) -> p(HBP:"Tau epitope, AT180")
kin(p(HGNC:CDK2)) => p(HGNC:MAPT, pmod(Ph, Ser, 235))
kin(p(HGNC:CDK2)) => p(HGNC:MAPT, pmod(Ph, Thr, 212))
kin(p(HGNC:CDK2)) => p(HGNC:MAPT, pmod(Ph, Thr, 217))
p(HGNC:MAPT, pmod(Ph, Ser, 235)) partOf p(HBP:"proline-rich region 2", pmod(Ph))
p(HGNC:MAPT, pmod(Ph, Thr, 212)) partOf p(HBP:"proline-rich region 2", pmod(Ph))
p(HGNC:MAPT, pmod(Ph, Thr, 217)) partOf p(HBP:"proline-rich region 2", pmod(Ph))
p(HBP:"proline-rich region 2", pmod(Ph)) pos bp(MESH:"Protein Conformation, alpha-Helical")
bp(MESH:"Protein Conformation, alpha-Helical") -- p(HGNC:MAPT, frag(235_324))
UNSET Confidence


SET Citation = {"PubMed", "24355211"}
SET Evidence = "Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor known to increase the level of many antioxidants, including glutathione-S transferase (GST), and is negatively regulated by the activity of GSK-3β.
Our results indicated the increased nuclear localization of Nrf2 and level of GST, suggesting the increased activity of the transcription factor as a result of GSK-3β suppression, consistent with the decreased oxidative stress observed.
Consistent with the improved learning and memory, and consistent with GSK-3b being a tau kinase, we observed decreased tau phosphorylation in brain of GAO-treated SAMP8 mice compared to that of RAO-treated SAMP8 mice."
SET Confidence = "High"
SET Species = "10090"
SET Research_Model = "SAMP8 mice"
p(HGNC:NFE2L2) -> p(ECCODE:"2.5.1.18")
p(HGNC:GSK3B) -| p(HGNC:NFE2L2)
p(HGNC:GSK3B) pos bp(MESH:"Oxidative Stress")
p(HGNC:GSK3B) neg bp(GO:learning)
p(HGNC:GSK3B) neg bp(GO:memory)
kin(p(HGNC:GSK3B)) => p(MGI:Mapt, pmod(Ph, Thr, 231))
kin(p(HGNC:GSK3B)) => p(MGI:Mapt, pmod(Ph, Ser, 235))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "8226987"}
SET Evidence = ">8 phosphates per tau molecules (vs 2 in adult healthy brain); can also be increased during development, hibernation and temperature, heat and oxydative stress
These phosphorylated states are detected by specific antibodies and are targets of proline-directed kinases (SP motifs), non-proline kinases (KXGS motif)
Weakens tau-MT interaction especially S261 in R1 and S214 in proline-rich domain"
SET Confidence = "Medium"
bp(MESH:"Oxidative Stress") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
bp(MESH:"Hot Temperature") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
p(HGNC:MAPT, pmod(Ph, Ser, 261)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ph, Ser, 214)) -| complex(p(HGNC:MAPT),a(MESH:Microtubules))
UNSET Confidence


SET Citation = {"PubMed", "21910444"}
SET Evidence = "The highly vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and
disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1
levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages.
MAPK1 and PRKCB levels were low in the brainstem and cerebellum."
SET Confidence = "High"
SET Anatomy = "pyramidal layer of CA1"
SET MeSHDisease = "Alzheimer Disease"
SET Braak_Stage = {"Stage I", "Stage II"}
path(MESH:"Alzheimer Disease") -> p(HGNC:MAPK1)
UNSET Braak_Stage
path(MESH:"Alzheimer Disease") -> p(HGNC:PRKCB)
UNSET Anatomy
SET Anatomy = "pyramidal layer of CA2"
SET Braak_Stage = {"Stage I", "Stage II", "Stage III"}
path(MESH:"Alzheimer Disease") -> p(HGNC:MAPK1)
UNSET Braak_Stage
SET Braak_Stage = {"Stage V", "Stage VI"}
path(MESH:"Alzheimer Disease") -> p(HGNC:MAPK1)
path(MESH:"Alzheimer Disease") -> p(HGNC:PRKCB)
UNSET Braak_Stage
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "24401760"}
SET Evidence = "We show here that ITPKB protein level was increased 3-fold in the cerebral cortex of most patients with Alzheimer's disease compared with control subjects, and accumulated in dystrophic neurites associated to amyloid plaques.
In mouse Neuro-2a neuroblastoma cells, Itpkb overexpression was associated with increased cell apoptosis and increased β-secretase 1 activity leading to overproduction of amyloid-β peptides.
In this cellular model, an inhibitor of mitogen-activated kinase kinases 1/2 completely prevented overproduction of amyloid-β peptides.
Transgenic overexpression of ITPKB in mouse forebrain neurons was not sufficient to induce amyloid plaque formation or tau hyperphosphorylation.
However, in the 5X familial Alzheimer's disease mouse model, neuronal ITPKB overexpression significantly increased extracellular signal-regulated kinases 1/2 activation and β-secretase 1 activity,
resulting in exacerbated Alzheimer's disease pathology as shown by increased astrogliosis, amyloid-β40 peptide production and tau hyperphosphorylation."
SET Confidence = "Medium"
SET MeSHDisease = "Alzheimer Disease"
SET Anatomy = "cerebral cortex"
path(MESH:"Alzheimer Disease") -> p(HGNC:ITPKB)
p(HGNC:ITPKB) pos path(MESH:"Plaque, Amyloid")
path(MESH:"Plaque, Amyloid") -- a(HBP:"dystrophic neurite")
p(HGNC:ITPKB) pos a(HBP:"dystrophic neurite")
UNSET Anatomy
UNSET MeSHDisease
SET Species = "10090"
SET Cell_Line = "N2a"
p(MGI:Itpkb) -> bp(GO:"apoptotic process")
p(MGI:Itpkb) -> act(p(MGI:Bace1))
act(p(MGI:Bace1)) -> a(CHEBI:"amyloid-beta")
#inhibitor: SL-327
a(PUBCHEM:9549284) =| p(MGI:Map2k1)
a(PUBCHEM:9549284) =| p(MGI:Map2k2)
a(PUBCHEM:9549284) -| a(CHEBI:"amyloid-beta")
UNSET Cell_Line
SET Research_Model = "5xFAD mice"
p(MGI:Itpkb) -> act(p(MGI:Map2k1))
p(MGI:Itpkb) -> act(p(MGI:Map2k2))
p(MGI:Itpkb) -> act(p(MGI:Bace1))
p(MGI:Itpkb) -> path(HBP:Astrogliosis)
p(MGI:Itpkb) -> p(HGNC:APP, frag(672_711))
p(MGI:Itpkb) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
path(HBP:Astrogliosis) pos path(MESH:"Alzheimer Disease")
p(HGNC:APP, frag(672_711)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) pos path(MESH:"Alzheimer Disease")
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23737518"}
SET Evidence = "Small molecules in the diaminothiazole class are potent Tau kinase inhibitors that target CDK5 and GSK3β.
Lead compounds from the series have IC50 values toward CDK5/p25 and GSK3β in the low nanomolar range and no observed toxicity in the therapeutic dose range.
Neuronal protective effects and decreased PHF-1 immunoreactivity were observed in two animal models, 3×Tg-AD and CK-p25.
Treatment nearly eliminated Sarkosyl-insoluble Tau with the most prominent effect on the phosphorylation at Ser-404.
Treatment also induced the recovery of memory in a fear conditioning assay."
SET Confidence = "Medium"
#Statements taken from figure 1
SET Species = "10116"
SET Half_life = "30 min"
SET IC50 = "30 nM"
a(PUBCHEM:54581340) =| act(p(RGD:Cdk5))
UNSET IC50
a(PUBCHEM:54581340) -| p(HBP:"Tau epitope, PHF1")
a(PUBCHEM:54581340) -| act(p(HBP:"CDK5R1 p25"))
SET IC50 = "45 nM"
a(PUBCHEM:54581340) =| act(p(RGD:Gsk3b))
UNSET Half_life
UNSET IC50
a(PUBCHEM:54581340) isA a(HBP:"diaminothiazole")
a(HBP:"LDN-193665") isA a(HBP:"diaminothiazole")
a(HBP:"LDN-213843") isA a(HBP:"diaminothiazole")
SET Half_life = "29 min"
SET IC50 = "62 nM"
a(HBP:"LDN-193665") =| act(p(RGD:Cdk5))
UNSET IC50
SET IC50 = "19 nM"
a(HBP:"LDN-193665") =| act(p(RGD:Gsk3b))
UNSET IC50
UNSET Half_life
SET Half_life = "70 min"
SET IC50 = "90 nM"
a(HBP:"LDN-213843") =| act(p(RGD:Cdk5))
UNSET IC50
SET IC50 = "38 nM"
a(HBP:"LDN-213843") =| act(p(RGD:Gsk3b))
UNSET IC50
UNSET Half_life
a(HBP:"diaminothiazole") -| p(HGNC:MAPT, pmod(Ph, Ser, 404))
a(HBP:"diaminothiazole") -> bp(GO:memory)
UNSET Confidence


#########################################################################################################################################
#######################################################Tau Oxidation###########################################################

SET Citation = {"PubMed", "7667312"}
SET Evidence = "Though whole tau assembled poorly, constructs containing three internal repeats (corresponding to the fetal tau isoform) formed PHFs reproducibly.
This ability depended on intermolecular disulfide bridges formed by the single Cys-322. Blocking the SH group,
mutating Cys for Ala, or keeping T in a reducing environment all inhibited assembly. On the other hand, Cys-322 can be oxidized, and this
leads to PHF assembly (ref. 11; this report). In vitro this is achieved most easily by using constructs of the 'fetal' isoform
of T (htau23) that has only three repeats. Conversely, reducing agents or the second repeat or T can be viewed as 'antidotes'
against PHF assembly.The synthetic PHFs bound the dye thioflavin S used in Alzheimer disease
diagnostics."
SET Confidence = "High"
p(HGNC:MAPT, var("p.Cys291Ala")) -| a(HBP:"paired helical filaments")
bp(MESH:"Oxidative Stress") -> a(HBP:"paired helical filaments")
a(HBP:"Thioflavin S") pos a(HBP:"paired helical filaments")

a(HBP:"paired helical filaments") partOf complex(GO:"neurofibrillary tangle")
UNSET Confidence

#################################################################################################################################
####################################################Tau Acetylation##############################################################


##################################################Tau Acetylation Enzymes########################################################


SET Citation = {"PubMed", "25672970"}
SET Evidence = "In this study, we modified the PCAF inhibitor by chemical derivatization and selected compound C-30-27 as the most potent PCAF inhibitor.
We demonstrated that C-30-27 selectively inhibited acetylation-dependent nuclear factor-κB (NF-κB) at Lys-122 and suppressed the NF-κB-mediated inflammatory
response induced by lipopolysaccharide (LPS) or Aβ in both BV2 and Neuro-2A (N2A) cells.
Finally, we demonstrated that C-30-27 improved cognitive deficits, as well as the capacity for locomotion and the damaged cholinergic system in the Aβ-treated rats."
SET Confidence = "Medium"
#PCAF is KAT2B
SET Cell_Line = {"BV2", "N2a"}
a(HBP:"C-30-27") =| act(p(HGNC:KAT2B))
a(HBP:"C-30-27") -| p(FPLX:NFkappaB, pmod(Ac, Lys, 122))
act(p(HGNC:KAT2B)) -> p(FPLX:NFkappaB, pmod(Ac, Lys, 122))
a(CHEBI:lipopolysaccharide) -> bp(GO:"neuroinflammatory response")
a(CHEBI:"amyloid-beta") -> bp(GO:"neuroinflammatory response")
a(HBP:"C-30-27") -| bp(GO:"neuroinflammatory response")
UNSET Cell_Line
SET Species = "10116"
a(HBP:"C-30-27") -> path(MESH:Cognition)
a(HBP:"C-30-27") -> bp(GO:locomotion)
a(HBP:"C-30-27") -> bp(GO:"synaptic transmission, cholinergic")
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "11691934"}
SET Evidence = "Taking data from three independent experiments, the apparent Km of the p300 AT domain for histone H4 was determined to be 2.7 µM."
SET Confidence = "High"
SET Km = "2.7 µM"
p(HGNC:EP300) -> p(FPLX:"Histone_H4", pmod(Ac))
UNSET Km
UNSET Confidence

##################################################Tau Deacetylation Enzymes########################################################

SET Citation = {"PubMed", "24844691"}
SET Evidence = "In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD.
We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects.
Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of Aβ and hyperphosphorylated tau."
SET Confidence = "Medium"
#Tubastatin A is PUBCHEM:49850262
#ACY-1215 is PUBCHEM:53340666
a(PUBCHEM:49850262) =| act(p(HGNC:HDAC6))
a(PUBCHEM:53340666) =| act(p(HGNC:HDAC6))
SET MeSHDisease = "Alzheimer Disease"
SET Species = "10090"
a(PUBCHEM:49850262) -> bp(GO:behavior)
a(PUBCHEM:53340666) -> bp(GO:behavior)
a(PUBCHEM:49850262) -| a(CHEBI:"amyloid-beta")
a(PUBCHEM:53340666) -| a(CHEBI:"amyloid-beta")
a(PUBCHEM:49850262) -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
a(PUBCHEM:53340666) -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
a(PUBCHEM:49850262) -> p(FPLX:Tubulin, pmod(Ac))
a(PUBCHEM:53340666) -> p(FPLX:Tubulin, pmod(Ac))
a(PUBCHEM:49850262) -> bp(GO:autophagy)
a(PUBCHEM:53340666) -> bp(GO:autophagy)
bp(GO:autophagy) -> deg(a(CHEBI:"amyloid-beta"))
bp(GO:autophagy) -> deg(p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)))
UNSET MeSHDisease
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "25546293"}
SET Evidence = "The N-terminus of β-catenin has phosphorylation, ubiquitination, and acetylation sites that regulate its stability and signaling.
In the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β).
β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in ubiquitination and degradation by the ubiquitin-proteasome pathway.
The N-terminal regulatory domain of β-catenin also includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase p300/CBP-associated factor (PCAF).
The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin is an active area of investigation.
We find that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do not affect Ser33, Ser37, and Thr41 phosphorylation.
Lys49 acetylation results in decreased ubiquitination of β-catenin in the presence of proteasome inhibition.
While increased Lys49 acetylation does not affect total levels of β-catenin, it results in increased membrane localization of β-catenin."
SET Confidence = "Medium"
kin(p(HGNC:GSK3B)) => p(HGNC:CTNNB1, pmod(Ph, Ser, 33))
kin(p(HGNC:GSK3B)) => p(HGNC:CTNNB1, pmod(Ph, Ser, 37))
kin(p(HGNC:GSK3B)) => p(HGNC:CTNNB1, pmod(Ph, Thr, 41))
p(HGNC:CTNNB1, pmod(Ph, Ser, 33)) -> deg(p(HGNC:CTNNB1))
p(HGNC:CTNNB1, pmod(Ph, Ser, 37)) -> deg(p(HGNC:CTNNB1))
p(HGNC:CTNNB1, pmod(Ph, Thr, 41)) -> deg(p(HGNC:CTNNB1))
p(HGNC:CTNNB1, pmod(Ph, Ser, 33)) -> act(p(HGNC:BTRC))
p(HGNC:CTNNB1, pmod(Ph, Ser, 37)) -> act(p(HGNC:BTRC))
p(HGNC:CTNNB1, pmod(Ph, Thr, 41)) -> act(p(HGNC:BTRC))
act(p(HGNC:BTRC)) -> p(HGNC:CTNNB1, pmod(Ub))
p(HGNC:CTNNB1, pmod(Ub)) -> act(p(FPLX:Proteasome))
act(p(FPLX:Proteasome)) -> deg(p(HGNC:CTNNB1, pmod(Ub)))
p(HGNC:CSNK1A1) -> p(HGNC:CTNNB1, pmod(Ph, Ser, 45))
p(HGNC:KAT2B) -> p(HGNC:CTNNB1, pmod(Ac, Lys, 49))
act(p(HGNC:HDAC6)) -| p(HGNC:CTNNB1, pmod(Ac, Lys, 49))
act(p(HGNC:HDAC6)) -| p(HGNC:CTNNB1, pmod(Ph, Ser, 45))
act(p(HGNC:HDAC6)) cnc p(HGNC:CTNNB1, pmod(Ph, Ser, 33))
act(p(HGNC:HDAC6)) cnc p(HGNC:CTNNB1, pmod(Ph, Ser, 37))
act(p(HGNC:HDAC6)) cnc p(HGNC:CTNNB1, pmod(Ph, Thr, 41))
p(HGNC:CTNNB1, pmod(Ac, Lys, 49)) -| p(HGNC:CTNNB1, pmod(Ub))
p(HGNC:CTNNB1, pmod(Ac, Lys, 49)) -> p(HGNC:CTNNB1, loc(GO:membrane))
UNSET Confidence



SET Citation = {"PubMed", "27917100"}
SET Evidence = "In conclusion, ST7612AA1, prodrug of ST7464AA1, is the first of a new generation of HDAC inhibitors, very potent, orally administered, and well tolerated.
It is a thiol derivative, pan-histone deacetylase inhibitor, active against a broad panel of cancer cell lines and in vivo tumor models."
SET Confidence = "High"
a(HBP:ST7612AA1) =| act(p(FPLX:HDAC))
UNSET Confidence


SET Citation = {"PubMed", "26890116"}
SET Evidence = "Modification of the cap group of biphenylacrylohydroxamic acid-based HDAC inhibitors led to the
identification of a new derivative (3) characterized by an indolyl-substituted 4-phenylcinnamic skeleton."
SET Confidence = "High"
a(HBP:"Biphenyl-4-yl-acrylohydroxamoc acids") =| act(p(FPLX:HDAC))
UNSET Confidence


SET Citation = {"PubMed", "18558669"}
SET Evidence = "Highly potent, substrate competitive HDAC6 selective inhibitors were identified (12ac:IC 50 = 65 nM and K i = 110 nM).
Trithiocarbonate analogues with an aminoquinoline-substituted pyridinyl-thienoacetyl cap demonstrate a cytotoxicity profile and potency
comparable to that of suberoylanilide hydroxamic acid (SAHA) as an approved cancer drug."
SET Confidence = "High"
SET Ki = "110 nM"
SET IC50 = "65 nM"
a(HBP:Trithiocarbonates) =| act(p(HGNC:HDAC6))
UNSET IC50
UNSET Ki
UNSET Confidence

#################################################################################################################################

SET Citation = {"PubMed", "29540553"}
SET Evidence = "Here we show that the protein deacetylase SIRT1 reduces tau acetylation in a mouse model of neurodegeneration.
SIRT1 deficiency in the brain aggravates synapse loss and behavioral disinhibition, and SIRT1 overexpression ameliorates propagation of tau pathology."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "P301S mice"
#acetylated K174
p(MGI:Sirt1) -| p(MGI:Mapt, pmod(Ac, Lys, 174))
SET MeSHAnatomy = "Brain"
p(MGI:Sirt1) -| a(MESH:Synapses)
UNSET MeSHAnatomy
p(MGI:Sirt1) -> bp(GO:behavior)
p(MGI:Sirt1) neg path(MESH:Tauopathies)
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "29540553"}
SET Evidence = "After pretreating hTau neurons with oligo Aβ-42 (1000 ng/ml), Sirt3 levels were reduced (Fig. 6b and
e). This reduction in Sirt3 was translated into an increase in total tau and Ac-tau."
SET Confidence = "Medium"
SET Species = "10090"
p(HGNC:APP, frag(672_713)) -| p(MGI:Sirt3)
p(MGI:Sirt3) -| p(HGNC:MAPT)
p(MGI:Sirt3) -| p(HGNC:MAPT, pmod(Ac))
UNSET Species
UNSET Confidence

SET Evidence = "Sirt3 levels were reduced in the entorhinal cortex, the middle temporal gyrus, and the superior frontal gyrus of AD subjects
compared to those of CN and was associated with poorer test scores of neuropsychological evaluation and the severity of tau pathology."
SET Confidence = "High"
SET Anatomy = {"entorhinal cortex", "middle temporal gyrus", "superior frontal gyrus"}
path(MESH:"Alzheimer Disease") neg p(MGI:Sirt3)
UNSET Anatomy
UNSET Confidence


SET Citation = {"PubMed", "29276758"}
SET Evidence = "We also tested for ac-tau 280 in early stage Alzheimer's disease (Braak stage 1). Histopathological examination using
the ac tau 280 antibody was performed in three Alzheimer's cases and three CTE patients.
Presence of ac-tau 280 was confirmed in all cases at early sites of disease manifestation.
These findings suggest that tau acetylation may precede tau phosphorylation and could be the first "triggering" event leading to neuronal loss.
To the best of our knowledge, this is the first study to identify acetylation of the tau protein in CTE."
SET Confidence = "High"
SET MeSHDisease = "Alzheimer Disease"
SET Braak_Stage = "Stage I"
p(HGNC:MAPT, pmod(Ac, Lys, 280)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ac, Lys, 280)) -| a(MESH:Neurons)
UNSET Braak_Stage
UNSET MeSHDisease
SET MeSHDisease = "Chronic Traumatic Encephalopathy"
p(HGNC:MAPT, pmod(Ac, Lys, 280)) pos path(MESH:"Chronic Traumatic Encephalopathy")
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "27550730"}
SET Evidence = "Here we report the discovery of a new first-in-class small-molecule (CM-414) that acts as a dual inhibitor of PDE5 and HDACs.
We have used this compound as a chemical probe to validate this systems therapeutics strategy, where an increase in the activation of cAMP/cGMP-responsive element-binding protein (CREB)
induced by PDE5 inhibition, combined with moderate HDAC class I inhibition, leads to efficient histone acetylation.
This molecule rescued the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice.
Chronic treatment of Tg2576 mice with CM-414 diminished brain Aβ and tau phosphorylation (pTau) levels, increased the inactive form of GSK3β,
reverted the decrease in dendritic spine density on hippocampal neurons, and reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission."
SET Confidence = "Medium"
#CM-414 is PUBCHEM:136299192
SET Species = "10090"
a(PUBCHEM:136299192) =| act(p(MGI:Pde5a))
a(PUBCHEM:136299192) =| act(p(FPLX:HDAC))
act(p(HGNC:PDE5A)) neg act(p(FPLX:CREB))
act(p(FPLX:HDAC)) neg act(p(FPLX:CREB))
act(p(FPLX:CREB)) -> p(FPLX:Histone, pmod(Ac))
a(PUBCHEM:136299192) -> bp(GO:"long-term synaptic potentiation")
a(PUBCHEM:136299192) -| a(CHEBI:"amyloid-beta")
a(PUBCHEM:136299192) -| p(MGI:Mapt, pmod(Ph))
a(PUBCHEM:136299192) -| kin(p(MGI:Gsk3b))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "29559585"}
SET Evidence = "We found that NO production and tau acetylation at Lys280 occurred in the brain tissue in mice and in cultured mouse cortical neurons
in response to exposure to amyloid-β1-42 (Aβ1-42), a peptide that is also implicated in AD. An increased abundance of NO facilitated the S-nitrosylation
(SNO) of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
S-nitrosylated GAPDH (GAPDH-SNO) promoted the acetylation and activation of the acetyltransferase p300 and facilitated the nitrosylation and inactivation
of the deacetylase sirtuin 1 (SIRT1).
The abundance of GAPDH-SNO was increased in postmortem brain samples from AD patients. Preventing the increase in GAPDH-SNO abundance in both cultured
neurons and mice, either by overexpression of the nitrosylation mutant of GAPDH (GAPDH C150S) or by treatment with the GAPDH nitrosylation inhibitor
CGP3466B (also known as omigapil), abrogated Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that this
drug might be repurposed to treat patients with AD."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHAnatomy = "Brain"
p(HGNC:APP, frag(672_713)) -> p(MGI:Mapt, pmod(Ac, Lys, 280))
p(HGNC:APP, frag(672_713)) -> a(CHEBI:"nitric oxide")
a(CHEBI:"nitric oxide") -> p(MGI:Gapdh, pmod(NO))
p(MGI:Gapdh, pmod(NO)) -> p(MGI:Ep300, pmod(Ac))
p(MGI:Gapdh, pmod(NO)) -> act(p(MGI:Ep300))
p(MGI:Gapdh, pmod(NO)) -> p(MGI:Sirt1, pmod(NO))
p(MGI:Gapdh, pmod(NO)) -| act(p(MGI:Sirt1))
UNSET Species
p(HGNC:GAPDH, pmod(NO)) pos path(MESH:"Alzheimer Disease")
a(PUBCHEM:6419718) -| p(MGI:Gapdh, pmod(NO))
a(PUBCHEM:6419718) -| p(MGI:Mapt, pmod(Ac, Lys, 280))
a(PUBCHEM:6419718) -> bp(GO:memory)
a(PUBCHEM:6419718) -> bp(GO:locomotion)
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "28855586"}
SET Evidence = "We have used a knock-out/knock-in strategy in Drosophila to generate a strain with hTau inserted into the endogenous fly tau locus and expressed under the control of the endogenous fly tau promoter,
thus avoiding potential toxicity due to genetic over-expression. hTau knock-in (KI) proteins were expressed at normal, endogenous levels, bound to fly microtubules and were post-translationally modified, hence displaying physiological properties.
We used this new model to investigate the effects of acetylation on hTau toxicity in vivo. The simultaneous pseudo-acetylation of hTau at lysines 163, 280, 281 and 369 drastically decreased hTau phosphorylation and significantly reduced its binding to microtubules in vivo.
These molecular alterations were associated with ameliorated amyloid beta toxicity. Our results indicate acetylation of hTau on multiple sites regulates its biology and ameliorates amyloid beta toxicity in vivo."
SET Confidence = "Medium"
SET Species = "7227"
p(HGNC:MAPT, pmod(Ac, Lys, 163), pmod(Ac, Lys, 280), pmod(Ac, Lys, 281), pmod(Ac, Lys, 369)) -| p(HGNC:MAPT, pmod(Ph))
p(HGNC:MAPT, pmod(Ac, Lys, 163), pmod(Ac, Lys, 280), pmod(Ac, Lys, 281), pmod(Ac, Lys, 369)) -| complex(p(HGNC:MAPT, pmod(Ph)), a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ac, Lys, 163), pmod(Ac, Lys, 280), pmod(Ac, Lys, 281), pmod(Ac, Lys, 369)) neg act(a(CHEBI:"amyloid-beta"))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "28287136"}
SET Evidence = "Surprisingly, we show that tau acetylation alters phosphorylation at residues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk.
Using a series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly function and also significantly enhanced tau aggregation.
We also demonstrate that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel mechanism of action for this class of compounds"
SET Confidence = "Medium"
p(HGNC:MAPT, pmod(Ac, Lys, 280), pmod(Ac, Lys, 281)) -| p(HGNC:MAPT, pmod(Ph, Ser, 202), pmod(Ph, Thr, 205))
p(HGNC:MAPT, pmod(Ac, Lys, 280), pmod(Ac, Lys, 281)) -| complex(p(HGNC:MAPT, pmod(Ph)), a(MESH:Microtubules))
p(HGNC:MAPT, pmod(Ac, Lys, 280), pmod(Ac, Lys, 281)) -> a(HBP:"Tau aggregates")
a(CHEBI:"methylene blue") -| p(HGNC:MAPT, pmod(Ac))
UNSET Confidence

SET Evidence = "Thus, K → Q substitutions within the critical PHF6* motif, in the apparent absence of other tau PTMs, appears sufficient to accelerate tau aggregation in vitro."
SET Confidence = "High"
p(HGNC:MAPT, var("p.Lys280Gln")) -> a(HBP:"Tau aggregates")
UNSET Confidence


SET Citation = {"PubMed", "28002468"}
SET Evidence = "All three MAPs possess highly lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential for conserved acetylation within their repeats.
Notably, tau/MAP4 alignments showed conservation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the combined tau/MAP2c/MAP4 alignment showed conservation
of the 3rd repeat motif harboring tau lysine K311, 306VQIVYK311"
SET Confidence = "Low"
#not in evidence
p(HGNC:MAP4, frag(992_999)) eq p(HBP:"VQIINK motif")
p(HGNC:MAP4, frag(1023_1030)) eq p(HBP:"VQIINK motif")
p(HGNC:MAP2, frag(332_339)) eq p(HBP:"VQIVYK motif")
UNSET Confidence

SET Evidence = "Similar to tau, MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the presence of acetyl-CoA.
Tubulin reduced MAP2 acetylation, suggesting tubulin binding dictates MAP acetylation status."
SET Confidence = "Medium"
a(CHEBI:"acetyl-CoA") -> bp(HBP:"cystein-dependent auto-acetylation")
bp(HBP:"cystein-dependent auto-acetylation") -> p(HGNC:MAP2, pmod(Ac))
p(FPLX:Tubulin) -| p(HGNC:MAP2, pmod(Ac))
UNSET Confidence


SET Citation = {"PubMed", "27041503"}
SET Evidence = "Here we report abnormal acetylation of K274 and K281 on tau, identified in AD brains,
promotes memory loss and disrupts synaptic plasticity by reducing postsynaptic KIdney/BRAin (KIBRA) protein,
a memory-associated protein.Transgenic mice expressing human tau with lysine-to-glutamine mutations to mimic K274 and K281 acetylation (tauKQ)
exhibit AD-related memory deficits and impaired hippocampal long-term potentiation (LTP).
TauKQ reduces synaptic KIBRA levels and disrupts activity-induced postsynaptic actin remodeling and AMPA receptor insertion.
The LTP deficit was rescued by promoting actin polymerization or by KIBRA expression.
In AD patients with dementia, we found enhanced tau acetylation is linked to loss of KIBRA."
SET Confidence = "Medium"
#KIBRA is WWC1
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:MAPT, pmod(Ac, Lys, 274)) -| bp(GO:memory)
p(HGNC:MAPT, pmod(Ac, Lys, 281)) -| bp(GO:memory)
p(HGNC:MAPT, pmod(Ac, Lys, 274)) -| bp(GO:"regulation of synaptic plasticity")
p(HGNC:MAPT, pmod(Ac, Lys, 281)) -| bp(GO:"regulation of synaptic plasticity")
p(HGNC:MAPT, pmod(Ac, Lys, 274)) -| p(HGNC:WWC1)
p(HGNC:MAPT, pmod(Ac, Lys, 281)) -| p(HGNC:WWC1)
p(HGNC:WWC1) -- bp(GO:memory)
p(HGNC:WWC1) -- bp(GO:memory)
UNSET MeSHDisease
SET Species = "10090"
SET MeSHAnatomy = "Hippocampus"
p(MGI:Mapt, pmod(Ac, Lys, 274)) -| bp(MESH:"Long-Term Potentiation")
p(MGI:Mapt, pmod(Ac, Lys, 281)) -| bp(MESH:"Long-Term Potentiation")
UNSET MeSHAnatomy
SET MeSHAnatomy = "Synapses"
p(MGI:Mapt, pmod(Ac, Lys, 274)) -| p(MGI:Wwc1)
p(MGI:Mapt, pmod(Ac, Lys, 281)) -| p(MGI:Wwc1)
p(MGI:Mapt, pmod(Ac, Lys, 274)) -| bp(GO:"actin cytoskeleton reorganization")
p(MGI:Mapt, pmod(Ac, Lys, 281)) -| bp(GO:"actin cytoskeleton reorganization")
UNSET MeSHAnatomy
bp(GO:"actin filament polymerization") -> bp(MESH:"Long-Term Potentiation")
p(MGI:Wwc1) -> bp(MESH:"Long-Term Potentiation")
UNSET Species
SET MeSHDisease = {"Alzheimer Disease", "Dementia"}
p(HGNC:MAPT, pmod(Ac)) neg p(HGNC:WWC1)
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "26940749"}
SET Evidence = "hTau-K280Q mutants showed significantly increased phosphorylation on S262 as compared to both hTau-wt and hTau-K280R flies,
when normalised to total hTau (K9JA) levels (**p < 0.01, one-way ANOVA, Fig. 4b,c).
Mis-expression of pseudo-acetylated K280Q-hTau in the adult fly nervous system potently exacerbated fly locomotion defects and photoreceptor neurodegeneration."
SET Confidence = "High"
#hTau-K280Q mimics acetylation at this residue
SET Species = "7227"
p(HGNC:MAPT, pmod(Ac, Lys, 280)) -> p(HGNC:MAPT, pmod(Ph, Ser, 262))
p(HGNC:MAPT, pmod(Ac, Lys, 280)) -> path(HBP:Neurodegeneration)
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "26390242"}
SET Evidence = "The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo.
Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels.
In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total
tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy."
SET Confidence = "Medium"
SET Species = "10090"
p(HGNC:MAPT, pmod(Ac, Lys, 174)) -| deg(p(HGNC:MAPT))
p(HGNC:MAPT, pmod(Ac, Lys, 174)) -| bp(GO:cognition)

SET Anatomy = "hippocampal formation"
p(HGNC:MAPT, pmod(Ac, Lys, 174)) -> path(HBP:Neurodegeneration)
UNSET Anatomy

SET Research_Model = "PS19 mice"
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac))
a(CHEBI:salsalate) =| act(p(HGNC:EP300))
a(CHEBI:salsalate) -| p(HGNC:MAPT, pmod(Ac, Lys, 174))
a(CHEBI:salsalate) -| p(HGNC:MAPT)
a(CHEBI:salsalate) -> bp(GO:memory)
a(CHEBI:salicylate) =| act(p(HGNC:EP300))
a(CHEBI:salicylate) -| p(HGNC:MAPT, pmod(Ac, Lys, 174))
a(CHEBI:salicylate) -| p(HGNC:MAPT)
a(CHEBI:salicylate) -> bp(GO:memory)
SET Anatomy = "hippocampal formation"
a(CHEBI:salsalate) -| path(HBP:Neurodegeneration)
a(CHEBI:salicylate) -| path(HBP:Neurodegeneration)
UNSET Anatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "26192747"}
SET Evidence = "Clear evidence for acetylation and ubiquitination of the same lysine residues;
some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau."
SET Confidence = "Low"
#not in evidence
p(HGNC:MAPT, pmod(Ac, Lys, 163)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 225)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 259)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 280)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 317)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 321)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 331)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 343)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 347)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 369)) isA p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac, Lys, 385)) isA p(HGNC:MAPT, pmod(Ac))

p(HGNC:MAPT, pmod(Ac, Lys, 259)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 280)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 317)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 321)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 331)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 343)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 347)) partOf p(HBP:"microtubule-binding region")
p(HGNC:MAPT, pmod(Ac, Lys, 369)) partOf p(HBP:"microtubule-binding region")
UNSET Confidence


SET Citation = {"PubMed", "24686445"}
SET Evidence = "Here we show through systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor (PCAF)
promotes acetylation of histone 3 Lys 9 at the promoters of established key regeneration-associated genes following a peripheral but not a central axonal injury.
Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde signalling is required for PCAF-dependent regenerative gene reprogramming.
Finally, PCAF is necessary for conditioning-dependent axonal regeneration and also singularly promotes regeneration after spinal cord injury. "
SET Confidence = "Medium"
#not in evidence..
#SET Anatomy = "dorsal root ganglion"
#a(HBP:"peripheral nervous system injury") -> p(HGNC:NGF)
#p(HGNC:NGF) -> p(FPLX:ERK, pmod(Ph))
#p(FPLX:ERK, pmod(Ph)) -> act(p(FPLX:ERK))
path(HBP:"peripheral nervous system injury") -> act(p(FPLX:ERK))
act(p(FPLX:ERK)) -> act(p(HGNC:KAT2B))
#p(HGNC:NGF) -> act(p(HGNC:KAT2B))
act(p(HGNC:KAT2B)) -> p(HBP:"Histone H3", pmod(Ac, Lys, 9))
#p(HBP:"Histone H3", pmod(Ac, Lys, 9)) -> r(HGNC:GAP43)
#p(HBP:"Histone H3", pmod(Ac, Lys, 9)) -> r(HGNC:GAL)
#p(HBP:"Histone H3", pmod(Ac, Lys, 9)) -> r(HGNC:BDNF)
#UNSET Anatomy
UNSET Confidence


SET Citation = {"PubMed", "23487739"}
SET Evidence = "Overexpressed tau was hyperphosphorylated and resulted in decreased MT density and greater fragmentation.
Using genetic screen, a histone deacetylase 6 (HDAC6) null mutation rescued tau-induced MT defects in both muscles and neurons.
Genetic and pharmacological inhibition of the tubulin-specific deacetylase activity of HDAC6 indicates that the rescue effect may be mediated by increased MT acetylation."
SET Confidence = "Medium"
SET Species = "7227"
p(HGNC:MAPT, pmod(HBP:hyperphosphorylation)) -| a(GO:microtubule)
SET MeSHAnatomy = {"Neurons", "Muscles"}
p(HGNC:HDAC6) -| a(GO:microtubule)
UNSET MeSHAnatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "21427723"}
SET Evidence = "Although low-level tau acetylation was observed in untreated HEK-T40 cells,
treatment with the pan histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not the Sir2 class inhibitor nicotinamide,
resulted in a dramatic increase in acetylated tau levels."
SET Confidence = "High"
SET Cell_Line = "HEK293"
a(CHEBI:"trichostatin A") =| act(p(FPLX:HDAC))
act(p(FPLX:HDAC)) -| p(HGNC:MAPT, pmod(Ac))
a(CHEBI:"trichostatin A") -> p(HGNC:MAPT, pmod(Ac))
UNSET Cell_Line
UNSET Confidence

SET Evidence = "Thus, K280 acetylation is a feature found in a variety of human 4R or 3R/4R tauopathies including AD, but not 3R-tauopathies such as PiD."
SET Confidence = "Medium"
p(HGNC:MAPT, pmod(Ac, Lys, 280)) pos path(MESH:"Alzheimer Disease")
p(HGNC:MAPT, pmod(Ac, Lys, 280)) pos path(HBP:"Corticobasal Degeneration")
path(MESH:"Alzheimer Disease") isA path(HBP:"4R tauopathy")
path(HBP:"Corticobasal Degeneration") isA path(HBP:"4R tauopathy")
p(HBP:"4R tau") -- path(HBP:"4R tauopathy")
UNSET Confidence


SET Citation = {"PubMed", "20869593"}
SET Evidence = "Incubation with p300, not pCAF, led to tau acetylation, while both p300 and pCAF were active in transferring acetyl groups to histones as expected (Figure 1A).
A few putative acetylated lysines were in the N- and C- terminal regions; 13 were in microtubule-binding domains (Figure 1B and Table-S1).
Putative acetylated N-terminal lysines (e.g., lysines 163, 174, and 180) appeared to be acetylated in all MS analyses. Those in the microtubule-binding domains appeared to be acetylated in a subset of MS analyses,
suggesting variable acetylation at these sites in vitro. "
SET Confidence = "High"
#from figure 1A and table S1
SET Cell_Line = "HEK293T"
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 163))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 174))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 180))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 254))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 274))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 280))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 281))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 290))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 298))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 317))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 321))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 331))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 352))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 369))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 370))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 383))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 385))
act(p(HGNC:EP300)) -> p(HGNC:MAPT, pmod(Ac, Lys, 395))
UNSET Cell_Line
UNSET Confidence

SET Evidence = "Next, we treated primary neurons with C646, a pyrazolone-containing small-molecule inhibitor of p300 with a Ki of 400 nM (Bowers et al., 2010).
Under cell-free conditions, C646 at 10 μM inhibits p300 in a highly selective manner (86% inhibition vs. <10% for the six other acetyltransferases) (Bowers et al., 2010).
Inhibition of p300 with C646 (20 μM) drastically reduced levels of ac-tau in primary neurons within 8 h."
SET Confidence = "Medium"
a(CHEBI:"C646") =| act(p(HGNC:EP300)))
a(CHEBI:"C646") -| p(HGNC:MAPT, pmod(Ac))
UNSET Confidence

SET Evidence = "Thus, the increase in ac-tau induced by SIRT1 deficiency is accompanied by accumulation of pathogenic p-tau in primary neurons.
In mouse brains, deleting SIRT1, which elevated ac-tau, also increased AT8-positive p-tau."
SET Confidence = "Medium"
p(HGNC:SIRT1) -| p(HGNC:MAPT, pmod(Ac))
p(HGNC:MAPT, pmod(Ac)) pos p(HGNC:MAPT, pmod(Ph))
SET Species = "10090"
p(HGNC:MAPT, pmod(Ac)) pos p(HBP:"Tau epitope, AT8")
act(p(HGNC:SIRT1)) neg p(HBP:"Tau epitope, AT8")
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "29540553"}
SET Evidence = "SIRT1 overexpression into the hippocampus reduces acetylated K174 tau and significantly attenuates the spread of tau pathology into anatomically
connected brain regions of tauP301S transgenic mice of both sexes."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "P301S mice"
SET Anatomy = "hippocampal formation"
p(HGNC:SIRT1) -| p(HGNC:MAPT, pmod(Ac, Lys, 174))
p(HGNC:SIRT1) -| path(HBP:"Pathological Tau Spreading")
UNSET Anatomy
UNSET Research_Model
UNSET Species
UNSET Confidence

SET Evidence = "SIRT1 activation or elevation ameliorates pathology and neurodegeneration in AD (Qin et al., 2006; Kim et al., 2007).
Loss of SIRT1 induces impairment of learning and memory (Gao et al., 2010; Michán et al., 2010)."
SET Confidence = "Medium"
act(p(HGNC:SIRT1)) -| path(MESH:"Alzheimer Disease")
p(HGNC:SIRT1) -| path(MESH:"Alzheimer Disease")
act(p(HGNC:SIRT1)) -| path(HP:Neurodegeneration)
p(HGNC:SIRT1) -| path(HP:Neurodegeneration)
p(HGNC:SIRT1) -> bp(GO:learning)
p(HGNC:SIRT1) -> bp(GO:memory)
UNSET Confidence


SET Citation = {"PubMed", "29226865"}
SET Evidence = "We found that SIRT1 interacts with and deacetylates SC35, and inhibits SC35-promoted tau exon 10 inclusion.
Substituting K52 residue of SC35 by arginine impairs the role of SC35 in tau exon 10 inclusion.
These results suggest that SIRT1 may serve as a therapeutic target for tauopathy by regulating SC35-mediated tau exon 10 splicing."
SET Confidence = "High"
act(p(HGNC:SIRT1)) =| p(HGNC:SRSF2, pmod(Ac, Lys, 52))
p(HGNC:SRSF2, pmod(Ac, Lys, 52)) pos act(p(HGNC:SRSF2))
act(p(HGNC:SRSF2)) -> p(HBP:"4R tau")
UNSET Confidence


SET Citation = {"PubMed", "28760828"}
SET Evidence = "Our findings indicate that several acetylation sites in tau are responsive to HDAC6 and that acetylation on Lys-321 (within a KCGS motif)
is both essential for acetylation-mediated inhibition of tau aggregation in vitro and a molecular tactic for preventing phosphorylation on the downstream Ser-324 residue.
Tau phosphorylation of Ser-324 (pSer-324) has not previously been evaluated in the context of tauopathy, and here we observed increased deposition of pSer-324-positive tau both in mouse models of tauopathy and in patients with Alzheimer's disease.
These findings uncover a novel acetylation-phosphorylation switch at Lys-321/Ser-324 that coordinately regulates tau polymerization and function."
SET Confidence = "Medium"
p(HGNC:HDAC6) -> p(HGNC:MAPT, pmod(Ac, Lys, 321))
p(HGNC:MAPT, pmod(Ac, Lys, 321)) -| p(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(Ac, Lys, 321)) -| p(HGNC:MAPT, pmod(Ph, Ser, 324))
p(HGNC:MAPT, pmod(Ph, Ser, 324)) pos p(HBP:"Tau aggregates")
UNSET Confidence

SET Evidence = "HDAC6 inhibition leads to a significant reduction in tau levels as detected by the human tau-specific antibody E1 (Fig. 6 (a and c) and supplemental Fig. S6).
We also observed a striking decrease in phosphorylation at Ser-324, which was statistically significant even when normalizing to E1 to control for the reduction in tau levels (Fig. 6 (a and b) and supplemental Fig. S6)."
SET Confidence = "Medium"
p(HGNC:HDAC6) -> p(HGNC:MAPT)
p(HGNC:HDAC6) -> p(HGNC:MAPT, pmod(Ph, Ser, 324))
UNSET Confidence


SET Citation = {"PubMed", "28771976"}
SET Evidence = "HDAC3 overexpression in the hippocampus increases Aß levels, activates microglia, and decreases dendritic spine density in 6-month-old APP/PS1 mice."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "APPPS1 mice"
SET Anatomy = "hippocampal formation"
p(HGNC:HDAC3) -> a(CHEBI:"amyloid-beta")
p(HGNC:HDAC3) -> bp(GO:"microglial cell activation")
p(HGNC:HDAC3) -| a(GO:"dendritic spine")
UNSET Anatomy
UNSET Research_Model
UNSET Species
UNSET Confidence

SET Evidence = "RGFP966, a selective HDAC3 inhibitor, has been shown to affect sensory cortical plasticity and memory formation (Bieszczad et al., 2015)."
SET Confidence = "Medium"
#RGFP966 is PUBCHEM:56650312
a(PUBCHEM:56650312) =| act(p(HGNC:HDAC3))
a(HBP:RGFP966) -- bp(GO:memory)
UNSET Confidence


SET Citation = {"PubMed", "29844403"}
SET Evidence = "This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model. Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs.
This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins.
In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt
phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment."
SET Confidence = "Medium"
#MPT0G211 is PUBCHEM:132157820
SET Cell_Line = {"N2a", "SH-SY5Y"}
a(PUBCHEM:132157820) =| act(p(HGNC:HDAC6))
a(PUBCHEM:132157820) -| p(HGNC:MAPT, pmod(Ph))
a(PUBCHEM:132157820) -| a(HBP:"Tau aggregates")
a(HBP:"Tau aggregates") pos a(GO:"neurofibrillary tangle")
a(PUBCHEM:132157820) -> p(INTERPRO:"Heat shock protein Hsp90 family", pmod(Ac))
p(INTERPRO:"Heat shock protein Hsp90 family", pmod(Ac)) -| complex(p(INTERPRO:"Heat shock protein Hsp90 family"), p(HGNC:HDAC6))
p(INTERPRO:"Heat shock protein Hsp90 family", pmod(Ac)) -> p(HGNC:MAPT, pmod(Ph), pmod(Ub))
a(PUBCHEM:132157820) -> p(HGNC:GSK3B, pmod(Ph, Ser, 9))
p(HGNC:GSK3B, pmod(Ph, Ser, 9)) =| act(p(HGNC:GSK3B))
p(FPLX:AKT) -> p(HGNC:GSK3B, pmod(Ph, Ser, 9))
act(p(HGNC:GSK3B)) -| p(HGNC:MAPT, pmod(Ph, Ser, 396))
a(PUBCHEM:132157820) -| p(HGNC:MAPT, pmod(Ph, Ser, 396))
UNSET Cell_Line
UNSET Confidence

SET Evidence = "These results clearly indicated that MPT0G211 can penetrate the BBB, where it potentially ameliorates learning and memory deficits."
SET Confidence = "Medium"
SET Species = "10090"
SET Research_Model = "APPswe x P301L transgenic mice"
a(PUBCHEM:132157820) -> tloc(a(PUBCHEM:132157820), fromLoc(MESH:Blood), toLoc(MESH:Brain))
a(PUBCHEM:132157820) -> bp(GO:learning)
a(PUBCHEM:132157820) -> bp(GO:memory)
UNSET Research_Model
UNSET Species
UNSET Confidence

#######################################################################################################################################
#########################################################Tau O-GlcNAcylation###########################################################

SET Citation = {"PubMed", "19732809"}
SET Evidence = " This post-translational modification is likely an indicator of good health since its intracellular level correlates with the availability of extracellular glucose.
From a more practical point of view, it has been shown that O-GlcNAcylation impairments contribute to the etiology of cardiovascular diseases, type-2 diabetes and Alzheimer's disease (AD), three illnesses common in occidental societies."
SET Confidence = "Medium"
a(MESH:Proteins, pmod(HBP:"O-GlcNAcylation")) neg path(MESH:"Cardiovascular Diseases")
a(MESH:Proteins, pmod(HBP:"O-GlcNAcylation")) neg path(MESH:"Alzheimer Disease")
a(MESH:Proteins, pmod(HBP:"O-GlcNAcylation")) neg path(MESH:"Diabetes Mellitus, Type 2")
bp(MESH:"Hot Temperature") -- a(MESH:Proteins, pmod(HBP:"O-GlcNAcylation"))
UNSET Confidence

SET Evidence = "It has been reported that the proteasomal machinery is modified by O-GlcNAcylation [53,126] and that after modification by OGT, the
proteasome is inhibited [53]. Intriguingly, it has been proposed that a genetic impairment in the OGA gene results in proteasomal
dysfunction through a lack of hydrolysis of the inhibitory O-GlcNAc residues of the 19S regulatory cap. Indeed, the OGA gene is located in the 10q locus [127,128], a chromosomal region frequently mutated in
AD. The impairment of OGA in AD and the subsequent static OGlcNAcylation of the proteasome may explain why the latter fails to degrade neuronal aggregates.
In addition, it has been reported that OGlcNAcylation reduces the sensitivity of intracellular proteins to
proteasomal degradation by directly modifying them [43,129,130]. The two phenomena could thus act synergistically: a protein could
escape degradation by means of its own O-GlcNAcylation and by the inhibitory effect of glycosylation on the proteasome, leading to a
considerable decrease in the turnover of proteins that in turn may aggregate and cause neuronal death."
SET Confidence = "Medium"
a(MESH:Proteins, pmod(HBP:"O-GlcNAcylation")) -| act(complex(GO:"proteasome complex"))
g(HGNC:OGA, var("?")) -| act(complex(GO:"proteasome complex"))
g(HGNC:OGA, var("?")) pos path(MESH:"Alzheimer Disease")
UNSET Confidence

SET Evidence = "These results are in accord with our previous study showing that Tau hyperphosphorylation
is associated with a decrease in its O-GlcNAcylation level. A recent observation argues for
the hypothesis that O-GlcNAcylation occurs first and that its
modification reflects on the phosphorylation status."
SET Confidence = "High"
p(HGNC:MAPT, pmod(HBP:"O-GlcNAcylation")) neg p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Confidence

#######################################################################################################################################
#########################################################Tau Ubiquitination############################################################

SET Citation = {"PubMed", "26041011"}
SET Evidence = "We identified three specific RNA aptamers of USP14 (USP14-1, USP14-2, and USP14-3) that inhibited its deubiquitinating activity.
The nucleotide sequences of these non-cytotoxic USP14 aptamers contained conserved GGAGG motifs, with G-rich regions upstream, and similar secondary structures.
They efficiently elevated proteasomal activity, as determined by the increased degradation of small fluorogenic peptide substrates and physiological polyubiquitinated Sic1 proteins.
Additionally, proteasomal degradation of tau proteins was facilitated in the presence of the UPS14 aptamers in vitro."
SET Confidence = "High"
act(p(HGNC:USP14)) -| act(complex(GO:"proteasome complex"))
act(complex(GO:"proteasome complex")) -| a(HBP:"Tau aggregates")
a(HBP:"USP14 Aptamer") -| act(p(HGNC:USP14))
UNSET Confidence


SET Citation = {"PubMed", "27325702"}
SET Evidence = "the ACR (APP cytosolic region) interacts with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR,
and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn."
SET Confidence = "High"
p(HBP:"APP, ACR") -- p(HGNC:STUB1)
p(HGNC:STUB1) isA complex(GO:"ubiquitin ligase complex")
p(HBP:"APP, ACR") -- p(HBP:"CRL4 complex")
p(HBP:"CRL4 complex") eq complex(p(HGNC:CUL4A), p(HGNC:CUL4B), p(HGNC:DDB1), p(HGNC:CRBN))
p(HBP:"CRL4 complex") isA complex(GO:"ubiquitin ligase complex")
UNSET Confidence

SET Evidence = "As reported in Table 6, several brain-derived proteins associated with the ACR bait were ubiquitinated.
These proteins can be separated into four groups as follows: (a) group 1, proteins of the ubiquitin-conjugating system; (b) group 2, presynaptic proteins; (c) group 3, other proteins implicated in AD; and (d) group 4, phosphorylation-dependent ACR interactors."
SET Confidence = "High"
#table 6
p(HBP:"APP, ACR") -> p(HGNC:SCAMP1, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SV2A, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SV2B, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:VAMP2, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:ATP6V0A1, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SLC17A7, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SYT1, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SYT2, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:RAB14, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SNAP25, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SYN2, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:SYN1, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:RAB3A, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:APOE, pmod(Ub))
p(HBP:"APP, ACR") -> p(HGNC:MAPT, pmod(Ub))
UNSET Confidence

SET Evidence = "Together with the evidence that CRBN and CUL4B are linked to intellectual disability suggests a pathogenic mechanism, in which APP acts as a modulator of E3 ubiquitin-protein ligase(s)."
SET Confidence = "High"
p(HBP:"APP, ACR") reg complex(GO:"ubiquitin ligase complex")
UNSET Confidence


SET Citation = {"PubMed", "25378699"}
SET Evidence = "Furthermore, the enhanced SUMO-immunoreactivity, costained with the hyperphosphorylated tau, is detected in cerebral cortex of the AD brains,
and β-amyloid exposure of rat primary hippocampal neurons induces a dose-dependent SUMOylation of the hyperphosphorylated tau.
Our findings suggest that tau SUMOylation reciprocally stimulates its phosphorylation and inhibits the ubiquitination-mediated tau degradation,
which provides a new insight into the AD-like tau accumulation."
SET Confidence = "Medium"
SET MeSHAnatomy = "Cerebral Cortex"
SET MeSHDisease = "Alzheimer Disease"
p(HGNC:MAPT, pmod(Sumo, Lys, 340)) pos p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET MeSHAnatomy
UNSET MeSHDisease
p(HGNC:MAPT, pmod(Sumo, Lys, 340)) -> p(HGNC:MAPT, pmod(Ph))
p(HGNC:MAPT, pmod(Sumo, Lys, 340)) -| p(HGNC:MAPT, pmod(Ub))
p(HGNC:MAPT, pmod(Ub)) -> deg(p(HGNC:MAPT))
SET Species = "10116"
SET Anatomy = "hippocampal formation"
a(CHEBI:"amyloid-beta") -> p(RGD:Mapt, pmod(HBP:hyperphosphorylation), pmod(Sumo))
UNSET Anatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "26692334"}
SET Evidence = "Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo.
The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin
Exposure of slices from the early-stage mice to rolipram or db-cAMP for 8 h reduced amounts of total and insoluble tau (Fig. 3a), including phosphorylated tau (Supplementary Fig. 4a,b). In contrast, epoxomicin treatment increased levels of phosphorylated tau (Supplementary Fig. 4), although the amount of total tau remained unchanged (Fig. 3a). PKA is known to phosphorylate tau at Ser214 (pS214)29. We therefore monitored the amount of pS214 tau to determine whether rolipram and db-cAMP activated PKA. The amount of pS214 tau was higher in db-cAMP– and rolipram-treated samples than in control (DMSO) and epoxomicin-treated slices (Fig. 3a)."
SET Confidence = "Medium"
a(CHEBI:rolipram) =| act(p(FPLX:PDE4))
a(CHEBI:rolipram) -> a(CHEBI:"3',5'-cyclic AMP")
a(CHEBI:rolipram) -> act(p(FPLX:PKA))
a(CHEBI:rolipram) -> act(complex(GO:"proteasome complex"))
a(CHEBI:rolipram) -| a(HBP:"Tau aggregates")
a(CHEBI:rolipram) -> p(HGNC:MAPT, pmod(Ph, Ser, 214))
act(p(FPLX:PKA)) -> p(HGNC:MAPT, pmod(Ph, Ser, 214))
UNSET Confidence

SET Evidence = "PKA stimulation attenuated proteasome dysfunction, probably through proteasome subunit phosphorylation resulting in lower levels of aggregated tau and improvements in cognitive performance."
SET Confidence = "Medium"
act(p(FPLX:PKA)) -> act(complex(GO:"proteasome complex"))
act(p(FPLX:PKA)) -| a(HBP:"Tau aggregates")
act(p(FPLX:PKA)) -> bp(GO:cognition)
UNSET Confidence


SET Citation = {"PubMed", "24905733"}
SET Evidence = "We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity to E3 ubiquitin ligases interacts with tau.
We find here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain, which diminishes its microtubule-binding.
Tau becomes mono-ubiquitinated by recombinant tau-interacting RING-variant domain reducing microtubule-binding."
SET Confidence = "Medium"
p(HGNC:MARCH7) -> p(HGNC:MAPT, pmod(Ub))
p(HGNC:MAPT, pmod(Ub)) -| complex(p(HGNC:MAPT), a(MESH:Microtubules))
UNSET Confidence


SET Citation = {"PubMed", "8391280"}
SET Evidence = "Ubiquitination occurs at lysines (K254, K257 K311) in repeat domain; participates in triage process"
SET Confidence = "High"
p(HGNC:MAPT, pmod(Ub, Lys, 254)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(Ub, Lys, 257)) pos a(HBP:"paired helical filaments")
p(HGNC:MAPT, pmod(Ub, Lys, 311)) pos a(HBP:"paired helical filaments")
UNSET Confidence

#######################################################################################################################################
#########################################################Tau Aggregation############################################################


SET Citation = {"PubMed", "27260838"}
SET Evidence = "Previously, we have shown that TNT1 is a marker of PAD exposure and that this event occurs early in the progression of Alzheimer’s disease.
Establishing whether this was true for all N-terminal antibodies was important for understanding more about PAD exposure in Alzheimer’s disease.
We significantly extend these findings with TNT1 and show that TNT2 behaves similarly as a marker of PAD exposure.
In contrast, other N-terminal antibodies, with slightly different epitopes, do not function as pathological, PAD exposure-specific markers and recognize all forms of tau similarly.
Here, we found that TNT1 and TNT2 appear in Braak I–II stages and do not colocalize with ThR in the diffuse, granular pre-tangle pathology conclusively demonstrating that PAD exposure is an early event."
SET Confidence = "High"
SET Braak_Stage = {"Stage I", "Stage II"}
p(HBP:"Tau antibody, TNT1") -- p(HBP:"phosphatase-activating domain")
p(HBP:"Tau antibody, TNT2") -- p(HBP:"phosphatase-activating domain")
UNSET Braak_Stage
UNSET Confidence


SET Citation = {"PubMed", "27574109"}
SET Evidence = "Aggregation-induced increases in PAD exposure and oligomerization are common features among all tau isoforms.
The extent of PAD exposure and oligomerization was larger for tau aggregates composed of 4-repeat isoforms compared with those made of 3-repeat isoforms."
SET Confidence = "High"
p(HBP:"phosphatase-activating domain") pos p(HBP:"4R tau")
UNSET Confidence


SET Citation = {"PubMed", "27601475"}
SET Evidence = "Tau contains cysteine residues in the microtubule binding region following alternative splicing of exon 10, and formation of intermolecular cysteine disulfide bonds accelerates tau aggregation.
8-Nitro-cGMP (novel second messenger of NO) exposure induced S-guanylation of tau both in vitro and in tau-overexpressed HEK293T cells.
S-guanylated tau inhibited heparin-induced tau aggregation (thioflavin T). S-guanylated tau could not form tau granules and fibrils (AFM) inhibited at the step of tau oligomer formation.
In P301L tau-expressing Neuro2A cells, 8-nitro-cGMP reduced the amount of sarcosyl-insoluble tau.
NO-linked chemical modification on cysteine residues of tau could block tau aggregation"
SET Confidence = "High"
SET Cell_Line = {"N2a", "HEK293T"}
a(HBP:"8-nitro-cGMP") -| a(HBP:"Tau oligomers")
a(CHEBI:"nitric oxide") pos a(HBP:"8-nitro-cGMP")
act(p(ECCODE:"1.14.13.39")) => a(CHEBI:"nitric oxide")
a(CHEBI:heparin) -> p(HBP:"Tau aggregates")
UNSET Cell_Line
UNSET Confidence


SET Citation = {"PubMed", "27373205"}
SET Evidence = "Highlighting the relevance of these findings to human disease, pS422 tau was found to colocalize with tau oligomers and with a fraction of tau showing increased PAD exposure in the human AD brain.
This study identifies novel effects of pS422 on tau biochemical properties, including prolonged nucleation and enhanced dimer formation, which correlate with a distinct inhibitory effect on FAT."
SET Confidence = "High"
p(HGNC:MAPT, pmod(Ph, Ser, 422)) pos p(HBP:"phosphatase-activating domain")
p(HGNC:MAPT, pmod(Ph, Ser, 422)) pos p(HBP:"Tau dimers")
p(HGNC:MAPT, pmod(Ph, Ser, 422)) -| bp(GO:"anterograde axonal transport")
UNSET Confidence


SET Citation = {"PubMed", "11606569"}
SET Evidence = "We also show that two of the tau mutations found in hereditary frontotemporal dementias,
DeltaK280 and P301L, have a much stronger tendency for PHF aggregation which correlates with their high propensity for beta-structure around the hexapeptide motifs."
SET Confidence = "High"
p(HGNC:MAPT, var("p.Lys280del")) eq g(DBSNP:rs63750688)
p(HGNC:MAPT, var("p.Lys280del")) pos p(HBP:"VQIINK motif")
p(HGNC:MAPT, var("p.Lys280del")) pos p(HBP:"VQIVYK motif")
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HBP:"VQIINK motif")
p(HGNC:MAPT, var("p.Pro301Leu")) pos p(HBP:"VQIVYK motif")
p(HBP:"VQIINK motif") -> p(HBP:"Tau aggregates")
p(HBP:"VQIVYK motif") -> p(HBP:"Tau aggregates")
UNSET Confidence


SET Citation = {"PubMed", "28500862"}
SET Evidence = "In the HEK cell biosensor assay, tau from AD cases with plaques enhanced tau aggregates compared to tau from cases without plaques.
In APP/PS1 cross with rTg4510 mice (P301L mutant human tau), tau seeding activity was threefold increased over the rTg4510 strain, without change in tau production or extracellular release."
SET Confidence = "High"
SET Species = "10090"
SET Research_Model = "APP/PS1 x rTg4510 mice"
a(CHEBI:"amyloid-beta") pos p(HBP:"Tau aggregates")
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "27716675"}
SET Evidence = "The tauopathy mice that we used contained the P301L mutation, which is implicated in some genetic tauopathies.
In addition, this mutation, along with the related P301S mutation, has been associated with increased inflammation in the brain as well as retinal deficits"
SET Confidence = "Medium"
p(HGNC:MAPT, var("p.Pro301Leu")) pos path(HBP:neuroinflammation)
UNSET Confidence

SET Evidence = "Tau Oligomers co-localize with astrocytes, microglia, and HMGB1, a pro-inflammatory cytokine, are present in the retina and are associated with inflammatory cells."
SET Confidence = "High"
a(HBP:"Tau oligomers") pos path(HBP:neuroinflammation)
UNSET Confidence


SET Citation = {"PubMed", "27716675"}
SET Evidence = "This work supports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration."
SET Confidence = "Medium"
a(HBP:"Tau oligomers") -> path(HBP:"Pathological Tau Spreading")
a(HBP:"Tau oligomers") -> path(HP:Neurodegeneration)
UNSET Confidence

################################################################################################################################################
############################################################Tau SUMOylation#####################################################################


SET Citation = {"PubMed", "27716675"}
SET Evidence = "The plasma level of SUMO1 was significantly increased in dementia patients, as compared to control groups.
The levels of SUMO1 correlated to decreased Mini-Mental State Examination (r =-0.123, p = 0.029).
These results suggest that elevated plasma SUMO1 levels may be associated with AD."
SET Confidence = "High"
p(HGNC:SUMO1) pos path(MESH:"Alzheimer Disease")
UNSET Confidence


SET Citation = {"PubMed", "19765634"}
SET Evidence = "The genotype distribution of a polymorphism in intron 7 (rs761059) differed between AD cases and controls, with an adjusted odds ratio (OR) of 1.45 (p=0.046, 95% CI: 1.01-2.08).
One haplotype (ht2 CAGAG) was found in 14.0% of the AD patients and in 11.1% of the controls (p=0.04, OR=1.43. 95% CI; 1.01-2.01).
Stratification by the ApoE gave no significant difference between the groups but when stratified by gender,
two SNPs (rs8052688, rs8063) were significantly associated with the risk of MCI among women."
SET Confidence = "High"
SET Study_Group = "Korean population"
g(DBSNP:rs761059) pos path(MESH:"Alzheimer Disease")
SET Gender = "Female"
g(DBSNP:rs8052688) pos path(MESH:"Cognitive Dysfunction")
g(DBSNP:rs8063) pos path(MESH:"Cognitive Dysfunction")
UNSET Gender
UNSET Study_Group
UNSET Confidence


SET Citation = {"PubMed", "23229893"}
SET Evidence = "That SUMO-1 co-localizes with a subset of lysosomes in neurodegenerative diseases with glial protein aggregates and in glial cell culture models of protein aggregation suggests a role for SUMO-1 in lysosome function."
SET Confidence = "Medium"
SET MeSHDisease = {"Multiple System Atrophy", "Supranuclear Palsy, Progressive"}
p(HGNC:SUMO1) -- a(GO:lysosome)
UNSET MeSHDisease
UNSET Confidence


SET Citation = {"PubMed", "21843595"}
SET Evidence = "In 25-month-old mice, the number of errors and the latency in the learning phase negatively correlated with the Sumo3 level in the dorsal hippocampus."
SET Confidence = "High"
SET Species = "10090"
SET Anatomy = "hippocampal formation"
p(MGI:Sumo3) neg bp(GO:learning)
p(MGI:Sumo3) neg bp(GO:memory)
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "19782030"}
SET Evidence = "LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action.
LXRbeta forms a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins.
Both PIAS1 and HDAC4 belong to the SUMO E3 ligase family and LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression."
SET Confidence = "Medium"
SET Species = "10116"
SET Cell = "astrocyte"
act(p(RGD:Stat1)) -> r(RGD:Irf1)
act(p(RGD:Stat1)) -> r(RGD:Tnf)
act(p(RGD:Stat1)) -> r(RGD:Il6)
complex(p(RGD:Nr1h2),p(RGD:Pias1),p(RGD:Stat1, pmod(Ph)))
complex(p(RGD:Nr1h3),p(RGD:Hdac4),p(RGD:Stat1, pmod(Ph)))
p(RGD:Pias1) -> p(RGD:Nr1h2, pmod(Sumo))
p(RGD:Hdac4) -> p(RGD:Nr1h3, pmod(Sumo))
p(RGD:Nr1h2, pmod(Sumo)) -> act(p(RGD:Stat1))
p(RGD:Nr1h3, pmod(Sumo)) -> act(p(RGD:Stat1))
UNSET Cell
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "19323834"}
SET Evidence = "Noradrenaline (NA) attenuated the LPS-induced reductions and increased SUMO-1 above basal levels.
Over-expression of SUMO-1, Ubc9, or SENP1 reduced the activation of a NOS2 promoter, whereas activation of a 4 x NFkappaB binding-element reporter was only reduced by SUMO-1.
ChIP studies revealed interactions of SUMO-1 and C/EBPbeta with C/EBP binding sites on the NOS2 promoter that were modulated by LPS and NA.
SUMO-1 co-precipitated with C/EBPbeta confirmed by FRET analysis"
SET Confidence = "Medium"
SET Method = {"Chromatin Immunoprecipitation", "Fluorescence Resonance Energy Transfer"}
a(CHEBI:noradrenaline) -> p(HGNC:SUMO1)
a(CHEBI:"lipopolysaccharide") -| p(HGNC:SUMO1)
p(HGNC:SUMO1) partOf complex(p(FPLX:CEBP), p(HGNC:SUMO1))
p(FPLX:CEBP) partOf complex(p(FPLX:CEBP), p(HGNC:SUMO1))
complex(p(FPLX:CEBP), p(HGNC:SUMO1)) =| r(HGNC:NOS2)
p(HGNC:UBE2I) =| r(HGNC:NOS2)
p(HGNC:SENP1) =| r(HGNC:NOS2)
UNSET Method
UNSET Confidence


SET Citation = {"PubMed", "18675254"}
SET Evidence = "Lysines 587 and 595 of APP, immediately adjacent to the site of beta-secretase cleavage, are covalently modified by SUMO proteins in vivo.
Sumoylation of these lysine residues is associated with decreased levels of Abeta aggregates.
The results demonstrate that the SUMO E2 enzyme (ubc9) is present within the endoplasmic reticulum, indicating how APP, and perhaps other proteins that enter this compartment, can be sumoylated."
SET Confidence = "Medium"
p(HGNC:SUMO1) -> p(HGNC:APP, pmod(Sumo, Lys, 587))
p(HGNC:SUMO1) -> p(HGNC:APP, pmod(Sumo, Lys, 595))
p(HGNC:SUMO2) -> p(HGNC:APP, pmod(Sumo, Lys, 587))
p(HGNC:SUMO2) -> p(HGNC:APP, pmod(Sumo, Lys, 595))
p(HGNC:APP, pmod(Sumo, Lys, 587)) neg a(CHEBI:"amyloid-beta")
p(HGNC:APP, pmod(Sumo, Lys, 595)) neg a(CHEBI:"amyloid-beta")
p(HGNC:UBE2I) -- complex(GO:"endoplasmic reticulum")
UNSET Confidence


SET Citation = {"PubMed", "17346237"}
SET Evidence = "SUMO3 overexpression significantly increased Abeta40 and Abeta42 secretion, which was accompanied by an increase in full-length APP and its C-terminal fragments.
These effects of SUMO3 were independent of its covalent attachment or chain formation, as mutants lacking the motifs responsible for SUMO chain formation or SUMO conjugation led to similar changes in Abeta.
SUMO3 overexpression also up-regulated the expression of the transmembrane protease BACE (beta-amyloid-cleaving enzyme), but failed to affect levels of several other unrelated proteins."
SET Confidence = "Medium"
p(HGNC:SUMO3) -> p(HGNC:BACE1)
p(HGNC:SUMO3) -> p(HGNC:APP)
p(HGNC:SUMO3) -> sec(p(HGNC:APP, frag(672_711)))
p(HGNC:SUMO3) -> sec(p(HGNC:APP, frag(672_713)))
UNSET Confidence


SET Citation = {"PubMed", "16464864"}
SET Evidence = "Both brain proteins were preferentially modified by SUMO1, as compared with SUMO2 or SUMO3.
Tau contains two SUMO consensus sequences with Lys(340) as the major sumoylation site.
Although both tau and alpha-synuclein are targets for proteasomal degradation, only tau sumoylation was affected by inhibitors of the proteasome pathway.
Treatment with the phosphatase inhibitor, okadaic acid, or the microtubule depolymerizing drug, colchicine, up-regulated tau sumoylation."
SET Confidence = "Medium"
#brain proteins: mapt and snca
p(HGNC:SUMO1) -> p(HGNC:MAPT, pmod(Sumo, Lys, 340))
p(HGNC:SUMO1) -> p(HGNC:SNCA, pmod(Sumo))
a(CHEBI:"okadaic acid") -> p(HGNC:MAPT, pmod(Sumo, Lys, 340))
a(CHEBI:colchicine) -> p(HGNC:MAPT, pmod(Sumo, Lys, 340))
UNSET Confidence


SET Citation = {"PubMed", "12506199"}
SET Evidence = "Increased protein sumoylation resulting from overexpression of SUMO-3 reduces Abeta production and reducing endogenous protein sumoylation with dominant-negative SUMO-3 mutants increases Abeta production.
Mutant SUMO-3, K11R, which can only be monomerically conjugated to target proteins, has an opposite effect on Abeta generation to that by SUMO-3, which can form polymeric chains on target proteins.
Polysumoylation reduces whereas monosumoylation or undersumoylation enhances Abeta generation."
SET Confidence = "Medium"
p(HGNC:SUMO3) -| a(CHEBI:"amyloid-beta")
p(HGNC:SUMO3, var("p.Lys11Arg")) -> p(HGNC:APP, pmod(Sumo))
p(HGNC:SUMO3, var("p.Lys11Arg")) -> a(CHEBI:"amyloid-beta")
p(HGNC:APP, pmod(Sumo)) -> a(CHEBI:"amyloid-beta")
p(HGNC:APP, pmod(HBP:polysumoylation)) -| a(CHEBI:"amyloid-beta")
p(HGNC:SUMO3) -> p(HGNC:APP, pmod(HBP:polysumoylation))
UNSET Confidence


#############################################################################################################
###################################################Tau Dephosphorylation#####################################


#################################################Phosphatase Biochemistry####################################


SET Citation = {"PubMed", "29334120"}
SET Evidence = "We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability.
Overexpression of PP1α and PP1γ, but not PP1β, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion."
SET Confidence = "High"
act(p(HGNC:TARDBP)) -> p(HBP:"4R tau")
p(HGNC:PPP1CC) =| p(HGNC:TARDBP, pmod(Ph, Ser, 403))
p(HGNC:PPP1CC) =| p(HGNC:TARDBP, pmod(Ph, Ser, 404))
p(HGNC:PPP1CC) =| p(HGNC:TARDBP, pmod(Ph, Ser, 409))
p(HGNC:PPP1CC) =| p(HGNC:TARDBP, pmod(Ph, Ser, 410))
p(HGNC:PPP1CA) =| p(HGNC:TARDBP, pmod(Ph, Ser, 397))
p(HGNC:PPP1CA) =| p(HGNC:TARDBP, pmod(Ph, Ser, 403))
p(HGNC:PPP1CA) =| p(HGNC:TARDBP, pmod(Ph, Ser, 404))
p(HGNC:PPP1CA) =| p(HGNC:TARDBP, pmod(Ph, Ser, 409))
p(HGNC:PPP1CA) =| p(HGNC:TARDBP, pmod(Ph, Ser, 410))
p(HGNC:TARDBP, pmod(Ph, Ser, 409)) -> act(p(HGNC:TARDBP))
p(HGNC:TARDBP, pmod(Ph, Ser, 410)) -> act(p(HGNC:TARDBP))
UNSET Confidence


SET Citation = {"PubMed", "26142647"}
SET Evidence = "The growth arrest and DNA damage protein (GADD) 34 is up-regulated in response to ER stress and regulates subunit of
protein phosphatase 1 (PP1) complex that dephosphorylates eukaryotic translation initiator factor 2α (elF2α)."
SET Confidence = "Medium"
#GADD 34 is PPP1R15A
bp(GO:"response to endoplasmic reticulum stress") -> p(HGNC:PPP1R15A)
p(HGNC:PPP1R15A) reg act(p(HGNC:PPP1CA))
act(p(HGNC:PPP1CA)) =| p(HGNC:EIF2S1, pmod(Ph))
UNSET Confidence


SET Citation = {"PubMed", "29228318"}
SET Evidence = "These findings suggest a scenario in which MC-LR-mediated demethylation of PP2Ac is associated with GSK-3β phosphorylation at Ser9 and contributes to dissociation of Bα from PP2Ac,
which would result in Bα degradation and disruption of PP2A/Bα-tau interactions, thus promoting tau hyperphosphorylation and paired helical filaments-tau accumulation and, consequently, axonal degeneration and cell death."
SET Confidence = "Medium"
a(CHEBI:"microcystin-LR") -| p(HGNC:PPP2CA, pmod(Me))
p(HGNC:PPP2CA, pmod(Me)) -| act(p(HGNC:PPP2CA))
act(p(HGNC:PPP2CA)) =| p(HGNC:GSK3B, pmod(Ph, Ser, 9))
p(HGNC:PPP2CA, pmod(Me)) -> complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB))
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB)) -| deg(p(HGNC:PPP2CB))
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB)) -> complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB), p(HGNC:MAPT))
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB), p(HGNC:MAPT)) -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB), p(HGNC:MAPT)) -| a(HBP:"paired helical filaments")
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB), p(HGNC:MAPT)) -| a(MESH:Axons)
complex(p(HGNC:PPP2CA), p(HGNC:PPP2CB), p(HGNC:MAPT)) -| bp(GO:"cell death")
UNSET Confidence

#############################################################################################################


SET Citation = {"PubMed", "29421605"}
SET Evidence = "Interestingly, the middle-aged rats have higher levels of PTP-1B, lower phosphorylation of IRS-1, Akt, GSK3β, mTOR, and TrkB.
Also, the aging process increased Tau phosphorylation and β-amyloid content in the hippocampus region.
In summary, this study provides new evidence that aging-related PTP1B increasing, contributing to insulin resistance and the onset of the AD."
SET Confidence = "Medium"
SET Species = "10116"
bp(GO:aging) pos p(RGD:Ptpn1)
bp(GO:aging) neg p(RGD:Irs1, pmod(Ph))
bp(GO:aging) neg p(RGD:Akt1, pmod(Ph))
bp(GO:aging) neg p(RGD:Gsk3b, pmod(Ph))
bp(GO:aging) neg p(RGD:Mtor, pmod(Ph))
bp(GO:aging) neg p(RGD:Ntrk2, pmod(Ph))
SET MeSHAnatomy = "Hippocampus"
bp(GO:aging) pos p(RGD:Mapt, pmod(Ph))
bp(GO:aging) pos a(CHEBI:"amyloid-beta")
UNSET MeSHAnatomy
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "29062069"}
SET Evidence = "Here we show that resveratrol treatment directly interferes with the MID1-α4-PP2A degradation complex by reducing MID1 protein expression in vitro and in vivo.
This leads to an increase of microtubule-associated PP2A activity and a time- and dose-dependent dephosphorylation of Tau.
Interestingly, we further show that MID1 expression is elevated in AD tissue."
SET Confidence = "Medium"
a(CHEBI:resveratrol) -| p(HGNC:MID1)
a(CHEBI:resveratrol) -> act(p(HGNC:PPP2CA))
p(HGNC:MID1) -| act(p(HGNC:PPP2CA))
a(CHEBI:resveratrol) -| p(HGNC:MAPT, pmod(Ph))
p(HGNC:MID1) pos path(MESH:"Alzheimer Disease")
UNSET Confidence


SET Citation = {"PubMed", "28720530"}
SET Evidence = "Our results indicated a significant down-regulation of PPP2R5E gene expression and reduction in PP2A activity by ApoE4 compared with ApoE3.
This may also explain an elevated Tau phosphorylation in AD human brains that featured at least one ApoE4 allele."
SET Confidence = "Medium"
g(HBP:"APOE e4") -| p(HGNC:PPP2R5E)
g(HBP:"APOE e4") -| act(p(FPLX:PPP2))
UNSET Confidence


SET Citation = {"PubMed", "28422052"}
SET Evidence = "Folic acid reduced tau hyperphosphorylation at Ser396 in the brain of diabetes mellitus (DM) mice.
In addition, PP2A methylation and DNMT1 mRNA expression were significantly increased in DM mice post folic acid treatment.
GSK-3β phosphorylation was not regulated by folic acid administration. Folic acid can reduce tau phosphorylation by regulating PP2A methylation in diabetic mice."
SET Confidence = "Medium"
SET Species = "10090"
SET MeSHDisease = "Diabetes Mellitus"
SET Research_Model = "streptozotocin (STZ)-induced DB murine model"
a(CHEBI:"folic acid") -| p(MGI:Mapt, pmod(Ph, Ser, 396))
a(CHEBI:"folic acid") -> r(MGI:Dnmt1)
a(CHEBI:"folic acid") -> p(FPLX:PPP2, pmod(Me))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "25143394"}
SET Evidence = "We found strong Tau hyperphosphorylation in brain samples from R6/2 and 140CAG Tg knock-in, associated with a significant reduction in the levels of Tau phosphatases (PP1, PP2A and PP2B), with no apparent involvement of major Tau kinases."
SET Confidence = "High"
SET Species = "10090"
SET Research_Model = "HD murine model"
p(MGI:Ppp1ca) neg p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
p(MGI:Ppp2ca) neg p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
p(MGI:Ppp1cb) neg p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
UNSET Research_Model
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "23134599"}
SET Evidence = "PP2A expression decreased, whereas, PP1 and PP5 expression increased in lead-exposed rats.
These results demonstrate that early postnatal exposure to lead decrease PP2A expression and induce tau hyperphosphorylation at several serine and threonine residues."
SET Confidence = "Medium"
SET Species = "10116"
a(CHEBI:"lead diacetate") -| p(RGD:Ppp2ca)
a(CHEBI:"lead diacetate") -> p(RGD:Ppp1ca)
a(CHEBI:"lead diacetate") -> p(RGD:Ppp5c)
a(CHEBI:"lead diacetate") -> p(MGI:Mapt, pmod(HBP:hyperphosphorylation))
UNSET Species
UNSET Confidence


SET Citation = {"PubMed", "21734277"}
SET Evidence = "Filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding.
Amino acids 2-18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway.
Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm.
Immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity.
We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT"
SET Confidence = "Medium"
a(GO:"neurofibrillary tangle") -| bp(GO:"axonal transport")
a(GO:"neurofibrillary tangle") -> act(p(FPLX:PPP1))
a(GO:"neurofibrillary tangle") -> act(p(HGNC:GSK3B))
act(p(FPLX:PPP1)) -| bp(GO:"axonal transport")
act(p(HGNC:GSK3B)) -| bp(GO:"axonal transport")
p(HBP:"phosphatase-activating domain") neg bp(GO:"axonal transport")
p(HBP:"phosphatase-activating domain") pos p(HGNC:MAPT, pmod(Ph, Ser, 199))
p(HBP:"phosphatase-activating domain") pos p(HGNC:MAPT, pmod(Ph, Ser, 202))
p(HBP:"phosphatase-activating domain") pos p(HGNC:MAPT, pmod(Ph, Thr, 205))
p(HBP:"phosphatase-activating domain") -> act(p(FPLX:PPP1))
p(HBP:"phosphatase-activating domain") -> act(p(HGNC:GSK3B))
UNSET Confidence

SET Citation = {"PubMed", "21489990"}
SET Evidence = "In NGF-exposed PC12 cells, Egr-1 activates Cdk5 to promote phosphorylation of tau and inactivates PP1 via phosphorylation.
Cdk5 phosphorylates Ser(396/404) directly. By phosphorylating and inactivating PP1, Cdk5 promotes tau phosphorylation at Ser(262) indirectly."
SET Confidence = "Medium"
SET CellLine = "PC12"
SET Species = "10116"
p(RGD:Egr1) -> act(p(RGD:Cdk5))
act(p(RGD:Cdk5)) -> p(RGD:Mapt, pmod(Ph, Ser, 396))
act(p(RGD:Cdk5)) -> p(RGD:Mapt, pmod(Ph, Ser, 404))
p(RGD:Egr1) -> p(FPLX:PPP1, pmod(Ph))
p(FPLX:PPP1, pmod(Ph)) -| act(p(FPLX:PPP1))
act(p(RGD:Cdk5)) -> p(RGD:Mapt, pmod(Ph, Ser, 262))
act(p(FPLX:PPP1)) -| p(RGD:Mapt, pmod(Ph, Ser, 262))
UNSET Species
UNSET CellLine
UNSET Confidence


SET Citation = {"PubMed", "19623258"}
SET Evidence = "Kynurenic pathway is overactive in AD. QA is co-localized with hyperphosphorylated tau within cortical neurons in AD brain.
In primary cultures of human neurons, QA treatment increased tau phosphorylation at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner.
This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity, mostly in PP2A expression and modest in PP1."
SET Confidence = "Medium"
SET MeSHDisease = "Alzheimer Disease"
SET Cell = "cerebral cortex neuron"
a(CHEBI:"quinolinic acid") -- p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET MeSHDisease
UNSET Cell
SET MeSHAnatomy = "Neurons"
a(CHEBI:"quinolinic acid") -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
a(CHEBI:"quinolinic acid") -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
a(CHEBI:"quinolinic acid") -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
a(CHEBI:"quinolinic acid") -> p(HGNC:MAPT, pmod(Ph, Ser, 396))
a(CHEBI:"quinolinic acid") -> p(HGNC:MAPT, pmod(Ph, Ser, 404))
a(CHEBI:"quinolinic acid") -| act(p(FPLX:PPP2))
a(CHEBI:"quinolinic acid") -| act(p(FPLX:PPP1))
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "QA appears to act through NMDA receptor activation similar to other agonists, glutamate and NMDA and was abrogated by the NMDAR antagonist memantine.
NMDA receptor agonists, glutamate and NMDA at equimolar concentrations (500 nM) increased tau phosphorylation at serine 199/202 (AT8) and threonine 231 (AT-180), similar to QA."
SET Confidence = "Medium"
a(CHEBI:"quinolinic acid") -> act(complex(GO:"NMDA selective glutamate receptor complex"))
act(complex(GO:"NMDA selective glutamate receptor complex")) -> p(HGNC:MAPT, pmod(Ph, Ser, 199))
act(complex(GO:"NMDA selective glutamate receptor complex")) -> p(HGNC:MAPT, pmod(Ph, Ser, 202))
act(complex(GO:"NMDA selective glutamate receptor complex")) -> p(HGNC:MAPT, pmod(Ph, Thr, 231))
UNSET Confidence

SET Evidence = "Using PCR arrays, QA significantly induces 10 genes in human neurons known to be associated with AD pathology with 6 belonging to pathways involved in tau phosphorylation and 4 of them in neuroprotection."
SET Confidence = "High"
a(CHEBI:"quinolinic acid") -> r(HGNC:BRCA1)
a(CHEBI:"quinolinic acid") -> r(HGNC:MYC)
a(CHEBI:"quinolinic acid") -> r(HGNC:WNT1)
a(CHEBI:"quinolinic acid") -> r(HGNC:CCN4)
a(CHEBI:"quinolinic acid") -> r(HGNC:CDK5)
a(CHEBI:"quinolinic acid") -> r(HGNC:IL1A)
a(CHEBI:"quinolinic acid") -> r(HGNC:NOS2)
a(CHEBI:"quinolinic acid") -> r(HGNC:CEBPB)
a(CHEBI:"quinolinic acid") -> r(HGNC:CSF2)
a(CHEBI:"quinolinic acid") -> r(HGNC:LEP)
UNSET Confidence

###Insert complementary articles for the genes above

SET Citation = {"PubMed", "25001178"}
SET Evidence = "In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling.
In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b.
Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau.
Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo.
Importantly, DUSP6 and PPP1CA are also reduced in AD brains."
SET Confidence = "Medium"
m(MIRBASE:"hsa-mir-125b-1") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
m(MIRBASE:"hsa-mir-125b-1") -> act(p(HGNC:CDK5R1))
m(MIRBASE:"hsa-mir-125b-1") -> kin(p(HGNC:CDK5))
m(MIRBASE:"hsa-mir-125b-1") -> kin(p(HGNC:MAPK3))
m(MIRBASE:"hsa-mir-125b-1") -> kin(p(HGNC:MAPK1))
m(MIRBASE:"hsa-mir-125b-1") -| p(HGNC:PPP1CA)
m(MIRBASE:"hsa-mir-125b-1") -| p(HGNC:DUSP6)
m(MIRBASE:"hsa-mir-125b-1") -| p(HGNC:BCL2L2)
p(HGNC:PPP1CA) =| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
p(HGNC:DUSP6) =| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
p(HGNC:BCL2L2) -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
m(MIRBASE:"hsa-mir-125b-1") -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
SET MeSHAnatomy = "Brain"
p(HGNC:DUSP6) neg path(MESH:"Alzheimer Disease")
p(HGNC:PPP1CA) neg path(MESH:"Alzheimer Disease")
UNSET MeSHAnatomy
UNSET Confidence

SET Evidence = "Since Erk1/2 activity has been shown to induce cdk5 (Harada et al, 2001), miR-125b-induced Erk1/2 activation through DUSP6 downregulation might ultimately stimulate aberrant cdk5/p35 activation and, consequently, enhance pathological tau phosphorylation at multiple sites"
SET Confidence = "Medium"
p(FPLX:ERK) ->  kin(p(HGNC:CDK5))
m(MIRBASE:"hsa-mir-125b-1") -| p(HGNC:DUSP6)
p(HGNC:DUSP6) -| p(FPLX:ERK)
kin(p(HGNC:CDK5)) -> p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
UNSET Confidence


SET Citation = {"PubMed", "29281045"}
SET Evidence = "Western blot analyses showed a decrease of methyl-PP2A and an increase of demethyl-PP2A with a concomitant reduction in the methyl/demethyl PP2A ratio in both PSP (74%) and AD (76%) brains, associated with an LCMT-1 decrease and a demethylating enzyme increase, protein phosphatase methylesterase (PME-1), in both diseases."
SET Confidence = "Medium"
SET Method = "Western Blot"
path(MESH:"Alzheimer Disease") -| p(FPLX:PPP2, pmod(Me))
path(MESH:"Supranuclear Palsy, Progressive") -| p(FPLX:PPP2, pmod(Me))
path(MESH:"Alzheimer Disease") -| p(HGNC:LCMT1)
path(MESH:"Supranuclear Palsy, Progressive") -| p(HGNC:LCMT1)
path(MESH:"Alzheimer Disease") -> p(HGNC:PPME1)
path(MESH:"Supranuclear Palsy, Progressive") -> p(HGNC:PPME1)
p(HGNC:PPME1) -| p(HGNC:PPP2CA, pmod(Me, Leu, 309))
p(HGNC:LCMT1) -> p(HGNC:PPP2CA, pmod(Me, Leu, 309))
UNSET Method
UNSET Confidence


######################################################################################################################
#####################################################Tau Prolyl Isomerisation#########################################


SET Citation = {"PubMed", "24964035"}
SET Evidence = "The high degree of colocalization between pSmad2/3 and ubiquitin
(Figure 7) provides additional evidence for a forced degradation of Smad2 via the proteasome
pathway in AD which is controlled through binding of Pin1"
SET Confidence = "Medium"
SET MeSHDisease = "Alzheimer Disease"
act(p(FPLX:Proteasome)) -> deg(p(HGNC:SMAD2))
p(HGNC:PIN1) reg deg(p(HGNC:SMAD2))
UNSET MeSHDisease
UNSET Confidence

SET Evidence = "The results demonstrate a direct interaction of Smad2 with phospho-tau (Figure 8B) which is clearly
enhanced in the presence of Pin1. "
SET Confidence = "High"
p(HGNC:PIN1) -> complex(p(HGNC:SMAD2), p(HGNC:MAPT, pmod(Ph)))
UNSET Confidence

SET Evidence = "Alltogether, this provides evidence for a negative feed-back regulation of Pin1 by Smad.
A similar mechanism might be instrumental in AD, where nuclear Smad concentrations
are significantly reduced , which potentially contributes to increased levels of Pin1 [16]"
SET Confidence = "Medium"
p(FPLX:SMAD) -| p(HGNC:PIN1)
SET MeSHAnatomy = "Cell Nucleus"
p(FPLX:SMAD) neg path(MESH:"Alzheimer Disease")
UNSET MeSHAnatomy
UNSET Confidence


SET Citation = {"PubMed", "23157676"}
SET Evidence = "Pin1 accelerates cis to trans conversion to prevent accumulation of pathogenic cis p-tau conformation in AD, providing the first structural evidence for how Pin1 protects against AD."
SET Confidence = "Medium"
act(p(HGNC:PIN1)) -| p(HBP:"cis p-tau")
p(HBP:"cis p-tau") pos path(MESH:"Alzheimer Disease")
p(HBP:"cis p-tau") -> a(HBP:"Tau aggregates")
act(p(HGNC:PIN1)) -| path(MESH:"Alzheimer Disease")
UNSET Confidence


SET Citation = {"PubMed", "26903089"}
SET Evidence = "We identified a novel molecular interaction implying the PHF6 peptide of Tau and the FK1/FK2 domains of FKBP52 independent of FK506 binding;
suggesting a non-catalytic molecular interaction that might govern the effect of FKBP52 on Tau."
SET Confidence = "High"
act(p(HGNC:FKBP4)) -- p(HBP:"VQIVYK motif")
UNSET Confidence


SET Citation = {"PubMed", "26996941"}
SET Evidence = "We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain."
SET Confidence = "High"
act(p(HGNC:PIN1)) -- p(HGNC:MAPT, pmod(Ph, Ser, 235))
UNSET Confidence


SET Citation = {"PubMed", "23832849"}
SET Evidence = "We then investigated the function of FK506-binding protein (FKBP) 12, which is known to accumulate in neurofibrillary tangles in vivo, on aggregation of the R3 peptide and found that FKBP12 completely prevented the peptide from aggregating at a concentration ratio of 1 : 4 (peptide:FKBP12).
FKBP12 also restored the oligomer of the peptide to its monomeric status. Mutational studies on the catalytic center of FKBP12 indicated that peptidyl-prolyl isomerase activity of FKBP12 was essential for prevention of aggregation.
Assuming that the propensity of aggregation of the peptide is different in each cis-/trans-isomer, we propose that the aggregation behavior of the R3 peptide can be theoretically described with a simple kinetic scheme, in which only the cis-isomer can aggregate and FKBP12 catalyzes isomerization of the peptide in both the monomeric and aggregative states."
SET Confidence = "Medium"
p(HGNC:FKBP1A) -- a(GO:"neurofibrillary tangle")
p(HGNC:FKBP1A) -| a(HBP:"Tau aggregates")
p(HGNC:FKBP1A) -| a(HBP:"Tau oligomers")
UNSET Confidence


SET Citation = {"PubMed", "22926167"}
SET Evidence = "Because Pin1 has at least 4 major isovariants in addition to the native polypeptide, this means that Pin1 has 4 (possibly
more) posttranslational modifications including phosphorylation at 3 sites (Ser16 and Ser65/Ser71), N-acetylation
(amino-terminus and Lys46) and oxidation (Met130 and 146). In all experimental conditions, including tau-overexpressing
cells, tau transgenic mice and AD brains, global levels of Pin1 posttranslational modifications were decreased compared with control conditions."
SET Confidence = "Medium"
p(HGNC:PIN1, pmod(Ph, Ser, 16)) -| p(HGNC:PIN1)
p(HGNC:PIN1, pmod(Ph, Ser, 65)) -| p(HGNC:PIN1)
p(HGNC:PIN1, pmod(Ph, Ser, 71)) -| p(HGNC:PIN1)
p(HGNC:PIN1, pmod(Ac, Lys, 46)) -| p(HGNC:PIN1)
UNSET Confidence

SET Evidence = "Pin1 binds to phosphorylated Thr231 of tau and facilitates the dephosphorylation of phosphoThr231
through isomerization (Galas et al., 2006; Hamdane et al., 2006; Lu et al., 1999a). Phosphorylation at Thr231 on
tau is associated with the early events of tau aggregation and NFT (Augustinack et al., 2002). Pin1 binds and isomerizes
the proline imidic peptide bond following the phosphothreonine 231"
SET Confidence = "Medium"
complex(p(HGNC:PIN1), p(HGNC:MAPT, pmod(Ph, Thr, 231))) -| p(HGNC:MAPT, pmod(Ph, Thr, 231))
p(HGNC:MAPT, pmod(Ph, Thr, 231)) -> a(HBP:"Tau aggregates")
p(HGNC:MAPT, pmod(Ph, Thr, 231)) -> a(GO:"neurofibrillary tangle")
UNSET Confidence

SET Evidence = "In fact, phosphorylation of Pin1 at Ser16 inhibits its nuclear localization possibly through inhibition of Pin1 substrate-binding
property (Lu et al., 2002) while phosphorylation at Ser65 does not change activity of localization but stabilizes Pin1 by preventing its ubiquitination"
SET Confidence = "Medium"
p(HGNC:PIN1, pmod(Ph, Ser, 16)) -| p(HGNC:PIN1, loc(MESH:"Cell Nucleus"))
p(HGNC:PIN1, pmod(Ph, Ser, 65)) cnc p(HGNC:PIN1, loc(MESH:"Cell Nucleus"))
p(HGNC:PIN1, pmod(Ph, Ser, 65)) -| p(HGNC:PIN1, pmod(Ub))
p(HGNC:PIN1, pmod(Ub)) -> deg(p(HGNC:PIN1))
UNSET Confidence


SET Citation = {"PubMed", "19401603"}
SET Evidence = "Pin1 is indicated to facilitate Tau dephosphorylation via PP2A by binding to the phospho-Thr-231-Pro or phospho-Thr-212-Pro site"
SET Confidence = "Medium"
p(HGNC:PIN1) -> act(p(HGNC:PPP2CA))
act(p(HGNC:PPP2CA)) =| p(HGNC:MAPT, pmod(Ph, Thr, 231))
act(p(HGNC:PPP2CA)) =| p(HGNC:MAPT, pmod(Ph, Thr, 212))
UNSET Confidence

SET Evidence = "Taken together, these results indicate that the binding of P-Tau to microtubules suppresses its dephosphorylation."
SET Confidence = "Medium"
complex(a(MESH:Microtubules), p(HGNC:MAPT, pmod(Ph))) pos p(HGNC:MAPT, pmod(Ph))
UNSET Confidence
